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CHAPTER 1
General introduction and outline of the thesis
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Liver Transplantation
Liver transplantation is a highly successful treatment for patients with malignant and 
non-malignant end-stage liver diseases. About 6000 liver transplant procedures are 
performed each year in Europe and in the United States1, with a 5-year survival of more 
than 70% in most centers compared with 20% in the mid-1980s2. One of the keys to such 
success is the improvement of post-transplant immunosuppression strategies to prevent 
graft rejection. Before the advent of cyclosporine, the rate of acute rejection was as high 
as 80% at day 5-7 after liver transplantation and was in some cases a life-threating event3. 
The introduction of cyclosporine-based immunosuppression protocol decreased the acute 
rejection risk to 30-40% and chronic rejection risk to 10-15% in the early 1990s. With the 
current immunosuppression protocols, which mainly involve tacrolimus, mycophenolate 
mofetil (MMF) and corticosteroids, the rate of acute rejection is only 20% and a rate of 
chronic rejection 5%. However the long-term use of immunosuppression regimens leads 
to complications such as infections, de novo cancer, cardiovascular diseases, metabolic 
syndrome and impaired renal function4-12. Therefore immunosuppression minimization 
or complete withdrawal is advocated to improve the long-term outcomes of transplanted 
patients13. Unlike other transplanted organs, the liver has a tolerogeneic nature. For 
example, liver grafts can be accepted without the need of immunosuppression in pigs, and 
in some rat and mice strains14-16. In humans, transplantation of liver is possible without 
matching of major histocompatibility complex (MHC) antigens, and even across ABO 
blood groups between recipient and donor17, 18. Furthermore transplantation of liver can 
protect the other transplanted organs derived from the same donor from rejection19. and 
about 20 % of stable liver patients can be weaned of immunosuppression without losing 
the allograft20-23. Unfortunately, no accurate parameters are available to discriminate 
tolerant from non-tolerant liver transplant patients. Therefore it is crucial to understand 
the regulation of allogeneic immune responses with regard of liver transplantation 
in humans, in order to facilitate the individualization of patient management, and to 
contribute to a better long-term outcome.
Allorecognition by T lymphocytes
The immune system of humans has evolved to distinguish self from non-self. 
Transplantation of tissues or organs between genetic disparate individuals of the same 
species exerts strong and complicated immune responses targeting the allogeneic 
antigens, which are mainly major histocompatibility (MHC) molecules. T lymphocytes (T 
cells) are the main instigators of allogeneic immune responses, which can be categorized 
into cytotoxic T cells (CD8+ T cells) and T helper cells (CD4+ T cells). It has been known 
for more than three decades that there are mainly two pathways of allorecognition 
involved in activation of T cells against MHC molecules: the direct pathway and the 
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indirect pathway24, 25 (Figure 1). The direct pathway describes the recognition of intact 
allogeneic MHC molecules expressed on donor cells by recipient T cells, while the indirect 
recognition pathway describes a more “natural” process of T-cell activation, in which 
recipient APCs take up alloantigens from the transplanted organ and present them as 
peptides to recipient CD4+ T cells. Recently, another semi-direct pathway of alloantigen 
recognition has been suggested, in which recipient T cells recognize intact donor MHC 
molecules taken up and presented by recipient antigen-presenting cells (APC)26, 27. It has 
been hypothesized that the direct pathway dominates the allogeneic immune responses 
early after transplantation and is the main cause of early acute rejection. In contrast, the 
indirect pathway takes over later after transplantation and contributes to the occurrence 
of chronic rejection28-32. Therefore, to promote a better long-term patient outcome, the 
understanding and monitoring of indirect allogeneic immune responses is absolutely 
crucial and may help to personalize immunosuppressive medication. For this purpose, 
an assay to detect indirect T cells with high sensitivity and specificity is needed.
Infection and transplant rejection
Infections with bacteria and virusses are common after organ transplantation due the 
compromised immune system of the patients. Exposure to microbes before transplantation 
and infection after transplantation are accompanied by changes of both the innate and 
adaptive immune systems of the body, and can thereby directly or indirectly influence 
allogeneic immune responses and outcome after transplantation. Unlike experimental 
animals raised in a pathogen-free environment, humans are exposed to large numbers 
of microbial species, generating pools of memory T cells which may be cross-reactive to 
allogeneic antigens, a phenomena termed as “heterologous immunity”33, 34 (Figure 2). 
As cross-reactive memory T cells are more resistant to immunosuppression than naive 
T cells33, 35, heterologous immunity following infections has been hypothesized to be a 
significant barrier to the induction of transplantation tolerance. In addition, infections at 
the time of or after transplantation, can result in the engagement of pattern-recognition 
receptors (PRRs) on antigen-presenting cells (APCs) and thereby induce various signals 
and cytokines, resulting in enhanced alloreactivity of T cells36, 37. Infections occurring late 
after transplantation can also provide various pro-inflammatory signals that re-activate 
tolerant T cells, enabling their escape from immunoregulatory mechanisms of tolerance, 
and finally leading to allograft rejection38, 39. Indeed in clinical practice, correlations 
between increased incidence of infections and acute rejection have been observed40, 
however it is difficult to define a causal relationship38. 
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Indirect allorecognition and transplantation Go¨kmen, Lombardi and Lechler 569
Figure 1
Pathways of allorecognition. In the direct pathway (a), intact donor MHC:peptide complexes on donor APCs are recognized by recipient T cells, with
CD4+ cells recognizing MHC class II, and CD8+ cells recognizing class I molecules. The indirect pathway (b) involves the processing and presentation
in peptide form of donor allogeneic MHC by recipient APCs. Allogeneic material is taken up by recipient APCs by endocytosis, and processed to form
peptide fragments. In the MHC class-II-enriched compartment (MIIC), donor-derived peptide displaces class-II-associated invariant chain peptide
(CLIP) on the surface of recipient MHC class II molecules. The complex of recipient MHC and donor peptide is then expressed on the cell surface,
where it is recognized by self MHC-restricted CD4+ T helper cells. The semi-direct pathway (c) results from the transfer of intact donor MHC:peptide
complexes from donor to recipient APCs, either through cell–cell contact or exosomes. CD4+ T helper cells can recognize donor MHC class II
displayed in this way on recipient APCs (i); the uptake of intact donor MHC class I molecules can allow the activation of CD8+ T cells and CD4+ T cells
with indirect allospecificity on the surface of the same APC (ii).
www.sciencedirect.com Current Opinion in Immunology 2008, 20:568–574
Figure 1. Pathways of allorecognition. In the direct pathway (a), intact donor MHC:peptide 
complexes on donor APCs are recognized by recipient T cells, with CD4+ cells recognizing MHC class 
II, and CD8+ cells recognizing class I molecul s. The indirect pathway (b) involves the processing 
and presentation in peptide form of donor allogeneic MHC by recipient APCs. Allogeneic material 
is taken up by recipient APCs by endocytosis, and processed to form peptide fragments. In the 
MHC class-II-enric ed comp rtment (MIIC), donor-deriv d peptide disp aces class-II-associated 
invariant chain peptide (CLIP) on the surface of recipient MHC class II molecules. The complex 
of recipient MHC and donor peptide is then expressed on the cell surface, where it is recognized 
by self MHC-restricted CD4+ T helper cells. The semi-direct pathwa  (c) results from the transfer 
of intact donor MHC-peptide complexes from donor to recipient APCs, either through cell–cell 
contact or exosomes. CD4+ T helper cells can recognize donor MHC class II displayed in this way 
on recipient APCs (i); the uptake of intact donor MHC class I molecules can allow the activation of 
CD8+ T cells and CD4+ T cells with indirect or direct allospecificity on the surface of the same APC 
(ii). Adapted from Gökmen et al. Curr Opin Immunol 2008
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Figure 1 | Possible effects of infections before, at and after transplantation.  
Some T cells specific for microbial peptides presented by self MHC molecules can 
cross-react with allogeneic MHC molecules, and bacterial superantigens can directly 
activate large populations of T cells. Therefore, infections experienced before 
transplantation can give rise to heterologous memory alloreactive T cells that may be 
more resistant to immunosuppression than naive T cells15,18. The engagement of  
pattern-recognition receptors (PRRs) on antigen-presenting cells (APCs), T cells and/or 
parenchymal cells at the time of or after transplantation can induce various signals and 
cytokines. This can result in enhanced priming, survival and expansion of alloreactive 
T cells, as well as dictating the phenotype of differentiating alloreactive T cells. Infections 
occurring late after transplantation may elicit pro-inflammatory signals that activate 
tolerant T cells by enabling their escape from immunosuppression and/or peripheral 
mechanisms of tolerance, thereby precipitating rejection. T
Reg
 cell, regulatory T cell.
Donor-specific transfusion
(DST). A treatment for inducing 
transplant tolerance that 
involves the infusion into a 
transplant recipient of spleen 
cells from a donor who also 
provides the organ or tissue.
MHC tetramers 
Fluorescently labelled 
tetravalent complexes of MHC 
class I or class II molecules 
complexed with antigenic 
peptides. They can be used to 
identify antigen-specific T cells 
by flow cytometry.
Severe combined 
immunodeficiency mice 
(SCID mice). Mice with a defect 
in DNA recombination that 
results in an absence of B and 
T cell development. Such mice 
are incompetent at rejecting 
tissue grafts from allogeneic 
and xenogeneic sources.
Superantigen 
A microbial protein that 
activates all T cells expressing 
a particular set of T cell 
receptor (TCR) Vβ chains by 
crosslinking the TCR to a 
particular MHC molecule 
regardless of the peptide 
presented.
donor-specific memory IFNγ-producing lymphocytes in 
renal transplant patients correlated with the risk of post-
transplantation rejection episodes. These observations 
were confirmed in mice16 and more recently in non-
human primates17, in which memory T cells were shown 
to confer resistance to long-term graft acceptance.
The initial experimental demonstration of the impor-
tance of heterologous immunity in transplant rejection 
involved sequential viral infections that generated a 
population of alloreactive memory CD8+ T cells in mice. 
These animals then became resistant to the induction 
of transplant tolerance by co-stimulation blockade and 
donor-specific transfusion (DST) or by bone marrow chi-
merism protocols18. Data demonstrating the participa-
tion of virus-specific T cells in an alloresponse came 
from studies in which mouse memory CD8+ T cells spe-
cific for lymphocytic choriomeningitis virus (LCMV) 
were generated in vivo through LCMV infection19. 
These LCMV-specific T cells were isolated using LCMV 
peptide–self MHC tetramers and were shown to be 
cross-reactive with alloantigens and to induce the acute 
rejection of skin allografts when transferred into severe 
combined immunodeficiency mice (SCID mice).
Based on the structural understanding of direct 
alloreactivity, there is no reason to believe that only 
viruses can generate heterologous immunity. Indeed, 
the infection of mice with the parasite Leishmania 
major was shown to generate memory T cells that are 
cross-reactive with allogeneic MHC molecules and that 
prevent the induction of transplant tolerance to subse-
quent skin grafts20. In addition, some bacterial species 
(such as Staphylococcus and Streptococcus spp.) produce 
toxins with superantigen properties, which allow them to 
activate up to 20% of the T cell repertoire in mice, and 
so these bacteria may also contribute to the generation 
of alloreactive memory T cells21. The ability of infections 
that occur before transplantation to sensitize alloreac-
tive T cells may be particularly important in light of the 
potentially rich history of infections in patients waiting 
for a transplant. Indeed, cross-reactivity between virus-
specific T cells and allogeneic HLA molecules has been 
demonstrated with human T cells14, and a remarkable 
80% of T cell lines and 45% of T cell clones specific 
for EBV, CMV, varicella zoster virus or influenza virus 
cross-react with allogeneic HLA class I or II molecules22.
Nonetheless, despite widespread acceptance that 
hetero logous immunity is a demonstrable barrier to 
successful allograft acceptance in mice, some degree 
of caution is necessary in extrapolating from studies of 
T cell cross-reactivity to pathogenicity, and in assuming 
that hetero logous immunity contributes significantly to 
the T cell pool that mediates organ allograft rejection 
in humans. Indeed, it was observed recently that the 
adoptive transfer of cytotoxic T lymphocytes (CTLs) 
specific for EBV, CMV and/or adenovirus did not result 
in greater graft-versus-host disease in human recipients of 
HLA-mismatched CTLs (with demonstrated broad allo-
reactivity) than in patients who received HLA-matched 
CTLs23. One possible explanation for this observation is 
that memory T cells remain dependent on TCR signalling 
and are therefore susceptible to calci neurin inhibitors, 
which are essential components of clinical transplanta-
tion immunosuppression regimens24. Thus, the impact 
of heterologous immunity and of memory T cells in 
general may be diminished in clinical transplantation. 
In June 2011, belatacept — which is a modified 
CTLA4 (cytotoxic T lymphocyte antigen 4)–immuno-
globulin fusion protein that provides co-stimulatory 
blockade — was approved as an alternative to calci-
neurin inhibitors for the prophylactic treatment of rejec-
tion in adult kidney transplant recipients25. The relative 
resistance of memory T cells to co-stimulation block-
ade raises the possibility that belatacept-based regimens 
may not adequately control memory T cells, and thus 
the role of these cells in clinical rejection may become 
more apparent.
Infections in the post-transplant period. Pathogenic 
bacterial, fungal and viral infections are prevalent in the 
peri- and post-transplant periods as a result of surgi-
cal insult and immunosuppression. Studies evaluating 
defined categories of bacterial infections in transplant 
recipients have been able to link the incidence of bacterial 
infections with transplant rejection (reviewed in REF. 2). 
In patients who have received lung transplants, infections 
with Chlamydia pneumoniae26 or Simkania negeven-
sis27, and colonization of the allograft by Pseudomonas 
aeruginosa28 or Aspergillus spp.29, have been associated 
with the development of acute rejection or bronchiolitis 
obliterans syndrome. Furthermore, urinary tract infections 
(especially those occurring late after renal transplanta-
tion when prophylactic anti biotics have been discontin-
ued) have been associated with chronic rejection and 
renal graft loss30. When infections occur locally in the 
R E V I E W S
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Figure 2. Possible effects of infections before, at and after transplantation. Some T cells specific 
for microbial peptides presented by self MHC molecules can cross-react with allogeneic MHC 
molecules, and bacterial superantigens can directly activate large populations of T cells. Therefore, 
infections experienced before transplantation can give rise to heterologous memory allor active 
T cells that may be more resistant to immunosuppression than naive T cells. The engagement f
pattern-recognition receptors (PRRs) on antigen-presenting cells (APCs), T cells and/or parenchymal 
cells at the time of or after transplantation can induce various signals and cytokines. This can 
result in enhanced priming, survival and expansion of alloreactive T cells, as well as dictating 
the phenotype of differentiating alloreactive T cells. Infections occurring late after transplantation 
may elicit pro-inflammatory signals that activate tolerant T cells by enabling their escape from 
immunosuppression and/or peripheral mechanisms of tolerance, thereby precipitating rejection. 
Adapted from Chong et al. Nat Rev Immunol 2012
A good example of this relationship is human cytomegalovirus (CMV). CMV, also 
known as human herpesvirus-5 (HHV-5), is a m mber of t  β-her esvirus subfamily, 
and one of the most common viruses among humans with an extremely high 
w rldwide prevale ce41, 42. The infection of CMV is generally subclinical, except in 
immunocompromised individuals, such as patients after organ transplantation. CMV 
infection after organ transplantat on can cause f brile syndr me with leukopenia and/
or thrombocytopenia (CMV syndrome) as well as organ involvement, and is putatively 
associated with other opportunistic infections, malignancies and graft rejection43. 
Therefore, antiviral prophylaxis or preemptive therapies are widely used to prevent 
and control CMV infection in org  ransplant patients44, 45. Evidenc  from experimental 
animal models show that infection or re-activation of CMV abrogates the establishment 
of transplant tolerance46, 47, however evidence in humans have been less consistent48. 
Despite that, infection with CMV may have a yst ic immunosup ressive effects in 
humans49-51. How CMV infection alters the immune responses towards a transplanted 
organ in humans is not known.
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Co-stimulatory and co-inhibitory regulation of T-cell function
T cells are the key players and regulators of the adaptive immune system, the regulation 
of which is crucial to maintain the equilibrium between pathogen elimination and self-
tolerance. Three signals are need to fully activate T cells. The first signal is the recognition 
of antigenic peptides presented by major histocompatibility complex (MHC) molecules 
by the T-cell receptor (TCR)52. The second is the antigen-independent co-stimulatory 
signals provided by APCs, which mainly involves the interaction between CD28 on the T 
cell and CD80/CD86 molecules on the APCs53, 54. Without signal two, T-cells will become 
anergic even in the presence of signal one55. The third signal is provided a number of 
cytokines produced by APCs which enables T-cell proliferation and differentiation56. The 
discovery of co-inhibitory receptors in recent years complicated our understanding of 
this model of T-cell activation57. In contrast to co-stimulatory receptors, co-inhibitory 
receptors negatively regulate T-cell functions, such as PD-1, CTLA-4, TIM-3, LAG-3, 
2B4 (CD244), and CD160 (Figure 3). In some settings, such as chronic infections and 
malignancies, co-inhibitory receptors expressed on antigen-specific T cells restrict 
effective immune responses that are needed to clear the pathogens or tumor cells58-60. 
Monoclonal antibodies targeting PD-1, or its ligand PD-L1, have been shown to be 
effective in treatment of several types of cancer, and have been recently approved by 
the U.S. Food and Drug Administration (FDA)61-63. However in other settings, such 
as autoimmune diseases and organ transplantation, potent co-inhibitory regulatory 
pathways might help to limit the detrimental immune responses. For example, PD-1/
PD-L1 pathway has been shown to be critical in the maintenance of liver transplant 
tolerance in animal models64, 65, and agonistic targeting of this pathway which might 
have therapeutic potential66, 67. However pre-clinical evidence supporting the relevance 
of PD-1/PD-L1 pathway in the human transplant setting is still lacking.
transiently expressed on the surface of T cells within 24 to
48 hr of activation and constitutively expressed in Tregs (7, 8)
(Table 1). At rest, CTLA4 is localized in cytoplasmic vesicles
and is delivered to the cell surface upon activation, partici-
pating in the immunological synapse. The cell surface ex-
pression of CTLA4 molecule is tightly regulated through
continuous endocytosis and trafficking, and this effect is in
part mediated by the adaptor complex AP2 and regulated by
the strength of TCR signaling (9Y11).
The B7 family of proteins, B7-1 (CD80) and B7-2
(CD86), belong to Ig superfamily and is composed of one
extracellular immunoglobulin domain with a short intra-
cellular tail, providing the major co-stimulatory signal for
augmenting and sustaining T-cell response through inter-
actionwith CD28. At the same time, B7-1 and B7-2 are shared
ligands of CTLA4, and their expression is highly restricted
to lymphoid organs, including B cells, macrophages, dendritic
cells (DCs), and T cells (Table 1). B7-2 is constitutively ex-
pressed in APCs at low levels and rapidly up-regulated upon
activation, whereas B7-1 is expressed only upon activation.
The pattern and timing of expression of receptors and ligands
are critical modes of co-signaling control.
In contrast to the CD28:B7-1/B7-2 pathway, the in-
teraction of CTLA4 with these ligands relays a major co-
inhibitory signal. CTLA4 exhibits its inhibitory effects through
both cell-intrinsic and cell-extrinsic manners (Fig. 2A). Cell-
intrinsic inhibitory mechanisms include CD28 out-competition
and blockade of intracellular signaling pathways. CTLA4 has
a 10- to 20-fold higher affinity than CD28 for B7-1 (12), thus
it can out-compete CD28 for B7-1 binding (13). Although
the dominant intracellular signaling pathway of CTLA4 is
still unclear, some data suggest CTLA4 blocks TCR signal
transduction through blockade of ZAP70 complex formation
and activation of a serine-threonine phosphatase, protein
phosphatase 2A (PP2A), which then inhibits AKT (Fig. 2A)
(14, 15). On the other hand, cell-extrinsic mechanisms include
trans-endocytosis of B7-1/B7-2 ligands (16) and indoleamine
2,3-dioxygenase (IDO) secretion by APC upon ligation to B7-
1/B7-2 (Fig. 2A) (17). CTLA4:B7 complex is internalized in
a clathrin-plasma membrane-associated adaptor complexes
(AP2)-dependent fashion upon activation, through interac-
tion with a cytoplasmic tyrosine-based motif (11), thereby
inhibiting stimulatory signals through B7 sequestration from
cell surface. In addition, CTLA4 enhances IDO secretion by
APCs, leading to inhibition of T-cell proliferation by trypto-
phan depletion (17).
Function of CTLA4:B7-1/B7-2 in Immune
Homeostasis and in Disease
Autoimmunity and Peripheral Tolerance
CTLA4-deficient mice exhibit severe lymphoprolifera-
tive disease, with infiltration of activated T cells to various
organs and death within a few weeks of birth (18Y20). Ise et al.
elegantly showed that this phenomenon is not an autono-
mous T-cell proliferation but rather an autoimmune tissue-
specific response against autoantigens such as the pancreatic
acinar antigen (protein disulfide isomerase-associated 2, PIDA2)
(21). CTLA4 deficiency on either PDIA2-specific effector
T cells or Tregs enhanced tissue autoimmune infiltration
suggesting a critical role of CTLA4 in regulating both effector
and regulatory responses (22). In summary, CTLA4 plays a
major role in immune homeostasis in mice by enhancing
autoantigen-specific Treg function and attenuating effector
T-cell function.
In humans, CTLA4 gene polymorphisms have been
implicated in many autoimmune diseases, including thyroid
FIGURE 1. Co-inhibitory signals between antigen-presenting cells (APCs) and T cells. Representative illustration of the
main co-inhibitory interactions with details about direction of signal and binding partners.
4 www.transplantjournal.com Transplantation & Volume 98, Number 1, July 15, 2014
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Figure 3. Co-inhibitory signals betwe n antigen-pre enting cells (APCs) and T cells. 
Representative illustration of the main co-inhibitory interactions with details about direction of 
signal and binding partners. Adapted from Murakami et al. Transplantation 2014
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Mixed hematopoietic chimerism
Chimerism can be defined as a phenomenon in which cells from one individual are present 
in another genetically disparate individual, which may occur after organ and hematopoietic 
stem cell transplantation. Several types of chimerism after liver transplantation have been 
described, including (1) recipient-derived cells in the transplanted organ78, 79; (2) donor-
derived hematopoietic cells in the recipient peripheral blood80-82; and (3) donor-derived 
cells in the skin and lymph nodes of recipient83. The clinical relevance of the development 
of chimerism is not fully understood. It has been hypothesized that achieving chimerism 
might lead to a tolerogenic immune status against allografts, and therefore it has been 
considered as a strategy to achieve transplant tolerance in the clinical setting84. Indeed, 
successful tolerance induction has been reported in HLA-matched or mismatched renal 
transplant patients by inducing transient or durable mixed chimerism85. However other 
studies suggest that chimerism does not necessary correlate with graft tolerance86. In a 
recent study Wang et al. studied the blood chimerism in a large cohort liver transplant 
patients and analyzed the putative hematopoietic stem/progenitor cells (HSPCs) in 
adult human livers87. The authors concluded that there are two types of chimerisms in 
LT patients: transient chimerism resulting from mature donor leucocytes, and long-term 
chimerism derived from putative donor-derived HSPCs in the liver graft, and suggested 
that liver is a good ectopic niche for extra-marrow hematopoiesis. Still, the possibility of 
long-lived hematopoietic chimerism in the liver allograft has not been examined.
Aim of the thesis
The transplantation of human livers to save patients with end-stage liver diseases is 
always accompanied by immune responses trying to eliminate the transplanted organ, 
which are shaped and regulated by several environmental and genetic factors. Therefore, 
a better knowledge of the immune regulation in patients after liver transplantation is 
crucial to facilitate developing interventions to achieve a better long-term patient 
outcome. In this thesis, we study environmental and genetic factors that influence allo-
reactivity in liver transplant patients, investigate their impact on clinical outcomes, and 
suggest novel perspectives that may help to personalize patient immunosuppressive 
management to minimize adverse effects of life-long standard immunosuppressive 
medication. 
In chapters 2 and 3, we studied the impact of cytomegalovirus infection after liver 
transplantation on the allogeneic T-cell responses and graft rejection. Next in chapter 
4, we summarize and discuss the recent evidence supporting beneficial aspects of 
cytomegalovirus infection on human disease and health. Chapter 5 studies the influence 
of genetic variations in the co-inhibitory PD-1/PD-L1 pathway in regulation of allogeneic 
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T-cell responses and graft rejection in human liver transplant recipients. Chapter 6 
describes a novel assay which may help monitoring T cells that indirectly recognize 
major allo-antigens in transplanted patients, using messenger RNA electroporation. In 
chapter 7, we examine the phenomenon of hematopoietic chimerism within human liver 
allograft. Finally in chapter 8, we summarize and discuss in depth the work of this thesis.
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CMV primary infection is associated with 
donor-specific T-cell hyporesponsiveness and 
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ABSTRACT 
Viral infections, including cytomegalovirus (CMV), abrogate transplantation tolerance 
in animal models. Whether this also occurs in humans remains elusive. We investigated 
how CMV affects T cells and rejection episodes after liver transplantation (LT). 
Phenotype and alloreactivity of peripheral and allograft-infiltrating T cells from LT 
patients with different CMV status were analyzed by flow cytometry. The association 
of CMV status with early and late acute rejection was retrospectively analyzed in a 
cohort of 639 LT patients. CMV-positivity was associated with expansion of peripheral 
effector memory T-cell subsets after LT. Patients with CMV primary infection showed 
donor-specific CD8+ T-cell hyporesponsiveness. While terminally differentiated effector 
memory cells comprised the majority of peripheral donor-specific CD8+ T cells in CMV 
primary infection patients, they were rarely present in liver allografts. Retrospective 
analysis showed that R-D+ serostatus was an independent protective factor for late acute 
rejection by multivariate Cox regression analysis (hazard ratio=0.18, 95%CI=0.04-0.86, 
P=0.015). Additionally, CMV primary infection patients showed the highest Vδ1/Vδ2 
γδ T-cell ratio, which has been shown to be associated with operational tolerance after 
LT. In conclusion, our data suggest that CMV primary infection may promote tolerance 
to liver allografts, and CMV status should be considered when tapering or withdrawing 
immunosuppression.
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INTRODUCTION
Cytomegalovirus (CMV) is a prevalent β-herpesvirus that establishes lifelong latency 
in humans, and a leading viral infection after solid organ transplantation1. Immune 
responses to viruses, including CMV, have been proposed as one of the main barriers 
to the achievement of transplantation tolerance2 as they prevent tolerance induction 
in experimental animal models3-5. However, associations between CMV infection and 
graft rejection in humans vary between different types of organ transplants and show 
inconsistent results6. No consensus has been made on the effect of CMV infection on graft 
rejection or tolerance after liver transplantation (LT).
Acute rejection (AR) is primarily initiated by recipient T lymphocytes (T cells) that 
recognize nonself antigens derived from donor7. T cells can be classified into different 
subsets based on their differentiation status, reflecting distinct migration patterns and 
effector functions upon antigenic stimulation. While naive (TNaive) and central memory 
(TCM) T cells proliferate robustly in response to antigen, effector memory (TEM) and 
terminally differentiated effector memory (TEMRA) T cells produce high amounts of pro-
inflammatory cytokines and cytolytic mediators8, 9. In addition, TNaive and TCM recirculate 
between secondary lymphoid organs, while TEM home to inflamed peripheral tissues10. 
On one hand, accumulation of CD8+ TEMRA is a typical characteristic of CMV-driven 
immune senescence11, which is associated with increased susceptibility of the elderly 
to infections, and poor responses to vaccinations12, 13. On the other hand, CMV-specific 
memory T cells are hypothesized to be detrimental to allografts as they can be cross-
reactive to allogeneic HLA14, 15. However, no literature is available on how CMV infection 
alters T-cell alloreactivity after LT.
To address these issues, using ex vivo isolated cells from peripheral blood and liver 
allografts explanted during re-LT, we investigated the effect of CMV infection on T-cell 
differentiation and alloreactivity, as well as on γδ T-cell subset distribution, which has 
been shown to be associated with operational tolerance after LT16-18. In addition, we 
performed a retrospective study in a cohort of 639 LT patients, to analyze the association 
of CMV infection with both early (< 6 months) and late (> 6 months) acute rejection (EAR 
and LAR).
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PATIENTS AND METHODS
Study subjects
Peripheral blood samples were collected from 75 patients that underwent primary 
orthotopic LT between 2009 and 2012 at Erasmus MC, The Netherlands (Supplemental 
Table 1). Liver allograft biopsies were obtained from explants of 10 patients that 
underwent re-LT (Supplemental Table 2), and 9 heathy donor livers prior to LT. In the 
retrospective analysis to study the impact of CMV on graft rejection, 639 patients that 
underwent LT at Erasmus MC from 1992-2010 were included. Demographic details of 
donors and recipients are summarized in Table 1. Patients were followed up until graft 
loss, death, or the end of the study period on 31 December 2011. Immunosuppression 
therapies are described in Supplemental Materials and Methods. 
Written informed consent was obtained from all patients before collection of samples. 
The medical ethics committee of the Erasmus MC approved this study.
Cell isolation and flow cytometry
Protocols for cell isolation, list of antibodies, and flow cytometry details are described in 
Supplemental Materials and Methods.
Quantification of alloreactive T-cell frequencies
Alloreactive T cells were analyzed by determination of activation-induced CD137 
expression after allogeneic stimulation19, 20(Supplemental Figure 1). Protocol is described 
in Supplemental Materials and Methods.
CMV diagnostics, treatment, and patient groups
CMV serostatus of patients and donors was determined as part of the standard diagnostic 
routine. CMV viremia was determined by CMV-DNA polymerase chain reaction (PCR) 
assay, and 50 copies/mL was considered as the threshold for positive result. Patients 
included in the ex vivo T-cell analysis were grouped as: CMV-negative (R-D-), primary 
infection (R-D+), and R+ patients. CMV primary infection was confirmed by detection of 
viremia or IgG seroconversion after LT, and CMV-negative was defined as no detection 
of viremia nor IgG seroconversion prior to blood collection (Supplemental Table 1). No 
differences in baseline characteristics were observed between groups in all experiments. 
Detailed CMV diagnostics and treatment strategies are available in Supplemental 
Materials and Methods.
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Table 1: Demographic and baseline clinical characteristics of patients included in the 
retrospective analysis
Variable Total n=639  R- D- n=127 R- D+ n=122 R+ n=390 P-value
Recipient age, years 50 (16-71) 47 (17-68) 48 (16-71) 51 (16-67) 0.121
Recipient, female 264 (41%) 46 (36%) 54 (44%) 164 (42%) 0.039
Recipient BMI, kg/m2 25 (16-43) 24 (17-39) 24 (17-37) 25 (16-43) 0.299
Primary liver diseases     < 0.001
   AHF 119 (19%) 23 (18%) 25 (20%) 71 (18%)  
   HCC 64 (10%) 10 (8%) 10 (8%) 44 (11%)  
   PBC/PSC/AIH 149 (23%) 40 (31%) 37 (30%) 72 (18%)  
   HBV/HCV 84 (13%) 5 (4%) 2 (2%) 77 (20%)  
   Alcoholic cirrhosis 71 (11%) 14 (11%) 17 (14%) 40 (10%)  
   Cryptogenic cirrhosis 41 (6%) 10 (8%) 8 (7%) 23 (6%)  
   Others 111 (17%) 25 (20%) 23 (19%) 63 (16%)  
Donor age, years 46 (8-78) 43 (13-73) 45 (12-72) 46 (8-78) 0.149
Donor, female 333 (52%) 49 (39%) 61 (50%) 223 (57%) 0.001
DCD donor 49 (8%) 8 (6%) 9 (7%) 32 (8%) 0.775
   Cold ischemia time, minutes 470 (114-1099) 476 (120-1099) 479 (114-988) 455 (133-913) 0.441
   Warm ischemia time, minutes 36 (14-143) 34 (14-106) 35 (17-143) 37 (16-129) 0.121
Re-LT 75 (12%) 15 (12%) 9 (7%) 51 (13%) 0.233
Basiliximab as induction 
immunosuppression
375 (59%) 82 (65%) 72 (59%) 221 (57%) 0.290
Calcineurin inhibitor     0.645
   Cyclosporin A 249 (39%) 55 (43%) 46 (38%) 148 (38%)  
   Tacrolimus 367 (57%) 70 (55%) 68 (58%) 229 (59%)  
CMV prophylaxis  104 (16%) - 104 (85%) - < 0.001
CMV viremia 145 (23%) 4 (3%) 59 (48%) 82 (21%) < 0.001
Timing of CMV viremia detection 
after LT, days
35 (2-2502) 30 (17-35) 45 (22-288) 31 (2-2502) 0.001
Timing of first CMV viremia after LT 
< 180 days
134 (92%) 4 (100%) 54 (92%) 76 (93%) 0.703
Peak CMV-DNA copy number, 
copies/mL*
2.8 (1.8-6.8) 5.0 (4.0-6.8) 2.7 (1.8-5.3) 2.8 (1.9-6.5) 0.031
CMV IgG seroconversion** 97 (20%) 14 (14%) 83 (86%) - < 0.001
Early acute rejection 144 (23%) 26 (20%) 29 (24%) 89 (23%) 0.805
Timing of early acute rejection, days 9 (2-166) 8 (2-155) 9 (3-147) 8 (3-166) 0.999
Late acute rejection 41 (6%) 11 (9%) 2 (2%) 28 (7%) 0.048
Timing of late acute rejection, days 487 (186-6368) 997 (208-2967) 353 (186-521) 379 (206-6368) 0.138
* Log10 transformed
** Only patients with follow-up ≥ 180 days were taken into account (R-D- n=101, R-D+ n=97, R+ 
n=299; total n=497), and from 9 patients serology data after LT were not available (R-D- n=5, R-D+ 
n=4).
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Definition of early and late acute rejection
AR was defined as graft dysfunction accompanied by moderate or severe rejection activity 
(RAI≥5) detected in the liver biopsy according to Banff criteria, and responsiveness to 
additional immunosuppressive treatment. While EAR was defined as rejection occurring 
within 180 days after LT, LAR was defined as those occurring after 180 days after LT. 
Associations of CMV with EAR or LAR were analyzed separately, as EAR is most 
common during the first few weeks after LT, generally preceding CMV infection.
Statistical analysis
Patient baseline characteristics were summarized using median with range for 
continuous variables and percentage for discrete variables. Differences between groups 
were compared by Pearson Chi-Square test or one-way Kruskal-Wallis test. Experimental 
data were analyzed using nonparametric Mann-Whitney U test (unpaired) or Wilcoxon 
matched pairs test (paired) when comparing two groups, and one-way Kruskal-Wallis 
test (unpaired) or Friedman test (paired) with Dunn’s multiple comparison test when 
comparing three groups. In the retrospective analysis, EAR and LAR were used as 
separate endpoints. The cumulative incidences of EAR and LAR were estimated using 
the Kaplan-Meier method with log-rank test. Analysis of risk factors for EAR and LAR 
was performed using Cox proportional-hazards regression model with likelihood ratio 
test. We first performed univariate analysis for each potential independent variable. 
Independent variables with P-values less than 0.2 were included in the multivariate 
analysis together with CMV serostatus and viremia. Linearity of continuous variables 
and clinical relevant interactions were tested. Where multiple pairwise comparisons 
were made, a Bonferroni correction on the alpha level was applied. SPSS v.21 was used 
for statistical analysis, and P-values < 0.05 were considered significant.
RESULTS
CMV-positivity is associated with the expansion of effector memory T-cell subsets in 
peripheral blood after liver transplantation
We prospectively collected PBMC samples from 34 patients with distinct CMV status 
before, at 1 month and at 6 months after LT. Peripheral T-cell subsets were analyzed by 
flow cytometry on basis of CCR7 and CD45RO expression (Figure 1A)10. Patients were 
grouped based on CMV status (R-D- n=7, R-D+ n=10, R+ n=17), and distribution of CD8+ 
(Figure 1B) and CD4+ (Figure 1C) T-cell subsets at three time points were compared.
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Figure 1. Changes of circulating CD4+ and CD8+ T-cell subsets after LT in relation to patient 
CMV status. (A) T-cell subsets were defined as TNaive (CCR7+CD45RO-), TCM (CCR7+CD45RO+), 
TEM (CCR7-CD45RO+), and TEMRA (CCR7-CD45RO-), shown as representative FACS plots from one 
patient. Patients were grouped based on CMV status (R-D- n=7, R-D+ n=10, R+ n=17). Distribution of 
(B) CD8+ and (C) CD4+ T-cell subsets before (white), at 1 month (grey) and at 6 months (black) after 
LT were compared. Horizontal lines indicate median values. *P<0.05, **P<0.01, ***P<0.001.
The proportion of both CD4+ and CD8+ T-cell subsets remained stable in CMV-negative 
patients (R-D-). However in CMV primary infection (R-D+) and R+ patients, the proportion 
of CD8+ TNaive and TCM decreased continuously within the first 6 months, while the 
percentages of CD8+ TEM and TEMRA increased. Particularly CD8+ T-cell subsets from R-D+ 
patients underwent the most dramatic changes, characterized by rapidly increasing 
percentage of TEMRA (pre-LT 9%, 6 months 62%; median values). When dividing all 
patients at increased risk for CMV-replication (R-D+ and R+) by proven viremia, 
increasing percentage of CD8+ TEMRA were observed in both groups (Supplemental 
Figure 2), suggesting that the TEMRA increase was a result of CMV-positivity, rather than 
CMV-replication. However it was likely that not all viremia episodes were detected in 
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R+ patients. The change in CD8+ T-cell subset distribution was a manifestation of effector 
memory T-cell expansion rather than a selective disappearance of naive T cells, as 
absolute numbers of TEM and TEMRA increased in R-D+ and R+ patients, while the absolute 
numbers of TNaive remained relatively stable (Supplemental Figure 3). As for the CD4+ 
compartment, the percentages of TNaive also decreased within 6 months in CMV primary 
infection and R+ patients, which was mainly compensated by an increased percentage of 
TEM. Together, these data show that CMV-positivity is associated with the expansion of 
effector memory T-cell subsets in peripheral blood after LT.
CD8+ T cells from CMV primary infection patients develop donor-specific 
hyporesponsiveness
We hypothesized that the expansion of effector memory T-cell subsets driven by CMV 
might increase the frequencies of alloreactive T cells, as cross-reactive viral-specific 
memory T cells are common15. Thus we quantified the frequencies of donor-specific and 
third party-reactive T cells in 51 patients at minimum 6 months after LT by measuring 
the allogeneic activation-induced CD137 expression (Supplemental Figure 1A, B). The 
numbers of donor-recipient and third party-recipient HLA-mismatches were similar 
between groups (Supplemental Figure 4).
Overall CD8+ T cells showed donor-specific hyporesponsiveness (Figure 2A, left panel). 
We did not observe higher frequencies of alloreactive T cells in CMV primary infection 
or R+ patients than in CMV-negative patients. Unexpectedly, patients with primary 
infection showed prominent donor-specific hyporesponsiveness in CD8+ T cells (Figure 
2B, left panel), which was evident in TNaive, TCM and TEM (Figure 2C). In contrast, no 
donor-specific hyporesponsiveness was observed in CMV-negative patients, while in R+ 
patients significant donor-specific hyporesponsiveness was only observed in TEM. CD4+ 
T cells did not show any significant donor-specific hyporesponsiveness (Figure 2A, right 
panel), and the frequencies of alloreactive CD4+ T cells were also similar in patients with 
distinct CMV status (Figure 2B, right panel).
When focusing on patients with proven viremia, donor-specific hyporesponsiveness 
was only seen in R-D+ patients, and the frequency of donor-specific CD8+ T cells in R-D+ 
patients were lower than that in R+ patients (Supplemental Figure 5), indicating that the 
donor-specific hyporesponsiveness was not due to CMV-replication as such. However, 
the peak CMV-DNA copy number tended to be negatively associated with the frequency 
of donor-specific CD8+ T cells (P=0.06), but not with third-party reactive CD8+ T cells or 
alloreactive CD4+ T cells (Supplemental Figure 6).
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Figure 2. CMV primary infection is associated with the development of donor-specific CD8+ 
T-cell hyporesponsiveness after LT. The frequencies of peripheral alloreactive CD8+ and CD4+ 
T cells were analyzed by flow cytometric determination of CD137 expression on T cells after 
allogeneic stimulation. (A) Overall frequencies of donor-specific and third party-reactive CD8+ (left 
panel) and CD4+ (right panel) T cells were compared (n=51). Alloreactive T-cell frequencies of (B) 
total CD8+ (left panel) and CD4+ (right panel) T cells, and of each (C) CD8+ T-cell subset were 
compared between patients with different CMV status (R-D- n=18, R-D+ n=15, R+ n=18). Horizontal 
lines indicate median values. Subset composition of alloreactive CD8+ T cells was assessed by 
measuring CD45RO and CCR7 expression on CD137+CD8+ T cells. (D) Proportions of each T-cell 
subset within donor-specific and third party-reactive CD8+ T cells are shown as median values 
and interquartile ranges, (E) and summarized as pie charts presenting mean proportions. *P<0.05, 
**P<0.01, ***P<0.001.
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Furthermore, we assessed the subset composition of alloreactive CD8+ T cells (CD8+CD137+ 
T cells) (Supplemental Figure 1B). Compared to CMV-negative and R+ patients, donor-
specific T cells from patients with CMV primary infection were predominantly TEMRA (R-
D- 29.7%, R-D+ 57.7%, R+ 33.1%; mean values) (Figure 2D, E), which is possibly due to the 
robust donor-specific hyporesponsiveness in other subsets except for TEMRA.
CD8+ TEMRA are a minor T-cell population infiltrating liver allografts
As TEMRA were the major CD8+ T-cell subset present in peripheral blood after LT and 
comprised the majority of residual donor-specific CD8+ T cells in patients with CMV 
primary infection, we wondered whether CD8+ TEMRA are abundantly present in liver 
allografts and thereby contribute to allograft rejection. To investigate this, we isolated 
intrahepatic lymphocytes (IHLs) from liver allografts which were explanted during re-
LT (n=10; Supplemental Table 2). IHLs isolated from heathy donor livers prior to LT were 
used as healthy control. IHLs contained mainly CD4+ and CD8+ TEM and hardly any TNaive 
and TCM (Figure 3A, B). CD8+ TEMRA were present in the liver allografts but accounted for 
a significantly smaller proportion than in paired PBMC samples and IHLs of healthy 
donor livers (Figure 3B). The ratio of CD8+ TEM and TEMRA in liver allografts was 5-fold 
higher than that in peripheral blood, and 1.7-fold higher than that in healthy donor livers 
(median values, Figure 3C). Explant allografts with AR activity tended to have lower 
percentages of CD8+ TEMRA and a higher CD8+TEM/TEMRA ratio (Supplemental Figure 7). 
Sufficient amounts of IHLs were isolated from two of the liver explants to measure their 
allogeneic responses (Figure 3D). CD8+ TEM were enriched for donor-specific T cells, as 
20% and 33.9% of CD8+ TEM from these two IHLs samples, respectively, were reactive to 
donor splenocytes, while 8.8% and 7.5% of them responded to third-party stimulation 
(CD137 expression in conditions without stimulation were subtracted). In contrast, CD8+ 
TEMRA contained less alloreactive cells than TEM. Altogether, these data indicate that TEM 
preferentially infiltrate liver allografts, while CD8+ TEMRA largely remain in the circulation.
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Figure 3. CD8+ TEMRA are a minor T-cell population infiltrating liver allografts. Intrahepatic 
lymphocytes (IHLs) were isolated from explant liver allografts to study the subset composition 
of graft infiltrating T cells. CD8+ and CD4+ T-cell subsets of IHLs of explant allografts (n=10) were 
compared to those of paired PBMCs, and IHLs of healthy donor livers (n=9), and are shown (A) 
as representative FACS plots (PBMCs and paired explant IHLs) from one patient and (B) are 
summarized. (C) Ratios CD8+ TEM and TEMRA were also compared between groups. Large amounts 
of IHLs were isolated from two explant allografts and were co-cultured with donor and third-party 
splenocytes. Donor-specific and third party-reactive T cells were identified by CD137 upregulation. 
(D) Results are shown by FACS plots and percentages of CD137+ T cells for each subset are depicted 
in the plots for both allografts. *P<0.05, **P<0.01.
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CMV R-D+ status is associated with the protection against late acute rejection
To study whether the donor-specific T-cell hyporesponsiveness that we observed in CMV 
primary infection patients has any clinical impact, we performed a retrospective study 
on 639 patients that underwent LT in our center between 1992 and 2010 to investigate the 
impact of CMV infection on EAR and LAR. One, 3 or 6 months have been variably used 
in literature as the cut-off to define EAR and LAR21. The first episodes of CMV viremia 
were detected at median 35 days after LT, 92% of which were within the first 6 months 
(Table 1). Thus we choose 6 months as the cut-off to define LAR in order to focus on 
the effect of CMV infection on graft rejection and not the other way around. Of the 639 
patients, 144 (22.5%) developed EAR (median 9 days; range 2-166 days), and 41 (6.4%) 
developed LAR (median 487 days; range 186-6368 days) (Table 1).
EAR and LAR were set as separate endpoints for risk factor analysis. CMV serostatus 
was not associated with the cumulative incidence of EAR (P=0.77) (Figure 4A), while 
the incidence of LAR in R-D+ patients was lower than in R-D- patients (P=0.014) and 
R+ patients (P=0.017) (Figure 4B). In univariate Cox regression analysis, recipient age 
(P=0.007), recipient BMI (P=0.026), female donor (P=0.034), warm ischemia time 
(P<0.001), basiliximab induction (P<0.001), tacrolimus as CNI (P<0.001), and CMV 
viremia (P=0.008) were significantly associated with EAR (Supplemental Table 3). 
Meanwhile, CMV serostatus (P=0.015) was the only factor associated with LAR (Table 2).
Figure 4. CMV R-D+ status is associated with the protection against late acute rejection. Patients 
were grouped based on CMV serostatus before LT as follows: Group 1: R-D-; Group 2: R-D+; Group 
3: R+. The cumulative incidences of (A) early acute rejection (EAR) and (B) late acute rejection (LAR) 
were estimated using the Kaplan-Meier method and differences between curves were analyzed 
using the log-rank test. The number of patients at risk are depicted below the graphs.
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Table 2. Risk factor analysis for late acute rejection following liver transplantation
 Univariate analysis Multivariate analysis
Variable HR 95% CI P Value HR 95% CI P Value
Recipient age, year 0.99 (0.97-1.02) 0.455    
Recipient, female 1.29 (0.70-2.39) 0.416    
Recipient BMI, kg/m2 1.04 (0.97-1.12) 0.309    
Primary liver disease   0.189   0.217
   HBV/HCV (Ref) 1.00   1.00   
   AHF 1.45 (0.49-4.34)  1.75 (0.57-5.44)  
   HCC 0.29 (0.03-2.50)  0.35 (0.04-2.99)  
   PBC/PSC/AIH 1.54 (0.56-4.29)  1.90 (0.67-5.43)  
   Alcoholic cirrhosis 0.49 (0.10-2.54)  0.61 (0.12-3.16)  
   Cryptogenic cirrhosis 2.04 (0.59-7.07)  2.22 (0.63-7.87)  
   Others 0.81 (0.24-2.81)  1.05 (0.30-3.72)  
Donor age, year 0.99 (0.97-1.01) 0.239    
Donor, female 1.35 (0.72-2.51) 0.342    
DCD donor 1.43 (0.44-4.65) 0.575    
Cold ischemia time, 10 min 0.99 (0.97-1.01) 0.344    
Warm ischemia time, 10 min 1.01 (0.89-1.15) 0.877    
Re-LT 0.94 (0.33-2.63) 0.900    
Basiliximab induction 0.97 (0.51-1.85) 0.920    
Calcineurin inhibitor, Tacrolimus 0.63 (0.34-1.19) 0.154 0.69 (0.36-1.31) 0.258
Early acute rejection 0.90 (0.44-1.86) 0.781    
CMV serostatus   0.015   0.015
   R- D- (Ref) 1.00   1.00   
   R- D+ 0.18 (0.04-0.81)  0.18 (0.04-0.86)  
   R+ 0.87 (0.43-1.76)  0.99 (0.47-2.05)  
CMV viremia 0.87 (0.42-1.83) 0.711 1.10 (0.50-2.43) 0.813
Peak copy number during viremia 1.07 (0.55-2.09) 0.846
In the multivariate Cox regression analysis, recipient age (P=0.046, hazard ratio 
[HR]=0.99), female donor (P=0.020, HR=0.67), basiliximab induction (P=0.015, HR=0.59), 
tacrolimus as CNI (P<0.001, HR=0.47), and CMV viremia (P=0.018, HR=1.62) were 
considered as independent factors associated with EAR (Supplemental Table 3). In 
contrast, CMV serostatus was the only independent factor associated with LAR (P=0.015; 
HR for R-D+=0.18; HR for R+=0.99) (Table 2). CMV seroconversion and the use of CMV 
prophylaxis were not included in the analysis as they largely overlapped with R-D+ status, 
and yielded the same association as R-D+ status (data not shown). Altogether, these data 
indicate that CMV primary infection after LT protects patients against the occurrence of 
LAR, corroborating the ex vivo data on donor-specific T-cell hyporesponsiveness that we 
observed in CMV primary infection patients.
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CMV primary infection patients show the highest Vδ1/Vδ2 γδ T-cell ratio after LT
To further investigate whether patients with CMV primary infection show signs of 
tolerance, we measured peripheral Vδ1 and Vδ2 γδ T-cell subsets in patients at minimum 
6 months after LT, and calculated the Vδ1/Vδ2 γδ T-cell ratio, which has been shown to 
be associated with operational tolerance after LT16-18. CMV primary infection patients 
contained the highest percentage of Vδ1 γδ T cells within peripheral CD3+ cells, while 
CMV-negative patients contained the lowest (R-D- 0.73%, R-D+ 5.36%, R+ 2.29%; median 
values) (Figure 5A). In contrast, the percentages of Vδ2 γδ T cells were similar (R-D- 
0.56%, R-D+ 0.27%, R+ 0.39%; median values) (Figure 5B). As a result, patients with CMV 
primary infection showed higher Vδ1/Vδ2 γδ T-cell ratio than the other two groups (R-
D- 1.39, R-D+ 10.81, R+ 6.31; median values) (Figure 5C).
Figure 5. CMV primary infection patients show the highest peripheral Vδ1/ Vδ2 γδ T cell ratio 
after LT. Peripheral blood Vδ1 and Vδ2 γδ T-cell subsets were analyzed by flow cytometry in LT 
patients. The percentages of (A) Vδ1 and (B) Vδ2 γδ T cells within total CD3+ T cells, and (C) the 
subsequent Vδ1/ Vδ2 γδ T-cell ratio were compared between patients with different CMV status 
(R-D- n=20, R-D+ n=20, R+ n=27). Horizontal lines indicate median values. ***P<0.001.
DISCUSSION
Immune responses resulting from viral infections are proposed to promote allograft 
rejection and prevent the establishment of tolerance14. Cross-reactive viral-specific 
memory T cells are common in humans. Approximately 45% of viral-specific, including 
CMV-specific, T-cell clones are cross-reactive to at least one allogeneic HLA molecule15. 
Unexpectedly, and contrary to our initial hypothesis, we did not find higher frequencies 
of alloreactive T cells in either R+ patients or patients who developed CMV primary 
infection. In contrast, we found a robust donor-specific CD8+ T-cell hyporesponsiveness 
in patients with CMV primary infection. In accordance with the donor-specific 
hyporesponsiveness, retrospective analysis showed that LT patients with R-D+ serostatus 
had a significantly lower risk to develop LAR. Moreover, CMV primary infection patients 
showed the highest ratio of peripheral Vδ1/Vδ2 γδ T cells, which has shown to be 
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associated with operational tolerance after LT. This is the first study showing that CMV 
primary infection remarkably reduces donor-specific T-cell reactivity and is a protective 
factor against the occurrence of LAR, suggesting a prominent role for CMV infection in 
transplant tolerance to liver allografts in humans.
We first found that CMV-positivity, particularly CMV primary infection, is associated 
with the expansion of CD8+ effector memory T-cell subsets in peripheral blood after LT. 
Since TEM and TEMRA subsets can mount rapid effector responses upon allostimulation8, 
they are hypothesized to be detrimental to allografts22. Nonetheless we do not support 
a detrimental role of CD8+ TEMRA for LT patients, as our data suggest that CD8+ TEMRA 
rarely infiltrate liver allograft but largely remain in circulation. A recent study shows 
that increased numbers of circulating CD8+ TEMRA before kidney transplantation are 
associated with a reduced incidence of AR23. Similarly, few CD8+ TEMRA were found in 
rejecting kidney allografts24. However we cannot rule out the possibility that TEMRA may 
change their phenotype into TEM upon infiltration.
An intriguing question is how CMV infection induces donor-specific T-cell 
hyporesponsiveness. CMV infection is known to drive immunosenescence, which 
has been suggested to promote kidney allograft acceptance in elderly recipients25. 
Immunosenescence driven by CMV is manifested by inflation of CMV-specific effector 
memory T cells. It has been postulated that the massively expanded CMV-specific effector 
memory T-cell pool competes with newly generated T cells for niches and survival factors, 
and as a consequence T-cell diversity and responses to other pathogens are restricted26, 
27. Indeed both in humans and mice CMV infection causes impaired T-cell immunity to 
other pathogens28, 29, and CMV infection after organ transplantation is associated with 
a higher incidence of opportunistic infections30. This is supported by previous findings 
showing that high numbers of CMV-IE-1-specific memory T cells are associated with 
lower numbers of alloreactive T cells and improved renal allograft function after kidney 
transplantation31, and that high CMV-specific CD4+ T-cell responses correlate with 
protection from cardiac allograft rejection32. We hypothesize that the donor-specific T-cell 
hyporesponsiveness observed in CMV primary infection patients might be related to the 
multifaceted immune evasion capacity used by CMV to establish latency, in particular its 
capacity to modulate antigen presentation33. Alexander et al. reported the development of 
hematopoietic chimerism and donor-specific hyporesponsiveness in a patient with severe 
CMV disease early after LT34. We also reported three cases of long-term hematopoietic 
chimerism within liver allografts35, and interestingly all three patients were R+D+ with 
detection of viremia in two of them (unpublished data). The immune-modifying effects 
of CMV may have contributed to the engraftment of donor cells, leading to subsequent 
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donor-specific hyporesponsiveness. Moreover, dendritic cells present in liver graft 
are the main instigators of T-cell immunity against the graft36, 37, but CMV infected 
dendritic cells are impaired in their ability to stimulate allogeneic lymphocytes38. The 
immunomodulatory effect of primary infection has also been suggested, shown by 
higher bacterial and fungal infection-related mortality in R-D+ patients after allogeneic 
hematopoietic stem cell transplantation, which is independent from CMV-replication, 
diseases and treatments39. We hypothesize that the rapidly inflated anti-CMV immunity 
following primary infection in an immunocompromised environment, may contribute 
to its immunomodulatory effect. The exact mechanisms attributing to this phenomenon 
remain to be investigated.
In the retrospective analysis, we found that CMV viremia was positively associated with 
EAR. However, EAR occurred on median 9 days after LT, preceding the detection of 
CMV viremia in general. This finding is in line with the hypothesis that alloimmune 
stimulation triggers CMV-replication from latency40. Heavy immunosuppression 
during EAR treatment may also increase the risk of CMV viremia. In the multivariate 
analysis older patient age decreased the risk of EAR, which could be explained by the 
senescence of immune system25, 41. The use of basiliximab induction and tacrolimus both 
decreased the risk of EAR, which is in line with previous findings42, 43. Patients with 
female donors had a decreased incidence of EAR. However this could be a finding by 
chance, as previous studies showed that donor gender does not influence AR incidences. 
In contrast, we found that CMV R-D+ serostatus was an independent protective factor 
against LAR. Despite antiviral prophylaxis, the rate of seroconversion in R-D+ patients 
was 86%, in agreement with previous study44, indicating that almost all R-D+ patients 
get primarily infected eventually. LAR was not associated with viremia or peak CMV-
DNA copy number, suggesting that the lower incidence of LAR was not due to CMV-
replication as such. We cannot exclude an effect of prophylaxis, however it is unlikely 
since higher dosages of valGCV or GCV were administrated in case of CMV viremia, 
but viremia was not associated with lower incidence of LAR. As there is no indication 
that in R-D- or R+ patients immunosuppression was prescribed differently hence affecting 
the occurrence of LAR, the lower incidence of LAR is probably a reflection of the pro-
tolerogeneic status of the patients with CMV primary infection. The discrepancy of EAR 
and LAR in relation to CMV infection indicates that CMV during active replication or in 
a quiescent state may have differential effects on graft rejection. Careful distinguishing 
CMV primary infection from non-primary infection, and between EAR and LAR in our 
analysis, may be possible reasons why this association has never been reported before.
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Immunosuppression can be completely discontinued in more than 40% of stable, 
adult LT patients45, 46. Whether CMV infection plays a role in achieving operational 
tolerance has yet not been investigated. However, studies sought to identify biomarkers 
for operational tolerance have found expansion of peripheral Vδ1 γδ T cells, and an 
increased Vδ1/Vδ2 ratio in tolerant LT patients. Vδ1/Vδ2 ratio has even been used as 
a surrogate marker to predict operational tolerance16-18. Interestingly, expansion of Vδ1 
γδ T cells is also a feature that is observed upon CMV infection47, 48, arguing in favour 
of a potential association between CMV infection and liver graft tolerance. In addition 
to previous findings, we found that patients with CMV primary infection showed the 
highest Vδ1/Vδ2 ratio. This finding corroborates the lower incidence of LAR in our 
retrospective analysis and suggests that these patients may have the highest chance to 
achieve operational tolerance after immunosuppression discontinuance. Since we do not 
minimize immunosuppression routinely, we are not able to demonstrate a direct link 
between CMV infection and operational tolerance.
There are limitations of this study that need to be acknowledged. First, we focused on 
allogeneic T-cell responses in LT patients with different CMV status, however anti-CMV 
responses were not studied, which could help understanding the interplay between 
allogeneic and anti-viral immune responses31. Second, we were not able to demonstrate 
the direct link between the donor-specific T-cell hyporesponsiveness and the lower 
incidence of LAR in primary infection patients, as the overall incidence of LAR was 
low and we did not have enough PBMC samples available from LAR patients. A case-
control study comparing LAR cases to patients with stable graft function, or a large-scale 
prospective study with long follow-up, may reveal the direct relationship between T-cell 
responses and LAR.
To conclude, the primary findings of this study are that patients with CMV primary 
infection after LT show donor-specific CD8+ T-cell hyporesponsiveness, are protected 
from the occurrence of LAR, and show signs of operational tolerance. Further 
investigation into the role of CMV infection in the development of operational tolerance 
is necessary. Since CMV status is easily measured without additional effects or costs, this 
parameter can be taken into account by physicians when selecting patients for tapering 
or withdrawing immunosuppressive therapy in LT patients. Altogether, for the first 
time to our knowledge, we show evidences that CMV primary infection may promote 
immunological tolerance towards allogeneic liver graft in humans.
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SUPPLEMENTAL MATERIALS AND METHODS
Immunosuppression
The standard immunosuppressive therapy in our center consisted of prednisone, 
cyclosporine or tacrolimus, with or without azathioprine or mycophenolate mofetil 
(MMF). Since 1998, basiliximab was introduced as induction immunosuppression and 
was used in 58.7% of all patients in the retrospective cohort (Table 1), and meanwhile 
the use of cyclosporine was gradually replaced by tacrolimus. Tacrolimus was initiated 
within the first 5 days after transplantation in a dose of 1-2 mg/kg body weight/day. 
The target trough level was 10-15 ng/ml in the first month, 8-12 ng/ml between 1 to 6 
months, 5-10 ng/ml between 6 to 12 months, and 4-8 ng/ml after 1 year. Cyclosporine 
was initiated within 24 hours post-reperfusion in a dose of 10-15 mg/kg body weight/
day, and the dosage was adjusted to trough levels according to a range from 200-400 ng/
mL during the first 3 months and thereafter 100-200 ng/mL. Acute rejection episodes 
were treated with high dose of methylprednisolone intravenously, and standard levels of 
immunosuppression were applied again after the rejection resolved. Immunosuppressive 
regimens were similar in patients from whom blood samples were collected, consisting 
of corticosteroids, MMF, tacrolimus and induction with basiliximab (Supplemental Table 
1).
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll gradient 
centrifugation, and were cryopreserved for phenotyping and functional experiments. 
To isolate intrahepatic lymphocytes (IHLs), biopsies of explant allografts and pre-
LT healthy donor livers were collected in University of Wisconsin (UW) preservation 
solution. Fresh tissue was cut into small pieces and digested with 0.5 mg/mL collagenase 
IV (Sigma-Aldrich, St. Louis, MO) and 0.1 mg/mL DNase I (Roche, Indianapolis, IN) for 
30 minutes at 37°C. Cell suspensions were filtered through 70µm cell strainers and IHLs 
were obtained by Ficoll density gradient centrifugation. Phenotyping and functional 
experiments were performed immediately after IHLs isolation. Human splenocytes were 
isolated from splenic tissue derived from liver donors. Splenic samples were cut into 
small pieces and forced through 74 μm netwell filters (Costar, Corning International, 
NY) to obtain single cell suspensions. Mononuclear cells were isolated by standard Ficoll 
gradient centrifugation, and were cryopreserved for future experiments. 
Flow cytometry and antibodies
The following antibodies were used: CD3-HorizonV500, CD4-APC-H7, CD8-Pacific Blue 
(BD Biosciences, San Diego, CA); TCR-Vδ1-FITC (Thermo Scientific, Waltham, MA); 
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CD3-Pacific Blue, TCR-Vδ2-PE (BD Pharmingen, Erembodegem, Belgium); CD45RA-
PE-Vio770 (Miltenyi Biotec, Bergisch Gladbach, Germany); CCR7-FITC (R&D System, 
Minneapolis, MN); CD45RO-PerCP-Cy5.5, CD137-APC (Biolegend, San Diego, CA); 
CD3-PE-Cy7, TCR-αβ-APC (eBioscience, San Diego, CA); CD3-FITC (Beckman Coulter, 
Marseille, France). Non-viable cells were excluded using 7-AAD (BD Biosciences, San 
Diego, CA) or LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Carlsbad, CA). 
Flow cytometry was performed on FACSCanto II flow cytometer (BD Biosciences, San 
Diego, CA). Data were analyzed with BD FACSDiva software version 6.1.1.
Quantification of alloreactive T-cell frequencies
Alloreactive T cells were analyzed by determination of activation-induced CD137 
expression on T cells, as previously described with minor modifications1. In brief: 2.5x106 
PBMCs or intra-hepatic lymphocytes (IHLs) were co-cultured with donor or third-party 
(mismatched at HLA-A, B and DR loci with both donor and recipient) splenocytes at a 1:1 
ratio in polypropylene tubes (BD Pharmingen, Erembodegem, Belgium) in duplicate, in 
1 mL IMDM (Lonza, Breda, The Netherlands) supplemented with 10% heat-inactivated 
human serum and 1% Penicilline/Streptomycine. Co-stimulaton was provided by 
addition of 1 μg/mL anti-CD49d (BD Pharmingen, Erembodegem, Belgium) and 1 μg/
mL anti-CD28 (Serotec, Kidlington, Oxford, UK). Prior to co-culture, the splenocytes were 
labeled with PKH26 (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s 
instructions, to discriminate between stimulator splenocytes and responder PBMCs or 
IHLs during FACS analysis. As a control, cells were cultured in the presence of anti-
CD49d and anti-CD28 mAb only, without allogeneic stimulation. After 24 hours, cells 
were harvested for FACS analysis. Alloreactive CD4+ and CD8+ T cells were identified by 
the upregulation of CD137 (Supplemental Figure 1). Background expression of CD137 
in conditions without allogeneic stimulation was subtracted during analysis. This assay 
has been used in the identification and isolation of viral, tumor, and allospecific T cells 
regardless of their differentiation stage or cytokine production profile1, 2.
CMV diagnostics and treatment strategies
CMV-DNA PCR measurements were only performed on a weekly basis in high risk 
patients (R-D+) until 90 days post-LT. For all other patients, PCR was performed in case 
of clinical suspicion of CMV infection. Due to the non-protocolized CMV-DNA PCR 
monitoring, the incidence of CMV reactivation/reinfection in R+ patients was probably 
underestimated. Low-dose (450 mg once daily) valganciclovir (valGCV) prophylaxis 
was administered to high risk patients, starting at day 7 and continuing up to day 90 
post-LT. A therapeutic GCV-based regime, either intravenous GCV 5 mg/kg twice daily 
or valGCV 900 mg twice daily, was given to patients with positive PCR results. The 
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regimen was given for 10 to 14 days, and PCR results were negative before withdrawing 
GCV therapy. Adjustments of immunosuppressive therapy were made if necessary, and 
normal levels of immunosuppression were applied again after the clearance of viremia.
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Supplemental Table 1. Characteristics of patients included for peripheral blood T-cell analysis
Total: 75 patients R- D- (n=20) R- D+ (n=20) R+ (n=35) P value
Recipient     
   Age (median, range), years 54 (33-65) 48 (21-64) 54 (19-68) 0.190
   Sex, female 7 (35%) 10 (50%) 14 (40%) 0.614
Donor     
   Age (median, range), years 48 (16-64) 58 (22-73) 51 (13-78) 0.118
   Sex, female 8 (40%) 13 (65%) 15 (43%) 0.202
Primary liver disease*    0.831
   AHF 1 (5%) 4 (20%) 4 (11%)  
   HBV/HCV 1 (5%) 1 (5%) 3 (9%)  
   HCC 3 (15%) 3 (15%) 9 (26%)  
   Metabolic diseases 2 (10%) 1 (5%) 3 (9%)  
   PSC/PBC/AIH 9 (45%) 6 (30%) 8 (23%)  
   other 4 (20%) 5 (25%) 8 (23%)  
Initial immunosuppressive regimen     
   Basiliximab 16 (80%) 19 (95%) 29 (83%) 0.347
   Tacrolimus 20 (100%) 20 (100%) 33 (94%) 0.309
   Mycophenolate mofetyl 16 (80%) 13 (65%) 25 (71%) 0.569
Early acute rejection 4 (20%) 3 (15%) 6 (17%) 0.916
Late acute rejection 1 (5%) 1 (5%) 1 (3%) 0.894
CMV viremia 0 (0%) 17 (85%) 10 (29%) 0.000
Timing of viremia (median, range), days - 79 (23-288) 27 (12-60) 0.003
Peak CMV-DNA copy number, copies/mL** - 2.9 (1.9-5.0) 2.5 (2.1-5.5) 0.628
CMV IgG seroconversion 0 (0%) 20 (100%) - 0.000
*AHF, acute hepatic failure; HCC, hepatocellular carcinoma; HBV, hepatitis B virus infection; HCV, 
hepatitis C virus infection; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; 
AIH, autoimmune hepatitis.
**Log10 transformed
Supplemental Table 2. Characteristics of patients studied for liver allograft infiltrating T cells 
Patient no. Age Sex Time since first LT Re-LT indication RAI score CMV status
1 66 M 7 months Hepatic artery thrombosis 
and HCV recurrence 
7 R+ D-
2 40 M 6 years PSC recurrence 4 R- D-
3 67 M 3 years Chronic rejection 3-4 R+ D+
4 59 M 8 years HCV recurrence - R+ D-
5* 56 M 1 year Chronic rejection - R+ D+
6 56 F 1 year Ischemic cholangiopathy - R- D+
7 38 M 24 years Chronic rejection 4 R- D-
8* 29 M 6 years Chronic rejection - R+ D+
9 56 M 2 years Chronic rejection 3-4 R+ D-
10 50 M 2 years PSC recurrence - R+ D-
* Large amount of IHLs were isolated for functional experiments
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Supplemental Table 3. Risk factor analysis for early acute rejection following liver transplantation
 Univariate analysis Multivariate analysis
Variable HR 95% CI P Value HR 95% CI P Value
Recipient age, year 0.98 (0.97-0.99) 0.007 0.99 (0.97-1.00) 0.046
Recipient, female 1.26 (0.91-1.76) 0.164 1.14 (0.81-1.60) 0.448
Recipient BMI, kg/m2 0.96 (0.92-1.00) 0.026 0.98 (0.94-1.02) 0.375
Primary liver disease   0.415    
   HBV/HCV (Ref) 1.00      
   AHF 1.40 (0.78-2.53)     
   HCC 0.95 (0.46-1.96)     
   PBC/PSC/AIH 1.27 (0.72-2.24)     
   Alcoholic cirrhosis 0.82 (0.39-1.72)     
   Cryptogenic cirrhosis 0.64 (0.25-1.63)     
   Others 1.10 (0.60-2.03)     
Donor age, year 0.99 (0.98-1.00) 0.192 1.00 (0.99-1.01) 0.904
Donor, female 0.70 (0.50-0.98) 0.034 0.67 (0.47-0.94) 0.020
DCD donor 0.50 (0.22-1.14) 0.065 0.91 (0.39-2.11) 0.820
Cold ischemia time, 10 min 1.01 (1.00-1.02) 0.067 1.00 (0.99-1.01) 0.354
Warm ischemia time, 10 min 1.19 (1.12-1.26) 0.000 1.05 (0.97-1.15) 0.249
Re-LT 0.85 (0.50-1.45) 0.535    
Basiliximab induction 0.39 (0.28-0.55) 0.000 0.59 (0.39-0.90) 0.015
Calcineurin inhibitor, Tacrolimus 0.36 (0.26-0.50) 0.000 0.47 (0.32-0.71) 0.000
CMV serostatus   0.773   0.856
   R-/D- (Ref) 1.00   1.00   
   R-/D+ 1.20 (0.71-2.04)  0.92 (0.51-1.67)  
   R+ 1.14 (0.74-1.76)  1.05 (0.66-1.66)  
CMV viremia 1.62 (1.14-2.28) 0.008 1.62 (1.09-2.39) 0.018
Peak CMV-DNA copy number 1.17 (0.85-1.63) 0.352
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Supplemental Figure 1. Determination of allogeneic activation-induced CD137 expression on 
CD4+ and CD8+ T cells to study the frequencies and subset composition of alloreactive T cells by 
flow cytometry. (A) AQUA staining was used to exclude dead cells, and stimulatory splenocytes 
were labeled by PKH26 and were excluded from the analysis. (B) Alloreactive CD4+ and CD8+ T 
cells were identified by the up-regulation of CD137 after 24 hours of co-culture. Subset composition 
of alloreactive T cells was analyzed by measuring the expression of CCR7 and CD45RO on CD137+ 
T cells, and was defined as follows: TNaive (CCR7+CD45RO-), TCM (CCR7+CD45RO+), TEM (CCR7-
CD45RO+), and TEMRA (CCR7-CD45RO-). All events in culture were recorded to ensure the detection 
of alloreactive T cells. Background expression of CD137 in conditions without allogeneic stimulation 
was subtracted during analysis.
Supplemental Figure 2. Comparison of CD8+ TEMRA changes in CMV-positive patients with or 
without proven viremia. Viremia was detected in 16 of 27 CMV-positive patients (R-D+ and R+). 
We compared the percentages of CD8+ TEMRA before (Pre), at 1 month (1M) and at 6 months (6M) 
after LT (one-way Friedman test) in both groups. Horizontal lines indicate median values. *P<0.05, 
**P<0.01, ***P<0.001.
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Supplemental Figure 3. Changes in absolute numbers of CD8+ T-cell subsets after LT in relation 
to CMV status. Absolute numbers of CD8+ T-cell subsets were measured longitudinally in 11 
patients (R-D- n=3, R-D+ n=4, R+ n=4) before (Pre), at 1 month (1M) and at 6 months (6M) after LT. 
Black dots represent patients without detected viremia, and black triangles represent patients with 
detected CMV viremia after LT. Absolute numbers are shown on the Y-axis. 
Supplemental Figure 4. Numbers of HLA-mismatches between donor-recipient and third party-
recipient in ex vivo allogeneic stimulations. The total numbers of HLA-mismatches at HLA-A, 
B, DR loci between donor-recipient and third party-recipient in the ex vivo allogeneic stimulation 
experiments are shown as mean with standard deviation, and were compared between the three 
experimental groups. No statistically significant difference was observed.
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Supplemental Figure 5. Alloreactive CD8+ T-cell frequencies in patients with proven viremia. 
The frequencies of donor-reactive and third party-reactive CD8+ T cells were compared between 
R-D+ patients with viremia and R+ patients with viremia. Horizontal lines indicate median values. 
*P<0.05, **P<0.01.
Supplemental Figure 6. Correlation of alloreactive T-cell frequencies with CMV viremia level. In 
patients with proven viremia, the correlation between alloreactive T-cell frequencies and the peak 
CMV-DNA copy number during viremia was analyzed by linear regression. The CMV-DNA copy 
number was log10-transformed.
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Supplemental Figure 7. Comparison of CD8+ T-cell subsets in explant allografts with or without 
acute rejection activity. Five explant allografts presented acute rejection activity (AR, versus no-
AR). (A) Percentages of intragraft CD8+ TEM, TEMRA, and (B) the subsequent ratio were compared 
(Mann-Whitney U test). Horizontal lines indicate median values. 
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ABSTRACT
Chronic presence of viral antigens can induce T-cell exhaustion, characterized by 
upregulation of co-inhibitory receptors and loss of T-cell function. We studied whether 
a similar phenomenon occurs after liver transplantation (LTx), when there is continuous 
exposure to allo-antigen. Expression of co-inhibitory receptors on circulating CD4+ and 
CD8+ T cells was longitudinally analyzed in 19 patients until 6 months after LTx, and 
cross-sectionally in 38 patients late (1-12 years) after LTx. Expression of the co-inhibitory 
receptors CD160 and CD244 on circulating CD8+ T cells was already 6 months after LTx 
higher than pre-LTx, and the elevated expression was sustained late after LTx, with 
CD244 showing the most prominent increase. The strongest upregulation of CD244 on 
circulating CD8+ T cells was observed in patients who experienced cytomegalovirus 
(CMV) infection after LTx. CMV infection was also associated with reduced CD8+ T-cell 
proliferation and cytotoxic degranulation in response to allo-antigen late after LTx. 
Purified CD244+ CD8+ T cells of LTx patients showed lower proliferative responses 
to allo-antigen as well as to polyclonal stimulation than their CD244- counterparts. In 
addition, the CD244+ CD8+ T-cell population contained the majority of CMV-peptide-
loaded MHC class I tetramer-binding cells. In conclusion, CMV infection after LTx, rather 
than persistence of allo-antigen, induces accumulation of dysfunctional CD8+CD244+ T 
cells in the circulation which persist on long-term, resulting in reduced frequencies of 
circulating allo-reactive CD8+ T cells. These results suggest that CMV infection restrains 
CD8+ T-cell allo-responses after LTx. 
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INTRODUCTION
After liver transplantation (LTx), most patients need lifelong immunosuppression 
to prevent rejection of the allograft, but some patients develop spontaneously 
immunological tolerance to their liver graft and can be completely withdrawn from 
all immunosuppression1. This phenomenon occurs more frequently after LTx than in 
any other organ transplant setting2, suggesting that the immunological alloresponse is 
skewed towards tolerance. Allograft rejection is mainly mediated by T cells of the recipient 
that respond to allogeneic donor antigens3. In the transplantation setting, activation of 
allogeneic T cells via their T-cell receptor (TCR) is triggered by specific recognition of 
donor-derived allo-antigenic peptides presented by recipient major histocompatibility 
complex (MHC) molecules or by direct interaction of the TCR with allogeneic MHC 
molecules. However, T cells can also express co-stimulatory and co-inhibitory receptors 
that affect outcome of T-cell responses4. Hence, these receptors might also influence the 
outcome of T-cell responses towards the allograft. 
Expression of co-inhibitory receptors is upregulated on T cells in patients with chronic 
viral infections, such as hepatitis C virus (HCV) and HIV, and in patients with cancer5-12. 
High expression of co-inhibitory receptors is associated with T-cell dysfunction, or 
“exhaustion”, and in these patients virus-specific or tumor-specific T-cell responses are 
therefore impaired. T-cell exhaustion can be defined as a state of antigen-specific T-cell 
dysfunction in response to chronic persistence of high antigenic load5. Exhausted T cells 
have poor proliferative and effector function, show sustained expression of co-inhibitory 
receptors and their transcriptional state is distinct from that of functional effector or 
memory T cells5. Several co-inhibitory receptors have been described to be important 
in inhibiting T-cell responses, among which the most well-studied are: Programmed 
Death 1 (PD1), Lymphocyte-Activation Gene 3 (LAG3), T cell immunoglobulin mucin 
3 (TIM3), CD160 and CD2445, 6. PD1 has two ligands: PD-L1 and PD-L27, 13. PD-L1 is 
expressed on both hematopoietic cells (mainly on dendritic cells (DC) and macrophages) 
and non-hematopoietic cells (parenchymal cells of many organs including liver; and 
endothelial cells)7, 14. PD-L2 expression is restricted to DC and macrophages. Binding of 
PD1 to its ligand(s) negatively regulates T-cell responses13, 15. LAG3 is a protein closely 
related to CD4, and mediates negative regulation of T-cell functions through interactions 
with its ligand MHC class II to which it binds with higher affinity than CD416, 17. TIM3 
inhibits CD8+ T-cell responses by interaction with its ligand galectin-98, 9. CD160 is a 
glycosylphosphatidylinositol-anchored receptor that inhibits T-cell responses upon 
binding to its ligand herpes virus entry mediator (HVEM) that is expressed on both 
hematopoietic and non-hematopoietic cells (parenchymal cells)18. CD244, also called 2B4, 
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can mediate both activating and inhibitory signals upon binding with its ligand CD48. 
High levels of CD244 expression on T cells were found to be associated with inhibitory 
receptor function10, 14, 19.
After organ transplantation, numbers of circulating T cells that react to donor allo-
antigen decrease over time in a majority of patients20-22. The mechanism underlying this 
phenomenon is as yet unclear. Whether chronic stimulation by the persistence of a high 
allo-antigenic load induces upregulation of co-inhibitory receptors and exhaustion of 
donor-specific T cells, as observed during chronic viral infections, is unknown. However, 
various experimental animal studies have shown enhanced rejection and/or decreased 
graft survival after blockade of co-inhibitory receptors in organ transplanted mice. 
This implies that co-inhibitory receptors are involved in suppressing allograft rejection 
in mice23-26. However, the role of T-cell exhaustion and co-inhibitory receptor-ligand 
interactions in human solid organ transplantation has not yet been widely studied25. 
The aim of this study was to determine whether the expression of co-inhibitory receptors 
on circulating T cells is upregulated after LTx in humans, to analyze which clinical 
factors influence such upregulation, and to assess whether co-inhibitory receptors 
impair allogeneic T-cell responses after LTx. We hypothesized that long-term persistence 
of a high load of allo-antigens after LTx may induce exhaustion of allogeneic T-cells, 
characterized by upregulation of co-inhibitory receptors and hyporesponsiveness of 
CD8+ T cells to allo-antigens. 
MATERIALS AND METHODS
Study design and patients
Heparinized blood was collected at 1 and 6 months after transplantation from 19 
primary liver transplant recipients who were transplanted in the Erasmus Medical 
Centre Rotterdam (The Netherlands) (early post-LTx cohort). In addition, blood was 
collected during a single regular visit at the outpatient clinic from 38 stable primary 
liver transplant recipients 1 to 12 years after transplantation in the Erasmus Medical 
Centre Rotterdam (The Netherlands) (late post-LTx cohort). Multi-organ transplantation 
patients were excluded. The occurrence of CMV infection (either primary infection or 
reactivation) after transplantation was determined either by CMV DNA polymerase 
chain reaction (PCR) > 50 copies/ml or by CMV IgG seroconversion. All patients gave 
informed consent, and the study was approved by the Medical Ethics Committee of 
the Erasmus MC. Nineteen clinically healthy blood bank donors were used as healthy 
controls and were age-matched with the late post-LTx cohort.
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Cell culture
Peripheral blood mononuclear cells (PBMC) from patients and healthy individuals were 
isolated using Ficoll Hypaque density gradient centrifugation. From the same patients, 
cryopreserved PBMC collected before LTx (pre-LTx), that were available in our bio bank, 
were used for baseline measurements. Cryopreserved splenocytes, isolated according 
to standard procedures 27 from splenic tissue of liver transplant donors, were available 
in our bio bank as well. CD40-activated B cells were expanded from donor splenocytes, 
as described previously 27, and used as stimulator cells in allogeneic T-cell stimulation 
assays. Only B cells containing <1% CD3+ T cells were used. PBMC and expanded B cells 
were cryopreserved at -135°C until further use.
Flow cytometry 
Flow cytometry was performed to determine T-cell subsets and co-inhibitory receptor 
expression. For analysis of CD4+ and CD8+ T cells, isolated PBMC were stained with anti-
CD3-horizonV500 (UCHT1, BD Biosciences, Erembodegem, Belgium), anti-CD4-APC-H7 
(SK3, BD Biosciences), and anti-CD8-efluor450 (RPA-T8, eBioscience, Vienna, Austria). 
To distinguish naive and memory T-cell subsets, cells were stained with anti-CCR7-
FITC (150503, R&D systems, Abingdon, United Kingdom) and anti-CD45RO-PerCP-
Cy5.5 (UCHL1, Biolegend, London, United Kingdom). Naive T cells (Tn) were defined 
as CD45RO-CCR7+ T cells; central memory T cells (Tcm) as CD45RO+CCR7+; effector 
memory T cells (Tem) as CD45RO+CCR7- and terminally differentiated T cells (Temra) 
as CD45RO-CCR7- 28. Surface expression of co-inhibitory receptors was determined by 
staining cells with anti-CD279(PD1)-PECy7 (J105, eBioscience), anti-CD223(LAG3)-PE 
(polyclonal, R&D systems), anti-CD160-PE (688327, R&D systems) and anti-CD244-
APC (eBioDM244, eBioscience). Flow cytometry was performed using a FACS Canto II 
(BD Biosciences). Gates for PD1 expression were set using an isotype-matched control 
antibody and gates for LAG3, CD160 and CD244 expression were set on distinct positive 
populations. For analysis FACS Diva software was used (BD Biosciences).
Allogeneic T-cell stimulation using PBMC 
To quantify allo-reactive T-cell responses, PBMC were labeled with 0.5 µM CFSE 
(Invitrogen, Paisley, United Kingdom) and 1*105 recipient PBMC were stimulated with 
2*105 irradiated (30 Gy) donor-derived or third party-derived CD40-B cells. Third party 
CD40-B cells were expanded from splenocytes of an individual having the same number 
of HLA mismatches with the patient as the number of mismatches between patient and 
donor, but completely mismatched with the donor on HLA-A, B, and DR 27. Co-cultures 
were performed in 96-wells U-bottom plates in a final volume of 200 μl B-cell medium 
(IMDM + 10% human serum + 1% Penicillin/Streptomycin (Gibco) + 1% Insulin/
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 3
56
Transferrin/Selenium (Gibco)) 27. In addition, to determine responses to polyclonal 
stimulation, PBMC were stimulated with PHA (5μg/ml, Murex, Paris, France). Each 
assay was performed in duplicate. Flow cytometric analysis was performed after 5 days 
of culture at 37°C and 5% CO2. Cells were washed with PBS (Lonza) and staining for cell 
viability was performed using LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen), 
according to the manufacturer’s protocol. Cells were then stained with anti-CD3-PerCP-
Cy5.5 (UCHT1, BD Biosciences), anti-CD4-APC-H7 (SK3, BD Biosciences), anti-CD8-
efluor450 (RPA-T8, eBioscience) to distinguish T cells, and anti-CD19-horizonV500 
(HIB19, BD Biosciences) to exclude B cells. Cytotoxic degranulation was detected using 
CD107a-APC (eBioscience), added during the last 15 hours of the co-cultures. Cells were 
analyzed for proliferation using CFSE-dilution patterns, and for phenotype on a BD 
FACS Canto II Flow cytometer (BD Biosciences, San Jose, CA). For analysis of phenotypic 
markers we used FACS Diva software (BD Biosciences). Precursor frequencies (PF), 
which is the proportion of the cells that respond to the stimulus, of allo-reactive CD4+ 
and CD8+ T cells were calculated using ModFit LT® software (Verity Software House, 
USA), as previously described 27. From duplicate assays, average PF were calculated. 
Allogeneic T-cell stimulations of sorted T cells
To compare the proliferative capacities of CD8+CD244+ and CD8+CD244- T cells, post-LTx 
PBMC of patients of the late cohort were thawed and labeled with 0.5 µM CFSE. CFSE-
labeled PBMC were stained with anti-CD3-PerCP-Cy5.5 (UCHT1, BD Biosciences), anti-
CD4-APC-H7 (SK3, BD Biosciences), anti-CD8-efluor450 (RPA-T8, eBioscience) and anti-
CD244-APC (eBioDM244, eBioscience), and CD8+CD244+, CD8+CD244-, and CD4+ T cells 
were purified by flowcytometric sorting, using a FacsAria Cell Sorter (BD Biosciences). 
Only cells with purity >95% were used. Purified CD8+CD244+ or CD8+CD244- T cells 
(2*104) together with purified autologous CD4+ T cells (2*104) were stimulated with 
1.6*105 irradiated (30 Gy) donor CD40-B cells or third party CD40-B cells, as described 
above. To study the role of co-inhibitory receptor-ligand interactions in allogeneic T-cell 
responses, ligands of co-inhibitory receptors were blocked by addition of neutralizing 
anti-CD270 (HVEM/TNFRSF14) (Clone 94801, R&D systems 29), or anti-CD48 (eBio156-
4H9, eBioscience 10, 11) antibodies, either alone or in combination to selected allogeneic 
T-cells stimulations. After 5 days of culturing, cells were stained and ModFit analyses 
were performed as described above. 
Determination of CMV-specific T cells
To determine frequencies of CMV-specific CD8+ T cells in PBMC and to assess whether 
these cells expressed CD244, 1*106 PBMC were stained with a mixture of HLA-A*01:01, 
A*02:01, A*11:01, A*24:02, B*07:02, B*08:01, and B*35:01 MHC class I tetramers loaded 
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with Pp50-derived, Pp65-derived and IE-derived peptides (Department of Hematology, 
Leiden University Medical Center, The Netherlands), depending on the HLA-types 
of the patient. The following peptides were used: Pp50: VTEHDTLLY (HLA-A0101); 
Pp65: YSEHPTFTSQY (HLA-A0101), NLVPMVATV (HLA-A0201), ATVQGQNLK 
(HLA-A1101), AYAQKIFKIL (HLA-A2402), RPHERNGFTVL (HLA-B0702), 
TPRVTGGGAM (HLA-B0702), and IPSINVHHY (HLA-B3501); IE1: QIKVRVDMV 
(HLA-B0801) and ELRRKMMYM (HLA-B0801). In addition, cells were stained with anti-
CD4-PerCP (clone Leu3A SK7, BD Biosciences), anti-CD8-Pacific Blue (clone RPA-T8, 
BD Biosciences) and anti-CD244-APC (eBioDM244, eBioscience). Flow cytometry was 
performed using a LSRII (BD Bioscience) and data were analyzed using FACS Diva 
software. 
Statistical analysis
All data are presented as means + SEM. All data sets were tested for normal Gaussian 
distribution using the Shapiro-Wilk normality test. Significance of differences between 
paired observations was tested using the paired t-test for normally distributed data or 
the Wilcoxon signed rank test for non-normally distributed data. Differences between 
unrelated groups were tested using the Mann-Whitney U test. Statistical analyses were 
performed using GraphPad Prism (Version 5.01, GraphPad Software Inc, San Diego, 
CA). Multivariate analysis was performed using linear regression in SPSS for Windows 
(version 21.0 software package). A p-value <0.05 was considered statistically significant.
RESULTS
Rapid and sustained increase of CD244 and CD160 expression on circulating T cells 
after LTx
To investigate whether expression of co-inhibitory receptors on T cells changed after LTx, 
we first analyzed the longitudinal course of the expression of 5 well-known co-inhibitory 
receptors, namely PD1, LAG3, TIM3, CD160 and CD244 5, on circulating CD4+ and CD8+ 
T cells in 19 patients during the first 6 months after LTx. Patient characteristics are 
depicted in Table I and described in Materials and Methods. Because TIM3 was hardly 
expressed on T cells in any of the individuals, we excluded TIM3 from further analyses 
(data not shown). Representative FACS plots are shown in Figure 1A.
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Table 1. Demographic and clinical characteristics of patients included in the early post-LTx and 
late post-LTx cohorts
Already 1 month after LTx a slight rise in expression of PD1 on CD4+ T cells and CD244 
on CD8+ T cells was observed (Figure 1B). At 6 months post-LTx, expression of PD1 on 
CD4+ T cells had returned to baseline level, while CD244 expression on CD8+ T cells 
was further increased. In addition, expression of CD244 on CD4+ T cells and of CD160 
on CD8+ T cells were significantly increased at 6 months post-LTx. Longitudinal LAG3 
expression levels tended to rise at 1 month post-LTx on both CD4+ (p=0.145) and CD8+ 
(p=0.138) T cells, but at 6 months post-LTx returned to levels similar to pre-LTx (Figure 
1B). 
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Figure 1 
Figure 1 Expression of co-inhibitory receptors on circulating T cells after LTx. (A) Representative 
FACS plots showing analysis of co-inhibitory receptors on CD4+ and CD8+ T cells (B) Expression of 
co-inhibitory receptors on circulating CD4+ and CD8+ T cells of 19 liver transplant recipients before 
(pre-LTx) and early (1-6 months) post-LTx. (C) Expression of co-inhibitory receptors on circulating 
CD4+ and CD8+ T cells of healthy controls (HC) and 38 liver transplant recipients before (pre-LTx) 
and 1-12 years post-LTx. (D) Representative FACS plot showing co-expression of CD244 and CD160 
on circulating CD8+ T cells (E) Co-expression of CD244 and CD160 on circulating CD8+ T cells in 
patients late after LTx (n=25). Each dot represents 1 patient, and lines indicate mean with standard 
error of the mean. *p<0.05, **p<0.005, ***p<0.0005
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To establish whether the changes observed in the first 6 months after LTx were sustained 
later after LTx, we assessed co-inhibitory receptor expression on circulating T cells in 
blood samples collected from 38 patients 1 to 12 years after LTx and compared it with 
expression before LTx. Patient characteristics are depicted in Table I. We found no 
significant differences in PD1 and LAG3 expression on both CD4+ and CD8+ T cells 
between pre-LTx and post-LTX samples. However, CD160 and CD244 expression were 
increased late after LTx on both CD4+ and CD8+ T cells (Figure 1C). In addition, we found 
that CD160 and CD244 were strongly co-expressed on CD8+ T cells late after LTx: CD160 
was mainly expressed on CD244+ CD8+ T cells and almost no CD160+CD244- T cells 
were observed (Figure 1D-E). Interestingly, expression of co-inhibitory receptors on T 
cells did not differ between patients pre-LTx and healthy age-matched controls (Figure 
1C), indicating that liver disease had no influence on expression levels of co-inhibitory 
receptors.
Collectively, early after LTx a slight rise in PD1 expression on CD4+ T cells was found, 
which was not sustained, while the early increase of CD160 and CD244 expression on 
both CD4+ and CD8+ T cells was sustained late after LTx. We therefore further focused on 
these two co-inhibitory receptors.
Enhanced expression of CD244 and CD160 on circulating T-cell subsets after LTx 
Since CD244 and CD160 expression is low or absent on naive T cells and increases 
progressively with memory differentiation state of T cells 11, 30, we assessed whether the 
distribution of circulating naive and memory T-cell subsets changed after LTx (Figure 
2A; Materials and Methods). After LTx, a significant reduction of CD4+ and CD8+ Tn 
was observed, while CD4+ Tem and Temra and CD8+ Temra significantly increased 
(Supplemental Figure 1). Therefore, to establish whether the upregulation of CD160 and 
CD244 after LTx was due to the changes in T-cell subset distribution, we determined the 
expression of these co-inhibitory receptors on each individual T-cell subset.
In the early post-LTx cohort, we observed a significant increase in CD160 expression on 
CD8+ Tcm and Tem 6 months post-LTx (Figure 2B). In the late post-LTx cohort, CD160 
expression significantly increased after LTx on CD4+ Tem and CD8+ Tcm, Tem and Temra 
(Figure 2C).
On CD4+ Tem and Temra and on all CD8+ T-cell subsets we found increasing expression 
of CD244 during the first 6 months after LTx in the early post-LTx cohort (Figure 2B). In 
the late post-LTx cohort, CD244 expression on CD4+ and CD8+ Tem and Temra increased 
significantly after LTx (Figure 2C). A B        C Fi
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Taken together, these results show that the observed upregulation of CD160 and CD244 
expression on circulating T cells after LTx was not only caused by a shift in T-cell subset 
distribution, but was also due to increased expression on the individual T-cell subsets.
Upregulation of CD244 on CD8+ T cells after LTx is associated with CMV infection
Next, we focused on the expression of CD244 and CD160 in patients late after LTx. Since 
expression of CD244 and CD160 on T cells increases with age 31 and their expression 
can also be induced by viral infections, such as HBV, HCV and CMV 5, 10, 14, 32-34 we first 
asked whether the increasing expression of these co-inhibitory receptors after LTx was 
related to age of the patients, underlying disease (including chronic viral hepatitis), time 
after LTx, or CMV infection after LTx. Importantly, for this study CMV infection was 
only regarded as relevant when occurring between LTx and collection of the post-LTx 
blood sample. Multivariate linear regression analysis showed that the increases in CD160 
and CD244 expression (delta expression = expression post-LTx minus expression pre-
LTx) were not significantly associated with patient age, time after LTx, or underlying 
disease. However, upregulation of CD244, but not CD160, on CD8+ T cells after LTx 
showed a significant positive association with CMV infection after LTx (p=0.004) (Table 
II). Although we focused on the expression of CD244 and CD160, we also analyzed the 
association between CMV infection and the expression of PD1 and LAG3, but no increase 
in their expression levels was found in CMV infected patients.
Figure 3A shows that the expression of CD244 on CD8+ T cells was significantly 
upregulated after LTx in patients with CMV infection, but not in patients without CMV 
infection after LTx. The increases in CD244 expression observed in patients without 
CMV infection were small (on the average only 7%), while a significantly higher average 
increase of 38% was observed in patients with CMV infection (Figure 3B). We therefore 
conclude that CMV infection importantly contributes to the rise in CD244 expression on 
CD8+ T cells after LTx. Together, our data suggest that strong CD244 expression is induced 
by CMV-infection early after LTx and that CD244-expression remains high, even many 
years after CMV infection is cleared. To verify this, we determined CD244 expression 
levels on CD8+ T cells at 1 year post-LTx in a subgroup of CMV-infected patients (n=6) of 
the long-term cohort. As shown in Figure 3C, expression of CD244 was already increased 
in these patients at 1 year after LTx. Although expression levels showed a partial 
decrease in blood samples taken at 6-11 years post-LTx, they remained significantly 
higher than pre-LTx expression levels. These data indicate that CMV infection, which 
occurs predominantly in the first 9 months after transplantation, induces accumulation 
of CD8+ T cells expressing CD244, and after the clearance of infection (latency) these 
CD8+CD244+ T cells persist.
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Table 2. Associations of independent covariates with increasing (Δ) CD160 and CD244 expression 
on CD4+ and CD8+ T cells in multivariate linear regression analysis
Table 2. Associations of independent covariates with increasing (∆) CD160 and CD244 expression on CD4+ and CD8+ T 
cells in multivariate linear regression analysis 
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Figure 3 Expression of CD244 on CD8+ T cells before and after LTx in patients of the late post-LTx 
cohort with and without CMV infection after LTx. (A) Expression of CD244 on CD8+ T cells before 
and after LTx in patients of the late post-LTx cohort with and without CMV infection after LTx. (B) 
Increase of CD244 expression on CD8+ T cells, i.e. delta CD244 (= CD244 expression post-LTx minus 
pre-LTx expression) in patients with and without CMV-infection after LTx. (C) Expression of CD244 
on CD8+ T cells before (pre-LTx), at 1 year, and at 6-11 years post-LTx in a subgroup of patients with 
CMV infection (n=6) of the long-term cohort. Each dot represents 1 patient, and lines indicate mean 
with standard error of the mean. *p<0.05, **p<0.005, ***p<0.0005 
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Reduced allogeneic CD8+ T-cell responses in patients with CMV infection after LTx 
Since we found that CMV infection after LTx was associated with upregulation of CD244 
expression on CD8+ T cells after LTx, we asked whether CMV infection also affected 
the allo-reactivity of these cells. We therefore determined post-LTx CD8+ T-cell allo-
responses in patients of the late post-LTx cohort with and without CMV infection, by 
co-culturing CFSE-labeled patient PBMC with CD40-activated B cells from their liver 
transplant donors or from an HLA-mismatched third party. After 5 days, proliferation and 
effector function of CD8+ T cells were assessed. PF of proliferating cells were calculated 
using Modfit software 27, and representative examples of Modfit proliferation analyses 
are shown in Figure 4A. As depicted in Figure 4B, PF of CD8+ T cells proliferating in 
response to donor allo-antigens were significantly lower in PBMC from patients with 
CMV infection than from patients without CMV infection after LTx, with the same trend 
(p=0.213) in the responses to third party allo-antigens. 
To assess cytotoxic effector function of CD8+ T cells in both patient categories, we 
determined their cytotoxic degranulation capacity by analyzing CD107a surface 
expression at the end of the co-cultures (Figure 4C). After stimulation with donor or 
third party allo-antigens, CD8+ T cells of patients with CMV infection after LTx showed 
significantly lower levels of CD107a expression than CD8+ T cells of patients without CMV 
infection (Figure 4D). More specifically, CD107a expression in non-proliferating cells was 
lowered in patients with CMV-infection, but not CD107a expression in proliferating CD8+ 
T cells (Supplemental Figure 2). These data demonstrate the existence of circulating CD8+ 
T cells that do not proliferate but are still capable of cytotoxic degranulation in response 
to allo-antigens, and show that the decreased allogeneic cytotoxic degranulation capacity 
in CMV-infected patients was confined to these non-proliferating cells.
Together, these data demonstrate a reduction of allogeneic CD8+ T-cell proliferative and 
cytotoxic degranulation responses in LTx patients with CMV infection after LTx, and 
show that CMV-infection induces accumulation of a population of dysfunctional CD8+ 
T cells which does neither proliferate, nor degranulate in response to allo-stimulation.
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Figure 4 Allogeneic proliferative and cytotoxic degranulation responses of CD8+ T cells from 
patients with or without CMV infection after LTx. (A) Representative Modfit analysis plots 
showing CD8+ T-cell proliferation after 5 days of stimulation with donor-derived or 3rd party-
derived CD40-activated B cells. (B) Precursor frequencies (PF) of proliferating CD8+ T cells in post-
LTx PBMC of patients with or without CMV infection after LTx in response to donor (n=14 with 
CMV and n=9 without CMV) or third party (n=9 with CMV and n=8 without CMV) allo-antigens. 
Blood samples were collected 1-12 years after LTx (median 7 years). (C) Representative FACS plots 
showing CD107a expression on CFSE-labeled CD8+ T cells after 5 days of stimulation with donor-
derived CD40-activated B cells. (D) CD107a expression on both proliferated and non-proliferated 
CD8+ T cells as percentage of all CD8+ T cells in post-LTx PBMC of patients with (n=8) or without 
(n=7) CMV infection after LTx in response to donor or third party allo-antigen. Each dot represents 
1 patient, and lines indicate mean with standard error of the mean. *p<0.05
CD244+ CD8+ T cells show impaired proliferative responses to allogeneic stimulation 
Since we found that CMV infection was associated with a strong rise in CD244 expression 
on circulating CD8+ T cells and with hyporesponsiveness of CD8+ T cells to allo-antigens 
after LTx, we wondered whether CD244 expression hallmarks a subpopulation of CD8+ 
T cells with reduced functionality. To test this hypothesis, CFSE-labeled CD244- and 
CD244+ CD8+ T cells, as well as CD4+ T cells, were sorted from 17 LTx patients of the late 
post-LTx cohort. The sorted CD8+ T-cell subsets were co-cultured with autologous CD4+ 
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T cells to provide CD4-help to the CD8+ T cells, and stimulated with allogeneic CD40-
activated B cells either derived from the donor or from an HLA-mismatched third party. 
In addition, both sorted subsets were stimulated with PHA. After 5 days of culture, 
cells were harvested and proliferation was measured. Significantly lower numbers of 
CD244+ T cells than CD244- T cells proliferated in response to PHA (Figure 5A; p=0.0001). 
Similarly, significantly less CD244+ T cells than CD244- T cells proliferated in response 
to allogeneic stimulations (p=0.002 for donor and p=0.023 for third party stimulation). 
The impaired proliferative responses of CD244+ T cells were independent of the allo-
antigenic source, as differences between CD244+ and CD244- T cells were similar in 
response to donor and third party stimulations (Figure 5B). To assess whether blocking 
the interaction of CD244 with its ligand CD48 could restore the proliferative capacity 
of CD244+ CD8+ T cells, we repeated the above described experiments in a subgroup 
of patients in the presence of blocking antibodies directed against CD48. In addition, 
we studied the effect of blocking the interaction of CD160, which is co-expressed with 
CD244, with its ligand HVEM during culture. Both CD48 and HVEM were expressed 
on CD40-activated B cells (data not shown). After 5 days, we did not find any difference 
in allogeneic proliferation of both CD244+ and CD244- CD8+ T cells between conditions 
with and without blocking antibodies (data not shown). Collectively, these data suggest 
that CD244 expression marks a subset of dysfunctional CD8+ T cells, but the receptor 
itself and the co-expressed CD160 receptor do not mediate the dysfunctionality. 
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Figure 5 Proliferation of CD244+ versus CD244- CD8+ T cells in response to polyclonal and 
allogeneic stimulation. (A) Precursor frequencies (PF) of sorted CD244+ versus CD244- CD8+ T cells 
in response to polyclonal stimulation (PHA). (B) Precursor frequencies of CD244+ versus CD244- 
CD8+ T cells of patients post-LTx in response to donor and third party stimulation. Cells were sorted 
from PBMC collected from 17 patients 2-10 years after LTx (median 6.2 years). Each dot represents 
1 patient, and lines indicate mean with standard error of the mean. *p<0.05, **p<0.005, ***p<0.0005 
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CD244+ CD8+ T cells contain the majority of CMV-specific cells 
Since upregulation of CD244 on circulating CD8+ T cells was strongly associated with 
CMV infection after LTx and CD8+CD244+ T cells were dysfunctional, we analyzed 
whether CD244+ CD8+ T cells contained CMV-specific cells. We therefore co-stained 
PBMC from 5 CMV-experienced LTx patients from our study with MHC class I tetramers 
loaded with CMV-peptides and CD244 mAb, as described in Materials and Methods. A 
representative FACS plot is shown in Figure 6A. We found that the CD244+ CD8+ T-cell 
population contained the majority of CMV-tetramer positive cells; significantly more 
than the CD244- CD8+ T-cell population (Figure 6B, p=0.033). These data support a causal 
relationship between CMV infection and the expansion of dysfunctional CD8+ CD244+ T 
cells after LTx.
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Figure 6 CMV-specific cells within CD244+ and CD244- CD8+ T-cell populations. (A) Representative 
FACS plots showing CD244+ and CD244- CMV-tetramer positive cells CD8+ T cells. (B) Percentage 
CD244+ and CD244- CMV-tetramer positive cells of CD8+ T cells of CMV-positive patients post-LTx 
(n=5).
DISCUSSION
In this study, we showed that the co-inhibitory receptor CD160 was upregulated on 
circulating memory CD8+ T cells, while the co-inhibitory receptor CD244 was upregulated 
on both CD4+ and CD8+ memory T cells of patients early after LTx. In addition, we found 
that the increased expression of both receptors was sustained late after LTx. In contrast, 
PD1 was transiently upregulated on CD4+ T cells 1 month after LTx, but its expression 
normalized already at 6 months after LTx. Our original hypothesis postulated that 
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long-term persistence of a high load of allo-antigens after LTx may induce exhaustion 
of allogeneic T-cells. In contrast to this hypothesis, impaired allogeneic CD8+ T-cell 
responses and strong upregulation of CD244 on CD8+ T cells after LTx were restricted 
to patients with CMV infection after LTx. Expression of CD244 on the majority of the 
CMV-specific CD8+ cells in patients with CMV infection after LTx suggested a causal 
relationship between CMV infection and the observed expansion of CD8+CD244+ T cells. 
The observed lower proliferative capacity of CD244+ CD8+ T cells than CD244-CD8+ 
T cells in response to allogeneic stimulation suggested that the allogeneic CD8+ T-cell 
hyporesponsiveness in LTx patients after CMV infection is caused by the accumulated 
CD8+CD244+ T cells. Together, these data suggest that CMV infection after LTx induces 
persistent accumulation of CD8+CD244+ T cells in the circulation, which display features 
of senescence or exhaustion, resulting in impaired peripheral CD8+ T-cell responses to 
allo-antigens in these patients.
The observed association between accumulation of CD8+CD244+ T cells and CMV 
infection 11, 14, 30, 35 as well as the selective expression of CD160 and CD244 on memory 
T-cell subsets is consistent with previous studies 4, 11, 30, 36. However, to our knowledge, 
this is the first study showing that CMV infection after organ transplantation induces 
sustained CD244 expression on memory CD8+ T cells and that the resulting CD8+CD244+ 
T-cell subset is hyporesponsive to allo-antigens. It has been well-documented that CMV 
infection induces vast expansion in the circulation of a population of CMV-specific CD8+ 
T cells which are actively cycling. After establishment of CMV-latency the majority of 
CMV-specific CD8+ T cells become long-lived terminally differentiated resting T cells 
with poor proliferative capacity 37, 38. Therefore, we hypothesize that expansion of these 
cells after LTx occurs during active CMV infection, while they differentiate into long-
lived CD244-expressing terminally differentiated T cells with poor proliferative capacity 
after establishment of CMV-latency. Expression of CD244 is also induced on CD8+ T 
cells by HIV and HCV infection, and results in impaired CD8+ T-cell responses to viral 
antigens. However, the impairment of anti-viral CD8+ T-cell responses in these patients 
can be abrogated by blocking the interaction between CD244 and its ligand CD48 10, 11, 14. 
In contrast, our data suggest that the observed allogeneic hyporesponsiveness of CMV-
induced CD244+CD8+ T cells was not mediated by CD244-CD48 interaction, neither by 
interaction of the co-expressed inhibitory CD160 receptor with its ligand HVEM, since 
blocking CD48 or HVEM did not lead to abrogation of hyporesponsiveness of CD8+CD244+ 
T cells to allo-antigens in experiments with sorted CD244+ T cells. The impaired response 
of this subset to allo-antigens may be related to its high content of CMV-specific T 
cells, resulting in lower proportions of T cells with other specificities, including allo-
reactive T cells 39-41. In addition, the limited TCR repertoire of CMV-specific cells 39, 42, 
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43 accumulated in this subset may result in poor cross-reactivity to directly presented 
allo-antigens. However, these phenomena do not explain the impaired proliferation of 
the expanded CD8+CD244+ T cells to PHA (this study), or to CD3/CD28 stimulation in a 
previous study 30. Interestingly, CMV-induced expansion of CD8+ effector memory cells 
correlates with a decrease in T-cell telomere length, indicating T-cell senescence 44, and 
T-cell senescence has particularly been related to impaired proliferative capacity 45. We 
therefore propose that the observed rise in CD244 expression in LTx patients with CMV 
infection marks expansion of a subset of highly differentiated but dysfunctional CD8+ 
T cells, which shows features of senescence or exhaustion. However, its proliferative 
capacity is hampered by an as yet unknown mechanism. 
The observed reduction in allo-reactive CD8+ T-cell responses in LTx patients after CMV 
infection challenges the broadly accepted notion, based on experimental animal studies, 
that viral infections stimulate heterologous immunity resulting in increased frequencies 
of allo-reactive T-cells 46. Indeed, reactivation of CMV infection as well as primary 
CMV infection abrogate transplant acceptance in mice and rat 47, 48. However, several 
previously published observations in humans support our finding. First, CMV infection 
leads to T-cell senescence, and thereby impairs T-cell responses to other antigens and to 
vaccinations 34, 40, 49-51. Interestingly, CMV infection after LTx is associated with an increased 
predisposition to develop opportunistic infections 52. Secondly, immune senescence 
has been associated with improved kidney allograft survival 53. Thirdly, the majority 
of CD8+CD244+ T cells in our patients belong to the Temra subset, and accumulation 
of circulating CD8+ Temra has recently been shown to be associated with lower risk of 
acute rejection after kidney transplantation 41. It was not feasible to investigate whether 
CMV infection or accumulation of CD8+CD244+ cells were associated with differences 
in clinical outcome such as graft or patient survival or acute rejection in our long-term 
study cohort, since all patients have stable graft function and are still alive. In addition, 
only 5 patients suffered from acute rejection. A larger prospective study is required to 
investigate associations between CMV infection or rise in CD244 and clinical outcomes.
The mechanism by which CMV infection induces expansion of CD244+CD8+ memory T 
cells is as yet unknown, but may be related to bystander effects of inflammatory responses 
caused by CMV or by its immune evasion strategies. A recent mouse study showed that 
CD244 is more highly upregulated during secondary than during primary CD8+ T-cell 
responses, suggesting that T-cell reactivation is required for induction of high CD244 
expression 54. In addition, it has been shown that chronic lymphocytic choriomeningitis 
virus (LCMV) or Toxoplasm infections in mice impair memory T-cell responses against 
unrelated antigens due to generation of CD8+ Temra. This was caused by increased 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 3
70
IFN-type signalling due to chronic inflammation caused by the persistent infections 
55. A similar mechanism may be driven by CMV infection after LTx, which also causes 
inflammation in the graft and in other organs 52, while CMV is able to induce IFN-α 
production 56. A possible relation between inflammation and reduced allo-responses 
after LTx is supported by a recent study that showed that chronic HCV patients who are 
operationally tolerant after LTx over-express type I IFN and Interferon-Stimulated Genes 
in the liver graft 57. A second explanation for the association between CMV infection 
and CD8+ T-cell hyporesponsiveness may be that CMV produces viral IL-10 58, which 
inhibits expansion of allo-reactive CD8+ T cells. A third explanation may be that the 
immunological space of the recipient is occupied by large quantities of CMV-specific 
CD8+ Temra that compete with and thus hamper the expansion of T cells with other 
specificities 59. However, these explanations remain speculative, and further research 
is needed to decipher the mechanisms by which CMV infection induces expansion of 
CD8+CD244+ memory T cells, which is beyond the scope of the present study. 
In contrast to the sustained increase in CD244 and CD160 expression on circulating T 
cells after LTx, we found that PD1 was only transiently upregulated following LTx. As 
PD1 can be upregulated by TCR-activation, this finding may be explained by the early 
and transient activation of donor-specific T cells after LTx that we observed previously 
27. However, the use of calcineurin inhibitors (CNI) by the majority of our patients may 
prevent sustained upregulation of PD1, since PD1 induction by TCR-ligation involves 
NFAT-signaling, which is inhibited by CNI 32. PD1 upregulation is also prevented by 
mTOR inhibitors 60, immunosuppressive drugs used by a small group of patients in our 
cohorts. LAG3 and TIM3 expression did not show an increase after LTx, but we do not 
know whether this is related to the use of immunosuppressive drugs since no evidence 
exists on the effect of immunosuppressive drugs on the expression of these receptors. 
A limitation of our study is that we were not able to link the CD8+ T-cell hyporesponsiveness 
to an immunologically tolerant state towards the liver allograft. To investigate the 
clinical impact of the findings presented in our study, it will be interesting to determine 
the implications of CMV infection in LTx patients on the success rate of withdrawal of 
immunosuppressive drugs. A prospective study in which immunosuppressive drugs are 
weaned off is needed to investigate this.
In conclusion, in this study we showed that CMV infection after LTx was associated with 
the expansion of CD8+CD244+ T-cells with impaired proliferative capacity in response to 
allo-antigen, causing allogeneic CD8+ T-cell hyporesponsiveness. These results suggest 
that CMV infection may hamper T-cell immunity and thereby promote immunological 
graft acceptance after LTx. 
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Supplemental Figure 1 Subset distribution of circulating CD4+ and CD8 + T cells of healthy controls and patients before 
and late after LTx
Differentiation stages of T cells in LTx patients of the late post-LTx cohort (n=38) before and after LTx, and in healthy 
control subjects (HC) (n=18).
Supplemental Figure 1
Supplemental Figure 1Subset distribution of circulate CD4+ and CD8+ T cells of healthy controls 
and patients before and late after LTx. Differentiation stages of T cells in LTx patients of the late 
post-LTx cohort (n=38) before and after LTx, and in healthy control subjects (HC) (n=18).
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Supplemental Figure 2 Allogeneic cytotoxic degranulation responses of CD8+ T cells from patients with or without 
CMV infection after LTx
(A) CD107a expression on proliferated CD8+ T cells as percentage of all proliferated CD8+ T cells in post-LTx PBMC of 
patients with (n=8) or without (n=7) CMV infection after LTx in response to donor or third party allo-antigen. (B) CD107a 
expression on non-proliferated CD8+ T cells as percentage of all non-proliferated CD8+ T cells in post-LTx PBMC of 
patients with (n=8) or without (n=7) CMV infection after LTx in response to donor or third party allo-antigen. Each dot 
represents 1 patient, and lines indicate mean with standard error of the mean. 
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Supplemental Figure 2 Allogeneic cytotox degranulation responses of CD8+ T cells from patients with or without 
CMV infection aft r LTx
(A) CD107a expression on proliferated CD8+ T cells as percent ge of all prolifer ted CD8+ T cells in post-LTx PBMC of 
patients with (n=8) or without (n=7) CMV infection after LTx in response to donor or third party allo-antigen. (B) CD107a 
expression on non-pr liferated CD8+ T cells as percent ge of all non-proliferated CD8+ T cells in post-LTx PBMC of 
patients with (n=8) or without (n=7) CMV infection after LTx in response to donor or third party allo-antigen. E ch dot 
represents 1 patient, and l nes indicate mean with st dard error of th  mean. 
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patients with or without CMV infection after LTx. (A) CD107a expression on proliferated CD8+ 
T cells as percentage of all proliferated CD8+ T cells in post-LTx PBMC of patients with (n=8) or 
without (n=7) CMV infection after LTx in response to donor or third party allo-antigen. (B) CD107a 
expression on non-proliferated CD8+ T cells as percentage of all non-proliferated CD8+ T cells 
in post-LTx PBMC of patients with (n=8) or without (n=7) CMV infection after LTx in response 
to donor or third party allo-antigen. Each dot represents 1 patient, and lines indicate mean with 
standard error of the mean.
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INTRODUCTION
Human cytomegalovirus (CMV), also known as human herpesvirus-5 (HHV-5), is 
extremely prevalent among humans. The seroprevalence of CMV in western countries 
is on average 60% and increases to >90% in the elderly ≥80 years old, and almost 100% 
in developing countries1, 2. Since its discovery in 1904, described by German scientists 
as large intranuclear inclusions in luetic fetus tissues3, 4, substantial knowledge has 
been gained in the past century regarding its biology and pathogenesis, and the 
diagnostic and treatment options for CMV infection have considerably improved. 
CMV generally remains quiescent in healthy individuals, but can cause severe diseases 
in immunocompromised individuals, such as newborns, AIDS patients, and patients 
after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation 
(SOT)5. Because of the global disease burden associated with CMV infection, increasing 
international efforts have been made to design vaccines against CMV with encouraging 
outcomes in recent years, aiming at a universal immunization6, 7.
Nevertheless, every cloud has a silver lining. For the past three decades evidences have 
been emerging showing that CMV infection after HSCT is associated with a reduced 
incidence of hematological cancer recurrence. In recent years, evidences suggest that 
CMV infection could also exhibit anti-tumor effects after SOT, and promote transplant 
tolerance, and improve the immune response of childhood. Shadowed by the disease 
burden caused by CMV, these reports have not drawn much attention from the general 
medical and scientific community. The exact mechanisms behind these phenomena are 
not well understood, and the clinical implications are also not clear.
In this perspective review we summarize the accumulating evidences indicating 
beneficial effects of CMV infection, mainly focusing on its potential role in fighting 
malignancy, promoting transplant tolerance, and boosting childhood immunity, and 
discuss directions for future research and the potential impact of these findings on 
clinical practice.
MALIGNANCY
Leukemia
CMV infection is a frequent and major complication after HSCT, causing a variety of organ-
specific diseases in patients receiving HSCT, including pneumonia and gastrointestinal 
disease. Prior to the age of prophylactic and pre-emptive treatment of CMV infection, 
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CMV pneumonia was the most common infectious cause of death after HSCT, with a 
mortality of 85%. Despite advances in diagnostic techniques and treatment strategies, 
CMV seropositivity remains to be associated with inferior outcome after HSCT8. 
However, growing evidences are supporting an anti-leukemic role of CMV infection 
after HSCT (Table 1). The earliest description of a “virus-versus-leukemia” effect dates 
back to 1986, when Lönnqvist et al. found in a small cohort of bone-marrow transplant 
recipients that acute leukemia patients with CMV infection were protected from relapse, 
which was independent from the effect of chronic graft-versus-host disease (GVHD)9. In 
a follow-up study, Jacobsen et al. found in a small acute myeloid leukemia (AML) patient 
cohort of four Nordic centers that the protective effect from relapse was associated with 
CMV positive donors, independent from GVHD and CMV infection10. Next, in a larger 
retrospective study from the Nordic Bone Marrow Transplantation Group, Jacobsen et 
al. confirmed the association between post-transplantation CMV infection and lower 
relapse risk of acute leukemia11. During this time period the diagnosis of post-transplant 
CMV infection still relied on viral culture, immunofluorescent CMV detection in biopsies, 
and changes in IgM/IgG titers, and there was no effective treatment available for CMV 
infection. Thus the effects of CMV-replication, anti-viral treatment and anti-viral immune 
response could not be established. 
Shadowed by the adverse impact of CMV infection after HSCT, a possible “virus-versus-
leukemia” effect did not attract much attention. In the next two decades, there was much 
debate about the impact of donor and recipient CMV serostatus on HSCT outcomes, 
and the optimal strategy of donor selection regarding CMV serostatus, but studies on 
the effect of CMV serostatus on leukemic relapse were scarce. Nachbaur et al. found 
that donor CMV-positivity in bone-marrow transplants from HLA-identical sibling 
donors significantly reduced the incidence of relapse, resulting in an improved overall 
survival12. Interestingly the observed protective effect was restricted to HLA-A2 positive 
patients, suggesting cross-reactivity between donor-derived anti-CMV CD8+ T cells 
and recipient minor histocompatibility antigens presented by HLA-A2. Nachbaur et al. 
reported a similar finding in a cohort of reduced-intensity HSCT patients. Donor CMV-
positivity was associated with a significantly reduced risk for relapse, but it did not lead 
to improved survival due to higher rate of bacterial and fungal infection related mortality 
in CMV-seronegative recipients transplanted with seropositive donors13. Behrendt et al. 
reported that pediatric patients receiving HSCT for acute leukemia had reduced risk 
of relapse and superior relapse-free survival when recipient and/or donor was CMV-
seropositive before transplantation14. However, in these three studies, the anti-leukemia 
effect was not associated with CMV infection but with seropositivity. 
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After two decades of relative radio silence, a landmark study brought people’s attention 
back to the possible “virus-versus-leukemia” effect of CMV. In a homogeneous cohort 
of adult AML patients monitored by pp65 antigenemia assay and treated by preemptive 
anti-CMV therapy, Elmaagacli et al. showed that patients with early CMV-replication 
after allo-HSCT had a significantly reduced risk to develop relapse within 10 years after 
transplantation (cumulative incidence of relapse at 10 years: 9% versus 42% in patients 
without CMV-infection)15. After adjusting for disease stage and acute/chronic GVHD, 
which suggests a “graft-versus-leukemia” effect, the profound reduction of relapse risk 
by CMV-replication remained significant. The reduced risk for relapse also translated 
into improved overall survival. In a cohort of chronic myeloid leukemia (CML) patients, 
Ito et al. also found that early CMV-replication, monitored by pp65 antigenemia or CMV-
DNA PCR, was an independent protective factor against CML-relapse16. Later on, in a 
large cohort of allo-HSCT patients treated for different hematologic malignancies, Green 
et al. confirmed the anti-leukemia effect of early CMV-replication in AML patients, with 
a significant decreased rate of relapse at 100 days and 1 year after transplantation17. 
However the observed decrease in relapse was less striking than that described by 
Elmaagacli et al., and no improvement in overall survival was observed, probably due 
to the increased non-relapse mortality rate related to CMV infection. The observation 
of reduced CML relapse described by Ito et al. was also not verified by the study of 
Green et al. In contrast, the association between early CMV-replication after HSCT and 
reduction of relapse risk in AML patients was further validated by two independent 
studies recently18, 19.
Solid tumor and lymphoma
CMV has recently been suggested to promote several types of solid malignancies by 
providing mechanisms for oncogenic transformation, oncomodulation and tumor 
cell immune evasion20. However clinical evidence supporting this hypothesis merely 
indicate the presence of virus within tumor, but without demonstrating a causal effect 
on tumor occurrence or progression. Thus skepticism remains regarding the relationship 
between CMV and cancer. Unlike in hematopoietic malignancies, clinical evidence 
supporting an anti-tumor effect in solid cancer are scarce. Couzi et al. retrospectively 
analyzed the incidence of cancer in 131 kidney transplant recipients, and found that 
CMV-naive patients had a 5-fold higher risk of cancer compared with CMV-exposed 
patients during the 8 years of follow-up21. However, in a large cohort of 455 kidney 
transplant patients, an opposite correlation was observed between CMV exposure and 
cancer occurrence22. In a large multicenter retrospective study of 44828 kidney transplant 
recipients, the highest incidence of lymphoma is observed in CMV seronegative patients 
with CMV seronegative donors (p=0.09)23. A randomized clinical trial comparing 
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preemptive therapy with prophylaxis in kidney transplant recipients showed that, while 
CMV prophylaxis reduced the incidence of CMV infection compared to pre-emptive 
therapy, death associated with malignancy was more likely to occur in patients received 
prophylaxis, again suggesting protection from cancer by CMV-infection24.
Possible mechanism of the anti-malignancy effect
What could be the mechanisms for the anti-malignancy effect of CMV infection? 
Several possible explanations for this phenomena have been suggested. The most 
likely explanation could be the crosstalk between immune responses triggered by CMV 
infection and cancer cells. Infection of CMV leaves a deep and life-long imprint on the 
human immune system. Several types of immune cells induced by CMV infection, for 
example natural killer (NK) cells and γδ T cells as first line of defense, and the following 
adaptive immune response mainly dominated by CD8+ TCRαβ+ T cells, are described to 
recognize cancer cells.
NK cells are an important compartment of the innate immune system controlling viral 
infections. CMV infection after allogeneic HSCT and solid organ transplantation induces 
a lasting expansion of a “memory NK-cell” population, which express the activating 
NK-cell receptor NKG2C and are potent producers of IFN-γ25, 26. It has been shown 
that CMV latency alone is sufficient for expansion of these cells in both HSCT patients 
and healthy individuals27, 28. CMV-infected fibroblasts also promote NKG2C+ NK-
cell outgrowth in vitro29, 30. NK-cell self-tolerance is mediated by inhibitory receptors, 
such as killer cell immunoglobulin-like receptors (KIR), recognizing self-MHC class I 
molecules, and activating receptors recognizing ligands primarily expressed on infected 
or transformed cells. Therefore, allogeneic or tumor cells missing self-HLA ligands 
are targeted by NK cells by cytotoxic killing, namely the “missing-self hypothesis”31. 
In AML patients receiving T-cell depleted HSCT from KIR-MHC class I mismatched 
donors, donor-derived NK cells were found to exert a potent anti-leukemic effect and 
can prevent leukemia relapse32, 33. Pre-transplant infusion of alloreactive NK cells also 
eradicates advanced human leukemia in mice33. Therefore, the expansion of NKG2C+ 
NK cells by CMV infection after allogeneic HSTC could contribute to the elimination of 
residual leukemic blasts25.
γδ T-cell population provides a first line of host immune defense to microbial pathogens 
and have also some adaptive features34. A strong and durable expansion of Vδ2neg γδ 
T cells that reactive to CMV infected cells is a hallmark of CMV infection after solid 
organ transplantation and HSCT35-39. γδ T cells express Vδ1, Vδ3 or Vδ5, but not Vδ2, 
are collectively designated as Vδ2neg γδ T cells, which reside mainly in intestinal and 
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skin epithelia, spleen, and liver40. Vδ2neg γδ T cells infiltrate many types of tumors and 
exert strong cytotoxicity against tumor cells ex vivo41, 42. Adoptive transfer of expanded 
γδ T cell is currently under investigation as immunotherapy for cancer treatment43. In 
a human colon cancer xenograft mouse models, adoptive transfer of CMV-induced 
Vδ2neg γδ T cells inhibited tumor growth and metastasis in vivo44, 45. It has been shown 
in kidney transplant patients that circulating Vδ2-negative γδ T-cell expansion, which 
was induced by pre-transplant or post-transplant CMV infection, was associated with a 
reduced cancer risk21. In addition, Vδ2neg γδ T cells isolated from CMV-infected transplant 
recipients were found to cross-react to intestinal tumor epithelia cell lines and primary 
leukemic blasts in vitro39, 46, 47. Thus, the expansion of γδ T cells following CMV infection, 
and its cross-reactivity to malignant cells, could contribute to the observed protective 
effect of CMV infection against cancer.
As to the adaptive immunity, CMV also contributes to the reconstitution or repopulation 
of TCRαβ+ T cells after HSCT and organ transplantation48, 49. CMV is known to drive 
the expansion of differentiated effector memory T cells lacking costimulatory molecule 
CD2850. Poor CD8+ T cell recovery after allogeneic HSCT with diminished numbers 
of CD28- CD8+ T cells is associated with a greater risk of subsequent relapse of 
hematological malignancies51. Cross-reactivity between viral-specific cytotoxic T cells 
(CTLs) and unrelated antigens such as HLA are common52. It could be that CMV-specific 
CTLs are cross-reactive to tumor-associated antigens or allo-HLA molecules expressed 
on the leukemic blasts. However in the latter case, the anti-leukemia effect of CMV is 
independent from acute and chronic graft-versus-host disease (GVHD) in several studies. 
Nevertheless, a positive correlation between anti-viral T-cell response and protection 
from leukemic relapse has been reported53, 54. 
Apart from inducing immune responses against malignant cells, a direct anti-cancer 
effect of CMV has also been proposed, as CMV replication can be cytolytic during acute 
infection at epithelial surface. Cancer cells could be reservoir for CMV. Large copy 
numbers of CMV are found in cancer cells of many AML, B-ALL and B-ALL patients55, 
and the CMV presence has also been identified in several types of solid tumors56-58. 
Several types of viruses can exert oncolytic effects, and genetically engineered strains 
are under investigation as therapy targeting neoplastic cells in preclinical studies and 
human clinical trials with promising results59. CMV infection has been shown to inhibit 
proliferation and induce apoptosis of acute leukemia cell lines in vitro60. CMV reactivation 
in cancer cells may also induce changes cell phenotype and make them potential targets 
of cytotoxic immune cells61. 
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CHILDHOOD IMMUNITY
In experimental animal models, latent infection of herpesviruses, including MCMV, 
alters the immune responses of the hosts and exerts a durable protection from unrelated 
pathogens, a process known as heterologous immunity62-65. However little is known 
about how CMV influences immune responses to other unrelated pathogens in 
immunocompetent humans. It has been reported that CMV-seropositive individuals are 
less responsive to influenza vaccines66-68, which is suggested to be related to the CMV-
driven immune senescence in the elderly69. But this observation was not confirmed 
in another study analyzing more than 700 older subjects70. Meanwhile, evidences 
are emerging in favor of a beneficial effect in young populations. For example, Miles 
et al. studied the immune responses to measles vaccination and the polyclonal T-cell 
responses to the staphylococcal enterotoxin B (SEB), and found stronger CD8 T-cell 
proliferation in response to SEB in CMV-positive infants, and that the antibody response 
to measles vaccines correlated with the IFN-γ response to CMV71. Pera et al. found 
that CMV-positivity is associated with higher levels of polyfunctional CD8+ T cells in 
young and middle aged individuals72. More recently, Furman and coworkers applied 
a systemic approach to study the differences between CMV-positive and negative 
immunocompetent subjects, and found enhanced antibody responses to influenza 
vaccines, stronger CD8+ T cell responses to cytokine stimuli, and elevated levels of 
circulating IFN-γ in CMV-positive young individuals, in contrast no such effects were 
observed in elderly individuals73. Furthermore, their murine experiments confirmed a 
significant cross-protection against influenza in young mice infected with MCMV, and 
this effect declined with aging of mice. Together, these data suggest that CMV may 
improve immune responses to unrelated pathogens in young individuals.
TRANSPLANT TOLERANCE
Viral infection, including CMV, has long been considered to be associated with allograft 
rejection after organ transplantation74. In experimental animal models, both acute 
infection and reactivation of the latent MCMV prevent graft acceptance75, 76. However the 
association between CMV infection and graft rejection in the clinical setting is less clear74. 
Several observations suggest that CMV infection has systemic immunosuppressive effects 
in the clinical transplant setting. Firstly, CMV infection after organ transplantation is 
often associated with opportunistic superinfections of fungi, bacteria and other viruses77. 
Secondly, CMV might drive senescence of immune system in elderly kidney transplant 
recipients, which is associated with fewer acute rejection episodes78. Thirdly, increased 
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numbers of CMV-IE-1-specific memory T cells are associated with lower numbers of 
alloreactive T cells and improved renal allograft function after kidney transplantation79, 
and strong CMV-specific CD4+ T-cell responses correlate with protection from cardiac 
allograft rejection80. In addition, we recently showed that, even though CMV drives 
memory T-cell expansion after liver transplantation, it does not lead to a higher frequency 
of alloreactive T cells. Instead, liver transplant patients with CMV primary infection 
develop donor-specific CD8+ T-cell hyporesponsiveness, and are protected from the 
occurrence of acute rejection episodes late after transplantation81. 
As compared with other solid organ grafts, liver displays unique immunological 
features, and liver transplantation is the only setting in which a significant proportion 
of patients can eventually discontinue immunosuppressive medication without 
undergoing rejection, a phenomenon knowns as spontaneous operational tolerance82, 83. 
Recent prospective immunosuppression withdrawal studies showed that operational 
tolerance can be achieved in more than 40% of selected liver transplant patients, 
including patients with chronic hepatitis C virus (HCV) infection84, 85. Studies that sought 
to identify biomarkers for operational tolerance have found expansion of peripheral Vδ1 
γδ T cells, and an increased Vδ1/Vδ2 ratio has been observed in tolerant LT patients in 
several independent studies, which has even been used as a surrogate marker to predict 
operational tolerance after liver transplantation85-88. As mentioned earlier, expansion of 
circulating Vδ1 γδ T cells and an increased peripheral Vδ1/Vδ2 ratio is also a feature 
related to CMV infection. Increased numbers of highly differentiated and dysfunctional 
CD8+ T cells might be another common feature shared by CMV infection and operational 
tolerance after liver transplantation, suggesting a possible association81, 85.
How CMV restrains alloreactivity after liver transplantation remains elusive, and 
whether CMV-induced cell signatures play a functional role in promoting tolerance is 
as yet unknown. The well-established immune evasion strategies of CMV is a possible 
clue. For example, CMV produces viral IL-10 to establish latency, which may also 
have a systemic immunosuppressive effect89, 90. It is also associated with the inflation 
memory T-cell and immune senescence69. After liver transplantation, CMV infection 
induces the expansion of a CD8+ T-cell subset expressing inhibitory receptor 2B4, with 
reduced proliferative and degranulative abilities in response to alloantigen (de Mare-
Bredemeijer, J Immunol. 2015). Moreover, CMV has been recently shown to significantly 
modulate peripheral mixed T-cell chimerism after HSCT91. After organ transplantation, 
chimerism is rare in peripheral blood, but more commonly observed within grafted 
organ92, 93. It has been suggested in a case report that severe CMV disease early after 
LT contributed to the development of hematopoietic chimerism and subsequent donor-
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specific hyporesponsiveness94. In addition, we hypothesize that inflammation coupled 
with CMV infection may contribute to the induction of liver allograft tolerance. CMV 
is known to drive a T helper 1 cell (Th1) polarization in peripheral. Within the human 
liver, CMV infection of sinusoidal endothelium triggers significant production of type 
I interferon by HSEC, and recruit Th1 effector memory T cells and regulatory T cells95. 
Th1 cells produce high amounts of pro-inflammatory cytokine IFN-γ, which is strikingly 
absolutely needed for liver transplant tolerance in animal models96. Recently, Morita et 
al. described a mesenchyme-mediated immune control (MMIC) mechanism utilized by 
liver allograft to eliminate effector T cells and maintain tolerance through IFN-γ and B7-
H197. The importance of type I interferon signalling has also been highlighted recently by 
Bohne et al., showing in an immunosuppression withdrawal trial of HCV-infected liver 
transplant patients, that operational tolerant patients overexpress type 1 interferon and 
interferon-stimulated genes (ISG) in liver85. To sum, accumulating evidences suggest that 
in humans, the immunomodulatory effects exerted by CMV could restrict alloimmune 
responses and promote transplant tolerance.
DIRECTIONS FOR FUTURE RESEARCH
Various questions remain to be answered by future research. One of the key questions is 
how CMV infection, directly or indirectly, is associated with beneficial clinical outcomes, 
and more often paradoxical effects. Large-scale longitudinal studies covering different 
phases of CMV infection are needed. A variety of outcomes should be monitored in 
different cohorts, namely immunocompetent and immunocompromised, young and 
old populations. Meanwhile, systemic approaches should be applied to closely monitor 
the CMV-related virological and immunological measures, the status of immune 
system, and the antigen-specific immune responses targeting both CMV and other 
unrelated antigens (such as pathogens, TAAs, allo-antigens). Once those benefits and 
the underlying mechanisms become clear, another important area for research is to 
develop approaches to skew the natural course of CMV infection, or the related immune 
responses, to achieve those beneficial effects, while limiting the established adverse 
effects of CMV infection. Clinical trials of antiviral therapies and immunotherapies 
targeting CMV infection should also pay more attention to outcomes not directly linked 
to CMV infection, such as recurrent/de novo cancer and unrelated infectious diseases in 
longer terms, to understand better how these therapies effect the virus-host interaction. 
The ideal therapies in the future should aim at decreasing CMV-related morbidity, while 
conveying or even enhancing those beneficial effects of natural CMV infection.
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IMPLICATIONS FOR CMV VACCINE DEVELOPMENT
Due to the health burden associated with CMV, the development and licensure of an 
effective CMV vaccine has been on the schedule of government, industry and scientific 
community for two decades, however no licensed vaccine is available yet7. However, 
several clinical trials, of both modified virus vaccines (MVV) and individual antigen 
vaccines (IAV), are ongoing, with promising results in controlling congenital virus 
transmission and reducing viral replication and antiviral usage in SOT patients98-101. 
Despite all the difficulties in designing, effective CMV vaccines are likely to come available 
in the future. It is a matter of discussion which populations should be covered by CMV 
vaccines. It is advocated to add CMV vaccine to the childhood vaccination schedule 
to obtain universal immunization6, 7. However, the advantages and disadvantages of 
doing so should be carefully weighed. Firstly, the majority of the infant population is 
at very low risk to develop serious health problems caused by CMV. Secondly, given 
the extremely high prevalence of CMV, early childhood immunization is possibly only 
leading to delayed nature infection and increasing risk of infection late in life, which 
has been hypothesized to have extra negative effects102. Thus vaccinating the entire 
population would be ethically problematic. The ubiquity of CMV in humans suggests 
that CMV may convey certain mutual advantages to human beings through virus-host 
interactions, which possibly have been established and coevolved for over one hundred 
million years103. Actions disrupting this equilibrium should be taken with extra caution 
before a better understanding of it is achieved.
CONCLUSION REMARKS
While host-microbiota interaction has drawn increasing attention, and its impact on 
human diseases and health is becoming more and more clear in recent years, the interaction 
with life-long persistent virus remains a whole new world to explore104-106. The evidences 
summarized in this review may not be comprehensive, but rather provide examples 
showing that CMV, one of the most prevalent herpesvirus, can have paradoxical effects 
and benefit human health under certain circumstances, despite the diseases it causes in 
immunocompromised individuals. More research in different fields is definitely needed 
to better understand this paradigm, and such knowledge can be utilized to reduce the 
disease burden associated with CMV infection and improve human health from certain 
aspects. Meanwhile, the universal vaccination strategy advocated at this moment should 
be of concern and a matter of debate.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 4
88
REFERENCES
1. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and 
demographic characteristics associated with infection. Rev Med Virol 2010;20:202-13.
2. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and 
emerging treatments. Lancet Infect Dis 2004;4:725-38.
3. Rippert H. Uber protozoenartige Zellen in der Niere eines syphilitischen Neugoborenen und 
in der Parotis von Kindern. Zentralbl Allg Pathol 1904;15:945-948.
4. Jesionek A, Kiolemenoglou B. Ueber einen Befund von protozoenartigen Gebilden in den 
Organen eines hereditar-luetischen Foetus. Muenchner Med Wochenschr 1904;51:1905-1907.
5. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 
2011;121:1673-80.
6. Griffiths PD. Burden of disease associated with human cytomegalovirus and prospects for 
elimination by universal immunisation. Lancet Infect Dis 2012;12:790-8.
7. Krause PR, Bialek SR, Boppana SB, et al. Priorities for CMV vaccine development. Vaccine 
2013;32:4-10.
8. Ljungman P. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell 
transplantation. Curr Opin Hematol 2014;21:466-9.
9. Lonnqvist B, Ringden O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone 
marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986;63:671-9.
10. Jacobsen N, Keiding N, Ryder L, et al. Graft-versus-leukaemia activity associated with 
cytomegalovirus antibody positive bone marrow donors in acute myeloid leukaemia. Lancet 
1987;1:456-7.
11. Jacobsen N, Badsberg JH, Lonnqvist B, et al. Graft-versus-leukaemia activity associated 
with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic 
graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow 
Transplantation Group. Bone Marrow Transplant 1990;5:413-8.
12. Nachbaur D, Bonatti H, Oberaigner W, et al. Survival after bone marrow transplantation 
from cytomegalovirus seropositive sibling donors. Lancet 2001;358:1157-9.
13. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of 
leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006;76:414-9.
14. Behrendt CE, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome 
of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol 
Blood Marrow Transplant 2009;15:54-60.
15. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication 
after transplantation is associated with a decreased relapse risk: evidence for a putative virus-
versus-leukemia effect in acute myeloid leukemia patients. Blood 2011;118:1402-12.
16. Ito S, Pophali P, Co W, et al. CMV reactivation is associated with a lower incidence of relapse 
after allo-SCT for CML. Bone Marrow Transplant 2013;48:1313-6.
17. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse 
risk: evidence for early protection in acute myeloid leukemia. Blood 2013;122:1316-24.
18. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus 
reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid 
leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 
2014;20:46-52.
19. Jang JE, Kim SJ, Cheong JW, et al. Early CMV replication and subsequent chronic GVHD 
have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann 
Hematol 2015;94:275-82.
20. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011;157:193-203.
21. Couzi L, Levaillant Y, Jamai A, et al. Cytomegalovirus-induced gammadelta T cells associate 
with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010;21:181-8.
22. Courivaud C, Bamoulid J, Gaugler B, et al. Cytomegalovirus exposure, immune exhaustion 
and cancer occurrence in renal transplant recipients. Transpl Int 2012;25:948-55.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Sil
ve
r L
in
in
g i
n 
CM
V 
In
fec
tio
n
89
23. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with 
immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a 
multicentre retrospective analysis. Lancet Oncol 2007;8:212-8.
24. Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir 
on long-term renal allograft outcomes. Transplantation 2010;90:412-8.
25. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic 
transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with 
potent function. Blood 2012;119:2665-74.
26. Lopez-Verges S, Milush JM, Schwartz BS, et al. Expansion of a unique CD57(+)NKG2Chi 
natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci 
U S A 2011;108:14725-32.
27. Foley B, Cooley S, Verneris MR, et al. Human cytomegalovirus (CMV)-induced memory-like 
NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV 
antigen. J Immunol 2012;189:5082-8.
28. Guma M, Angulo A, Vilches C, et al. Imprint of human cytomegalovirus infection on the NK 
cell receptor repertoire. Blood 2004;104:3664-71.
29. Rolle A, Pollmann J, Ewen EM, et al. IL-12-producing monocytes and HLA-E control HCMV-
driven NKG2C+ NK cell expansion. J Clin Invest 2014;124:5305-16.
30. Guma M, Budt M, Saez A, et al. Expansion of CD94/NKG2C+ NK cells in response to human 
cytomegalovirus-infected fibroblasts. Blood 2006;107:3624-31.
31. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74.
32. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-
mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
33. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity 
in mismatched hematopoietic transplants. Science 2002;295:2097-100.
34. Scheper W, Grunder C, Straetemans T, et al. Hunting for clinical translation with innate-like 
immune cells and their receptors. Leukemia 2014;28:1181-90.
35. Dechanet J, Merville P, Berge F, et al. Major expansion of gammadelta T lymphocytes 
following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 1999;179:1-8.
36. Puig-Pey I, Bohne F, Benitez C, et al. Characterization of gammadelta T cell subsets in organ 
transplantation. Transpl Int 2010;23:1045-55.
37. Couzi L, Lafarge X, Pitard V, et al. Gamma-delta T cell expansion is closely associated with 
cytomegalovirus infection in all solid organ transplant recipients. Transpl Int 2011;24:e40-e42.
38. Knight A, Madrigal AJ, Grace S, et al. The role of Vdelta2-negative gammadelta T cells during 
cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 
2010;116:2164-72.
39. Scheper W, van Dorp S, Kersting S, et al. gammadeltaT cells elicited by CMV reactivation 
after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013;27:1328-38.
40. Couzi L, Pitard V, Moreau JF, et al. Direct and Indirect Effects of Cytomegalovirus-Induced 
gammadelta T Cells after Kidney Transplantation. Front Immunol 2015;6:3.
41. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition 
by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 
1999;96:6879-84.
42. Maeurer MJ, Martin D, Walter W, et al. Human intestinal Vdelta1+ lymphocytes recognize 
tumor cells of epithelial origin. J Exp Med 1996;183:1681-96.
43. Fisher JP, Heuijerjans J, Yan M, et al. gammadelta T cells for cancer immunotherapy: A 
systematic review of clinical trials. Oncoimmunology 2014;3:e27572.
44. Devaud C, Rousseau B, Netzer S, et al. Anti-metastatic potential of human Vdelta1(+) 
gammadelta T cells in an orthotopic mouse xenograft model of colon carcinoma. Cancer 
Immunol Immunother 2013;62:1199-210.
45. Devaud C, Bilhere E, Loizon S, et al. Antitumor activity of gammadelta T cells reactive against 
cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 2009;69:3971-
8.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 4
90
46. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of V{delta}2(neg) {gamma}{delta} T 
cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 
2005;201:1567-78.
47. Willcox CR, Pitard V, Netzer S, et al. Cytomegalovirus and tumor stress surveillance by 
binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. 
Nat Immunol 2012;13:872-9.
48. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic 
hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical 
reactivation. Blood 2003;102:3060-7.
49. Havenith SH, Remmerswaal EB, Bemelman FJ, et al. Rapid T cell repopulation after rabbit 
anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. Clin Exp 
Immunol 2012;169:292-301.
50. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype 
in different persistent virus infections. Nat Med 2002;8:379-85.
51. Yakoub-Agha I, Saule P, Magro L, et al. Immune reconstitution following myeloablative 
allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative 
CD8+ T cells on relapse. Biol Blood Marrow Transplant 2009;15:496-504.
52. Amir AL, D’Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T 
cells is common. Blood 2010;115:3146-57.
53. Parkman R, Cohen G, Carter SL, et al. Successful immune reconstitution decreases leukemic 
relapse and improves survival in recipients of unrelated cord blood transplantation. Biol 
Blood Marrow Transplant 2006;12:919-27.
54. Hoegh-Petersen M, Sy S, Ugarte-Torres A, et al. High Epstein-Barr virus-specific T-cell 
counts are associated with near-zero likelihood of acute myeloid leukemia relapse after 
hematopoietic cell transplantation. Leukemia 2012;26:359-62.
55. Hermouet S, Sutton CA, Rose TM, et al. Qualitative and quantitative analysis of human 
herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. 
Leukemia 2003;17:185-95.
56. Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in 
prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003;170:998-1002.
57. Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic 
acids and proteins in human colorectal cancer. Lancet 2002;360:1557-63.
58. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in 
human malignant glioma. Cancer Res 2002;62:3347-50.
59. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70.
60. Koldehoff M, Lindemann M, Opalka B, et al. Cytomegalovirus induces apoptosis in acute 
leukemia cells as a virus-versus-leukemia function. Leuk Lymphoma 2015:1-9.
61. Fletcher JM, Prentice HG, Grundy JE. Natural killer cell lysis of cytomegalovirus (CMV)-
infected cells correlates with virally induced changes in cell surface lymphocyte function-
associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of 
cell surface class I HLA. J Immunol 1998;161:2365-74.
62. Yager EJ, Szaba FM, Kummer LW, et al. gamma-Herpesvirus-induced protection against 
bacterial infection is transient. Viral Immunol 2009;22:67-72.
63. Barton ES, White DW, Cathelyn JS, et al. Herpesvirus latency confers symbiotic protection 
from bacterial infection. Nature 2007;447:326-9.
64. Selin LK, Varga SM, Wong IC, et al. Protective heterologous antiviral immunity and enhanced 
immunopathogenesis mediated by memory T cell populations. J Exp Med 1998;188:1705-15.
65. Welsh RM, Che JW, Brehm MA, et al. Heterologous immunity between viruses. Immunol Rev 
2010;235:244-66.
66. Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, 
enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-
influenza vaccination--an impact of immunosenescence. Vaccine 2003;21:3826-36.
67. Derhovanessian E, Theeten H, Hahnel K, et al. Cytomegalovirus-associated accumulation 
of late-differentiated CD4 T-cells correlates with poor humoral response to influenza 
vaccination. Vaccine 2013;31:685-90.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Sil
ve
r L
in
in
g i
n 
CM
V 
In
fec
tio
n
91
68. Derhovanessian E, Maier AB, Hahnel K, et al. Latent infection with cytomegalovirus is 
associated with poor memory CD4 responses to influenza A core proteins in the elderly. J 
Immunol 2014;193:3624-31.
69. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res 2011;157:175-9.
70. den Elzen WP, Vossen AC, Cools HJ, et al. Cytomegalovirus infection and responsiveness to 
influenza vaccination in elderly residents of long-term care facilities. Vaccine 2011;29:4869-74.
71. Miles DJ, Sanneh M, Holder B, et al. Cytomegalovirus infection induces T-cell differentiation 
without impairing antigen-specific responses in Gambian infants. Immunology 2008;124:388-
400.
72. Pera A, Campos C, Corona A, et al. CMV latent infection improves CD8+ T response to 
SEB due to expansion of polyfunctional CD57+ cells in young individuals. PLoS One 
2014;9:e88538.
73. Furman D, Jojic V, Sharma S, et al. Cytomegalovirus infection enhances the immune response 
to influenza. Sci Transl Med 2015;7:281ra43.
74. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect 
relationship? Lancet Infect Dis 2002;2:539-49.
75. Cook CH, Bickerstaff AA, Wang JJ, et al. Disruption of murine cardiac allograft acceptance by 
latent cytomegalovirus. Am J Transplant 2009;9:42-53.
76. Carlquist JF, Shelby J, Shao YL, et al. Accelerated rejection of murine cardiac allografts by 
murine cytomegalovirus-infected recipients. Lack of haplotype specificity. J Clin Invest 
1993;91:2602-8.
77. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and 
challenges. World J Gastroenterol 2008;14:4849-60.
78. Trzonkowski P, Debska-Slizien A, Jankowska M, et al. Immunosenescence increases the rate 
of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ 
T-cells. Mech Ageing Dev 2010;131:96-104.
79. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1-specific memory T cells are 
associated with less alloimmunity and improved renal allograft function. Transpl Immunol 
2009;20:238-42.
80. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection 
reduces cardiac allograft disease. Circulation 2006;114:1608-15.
81. Shi XL, de Mare-Bredemeijer EL, Tapirdamaz O, et al. CMV Primary Infection Is Associated 
With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver 
Transplantation. Am J Transplant 2015.
82. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 
2009;50:1247-57.
83. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 
2006;6:1774-80.
84. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of 
immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 
2013;58:1824-35.
85. Bohne F, Londono MC, Benitez C, et al. HCV-Induced Immune Responses Influence the 
Development of Operational Tolerance After Liver Transplantation in Humans. Sci Transl 
Med 2014;6:242ra81.
86. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to 
develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 
2008;118:2845-2857.
87. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in 
operational tolerance after pediatric living donor liver transplantation. Am J Transplant 
2004;4:2118-25.
88. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of 
operational tolerance in liver transplantation. Am J Transplant 2007;7:309-19.
89. Ouyang P, Rakus K, van Beurden SJ, et al. IL-10 encoded by viruses: a remarkable example of 
independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral 
genome. J Gen Virol 2014;95:245-62.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 4
92
90. Slobedman B, Barry PA, Spencer JV, et al. Virus-encoded homologs of cellular interleukin-10 
and their control of host immune function. J Virol 2009;83:9618-29.
91. Sellar RS, Vargas FA, Henry JY, et al. CMV promotes recipient T-cell immunity following 
reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. Blood 
2015;125:731-9.
92. Shi X, Moroso V, Metselaar HJ, et al. Long-lived intragraft donor leukocytes or relocated 
donor hematopoietic stem/progenitor cells can cause long-term hematopoietic chimerism 
after liver transplantation. Hepatology 2013;57:2542.
93. Wang XQ, Cheung CK, Lo CM. Donor-derived long-lived intragraft leukocytes are likely 
generated by hematopoietic stem/progenitor cells in liver. Hepatology 2013;57:2543.
94. Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-
donor liver transplant. N Engl J Med 2008;358:369-74.
95. Bruns T, Zimmermann HW, Pachnio A, et al. CMV infection of human sinusoidal endothelium 
regulates hepatic T cell recruitment and activation. J Hepatol 2015.
96. Mele TS, Kneteman NM, Zhu LF, et al. IFN-gamma is an absolute requirement for spontaneous 
acceptance of liver allografts. Am J Transplant 2003;3:942-51.
97. Morita M, Joyce D, Miller C, et al. Rejection triggers liver transplant tolerance: Involvements 
of mesenchyme-mediated Immune Control Mechanisms. Hepatology 2015.
98. Fu TM, An Z, Wang D. Progress on pursuit of human cytomegalovirus vaccines for prevention 
of congenital infection and disease. Vaccine 2014;32:2525-33.
99. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA 
vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, 
placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12:290-9.
100. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with 
MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 
2011;377:1256-63.
101. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. 
N Engl J Med 2009;360:1191-9.
102. White DW, Suzanne Beard R, Barton ES. Immune modulation during latent herpesvirus 
infection. Immunol Rev 2012;245:189-208.
103. McGeoch DJ, Cook S, Dolan A, et al. Molecular phylogeny and evolutionary timescale for the 
family of mammalian herpesviruses. J Mol Biol 1995;247:443-58.
104. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev 
Genet 2012;13:260-70.
105. Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. 
Nat Immunol 2013;14:654-9.
106. Virgin HW. The virome in mammalian physiology and disease. Cell 2014;157:142-50.
 
CHAPTER 5
Interplay between donor PD-L1 and recipient PD-1 
regulates acute graft rejection after liver transplantation
Xiao-Lei Shi1,4, Shanta Mancham1, Bettina E. Hansen1, Robert J. de Knegt1, 
Jeroen de Jonge3, Luc J.W. van der Laan3, Fernando Rivadeneira2, 
Herold J. Metselaar1, Jaap Kwekkeboom1
1Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Center, 
Rotterdam, The Netherlands
2Department of Internal Medicine, Erasmus MC - University Medical Center, 
Rotterdam, The Netherlands
3Department of Surgery, Erasmus MC - University Medical Center, Rotterdam, The Netherlands
4Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, 
Shanghai, China
Journal of Hepatology, accepted
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 5
94
ABSTRACT
Background & Aims: Co-inhibitory receptor-ligand interactions fine-tune immune 
responses by negatively regulating T-cell functions. Our aim is to examine the involvement 
of co-inhibitory receptor-ligand pair PD-1/PD-L1 in regulating acute rejection after liver 
transplantation (LT) in humans.
Methods: PD-L1/PD-1 expression in liver allograft was determined by 
immunohistochemistry or flow-cytometry, and the effect of blockade was studied using 
graft-infiltrating T cells ex vivo. Five single nucleotide polymorphisms within PD-1 and 
PD-L1 genes were genotyped in 528 LT recipients and 410 donors, and associations 
with both early (≤ 6 months) and late (> 6 months) acute rejection were analyzed using 
Cox proportional-hazards regression model. The effect of PD-L1 rs4143815 on PD-L1 
expression was analyzed using donor hepatic leukocytes.
Results: PD-L1 was expressed by hepatocytes, cholangiocytes and along the sinusoids 
in post-transplant liver allografts, and PD-1 was abundantly expressed on allograft-
infiltrating T cells. PD-L1 blockade enhanced allogeneic proliferative responses of graft-
infiltrating T cells. In the genetic association analysis, donor PD-L1 rs4143815 (CC/CG 
versus GG; HR=0.230; p=0.002) and recipient PD-1 rs11568821 (AA/AG versus GG; 
HR=3.739; p=0.004) were associated with acute rejection late after LT in multivariate 
analysis. Recipients carrying the PD-1 rs11568821 A allele who were transplanted with 
liver grafts of PD-L1 rs4143815 GG homozygous donors showed the highest risk for 
late acute rejection. PD-L1 rs4143815 is associated with differential PD-L1 expression on 
donor hepatic dendritic cells upon IFN-γ stimulation.
Conclusion: Our data show that PD-1/PD-L1 pathway regulates allograft rejection in 
humans, and suggest a critical interplay between donor PD-L1 and recipient PD-1.
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INTRODUCTION
T cells are the key drivers of the adaptive immune response, playing an important role in 
controlling infections by pathogens. T cells are also critically involved in graft rejection 
after allogeneic organ transplantation1. At the time of TCR ligation, costimulatory signals 
delivered by antigen presentation cells are required to fully activate T cells to proliferate 
and perform effector functions2. However to provide immune regulation and maintain 
tolerance, signaling through co-inhibitory pathways, such as PD-1/PD-L1, negatively 
regulates T cell functions and fine-tunes immune responses3.
Programmed death 1 (PD-1) receptor and its ligand PD-L1 (also known as CD274 or 
B7-H1) are important for the induction and maintenance of allograft tolerance in several 
experimental animal models4, 5. However whether PD-1/PD-L1 pathway is involved 
in regulation of graft rejection in humans is unknown. PD-1 is inducibly expressed on 
T cells after TCR engagement or during antigen persistence6. PD-1 was first found to 
be expressed on hepatic T cells of patients with chronic HBV and HCV-infection, and 
regulates virus-specific T-cell responses 7, 8. A recent study showed that T cells in healthy 
liver tissue also abundantly express PD-1, suggesting a role in maintaining the immune-
tolerant microenvironment of liver9. PD-L1 is characterized by its broad expression, 
being not only expressed on hematopoietic cells, such as Kupffer cells in the liver, but 
also on non-hematopoietic cells such as sinusoidal endothelial cells and hepatocytes10, 
11, and is critically involved in the regulation of intrahepatic CD8+ T cells accumulation 
and deletion12. Its expression in liver tissue is further upregulated by inflammatory 
stimuli, including ischemia/reperfusion injury 13, 14 However, whether PD-1 and PD-L1 
are expressed in human liver grafts after transplantation is unknown. 
Single nucleotide polymorphisms (SNPs) in PD-L1 and PD-1 have been found to be 
associated with the development of a variety of immunological disorders. We showed 
previously that SNPs in the co-inhibitory molecule cytotoxic T-lymphocyte antigen 
4 (CTLA-4) gene are associated with the development of acute rejection after liver 
transplantation (LT), indicating that CTLA-4 is involved in the regulation of allogeneic 
immunity in humans15, 16. Two studies did not find an association between PD-1 SNPs 
and graft rejection after LT, however both studies were limited by their small sample 
size17, 18.
In the current study, we hypothesize that T-cell co-inhibition via PD-1/PD-L1 pathway 
is involved in the regulation of allograft rejection in humans. For this purpose, we first 
examined the expression of PD-1 and PD-L1 in human liver allografts, and tested the effect 
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of PD-1/PD-L1 blockade on ex vivo proliferation of graft-infiltrating T cells in response 
to alloantigens. Next we studied whether common genetic variations within PD-1 and 
PD-L1 genes affect the incidence of graft rejection in patients after LT. Genotyping 
was performed in a large and well-characterized cohort of LT patients, including 528 
recipients and 410 donors. Associations with both early (≤ 6 months after LT) and late (> 
6 months after LT) acute rejection were analyzed. Finally, the functional relevance of the 
selected SNP was analyzed.
PATIENTS AND METHODS
Study population
Patients that underwent orthotopic LT between 1992 and 2012 at Erasmus MC, The 
Netherlands, from whom recipient and/or donor DNA samples were available, were 
included in this study. In total 584 patients were included in the analysis. From 354 
patients both recipient and donor DNA samples were available, from 174 patients only 
recipient DNA samples were available, and from 56 patients only donor DNA samples 
were available. Demographic details of donors and recipients are summarized in Table 
1. Patients were followed up until graft loss, death, or the end of the study period in May, 
2013. Immunosuppressive therapy is described in Supplemental Materials and Methods.
Acute rejection was defined as graft dysfunction accompanied by moderate or severe 
rejection activity (RAI≥5) detected in the liver biopsy according to Banff criteria, and 
responsiveness to additional immunosuppressive treatment. While early acute rejection 
was defined as rejection occurring within 180 days after LT, late acute rejections were 
defined as those occurring after 180 days after LT19.
Written informed consent was obtained from all patients before collection of samples. 
The medical ethics committee of the Erasmus MC approved this study.
DNA extraction, selection and determination of gene polymorphisms
Detailed protocols are described in Supplemental Materials and Methods.
Cell isolation, culture, stimulation, flow cytometry, and immunohistochemistry
Detailed protocols are described in Supplemental Materials and Methods.
Statistics
Statistics are described in Supplemental Materials and Methods.
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Table 1. Patient characteristics
Baseline characteristics Total n=584
Recipient  
   Age 50 (16-69)
   Gender, female 230 (39.4%)
Recipient ethnicity  
   Caucasian 500 (85.6%)
   African 44 (7.5%)
   Asian 40 (6.8%)
Donor  
   Age 47 (11-82)
   Gender, female 297 (50.9%)
Donor ethnicity
   Caucasian 410 (100%)
Primary liver diseases  
   AHF 85 (14.6%)
   HCC 69 (11.8%)
   PBC/PSC/AIH 154 (26.4%)
   HBV/HCV 71 (12.2%)
   Alcoholic cirrhosis 60 (10.3%)
   Cryptogenic 33 (5.7%)
   Metabolic 20 (3.4%)
   Others 92 (15.8%)
re-LTx 65 (11.1%)
Type of donor  
   DBD 508 (87.0%)
   DCD 76 (13.0%)
Basiliximab induction 413 (70.7%)
Tacrolimus as CNI 404 (69.2%)
Early acute rejection 125 (21.4%)
Late acute rejection 41 (7.0%)
AHF, acute hepatic failure; HCC, hepatocellular carcinoma; HBV, hepatitis B virus infection; HCV, 
hepatitis C virus infection; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; 
AIH, autoimmune hepatitis; DBD, donor after brain death; DCD, donor after cardiac death; CNI, 
calcineurin inhibitor.
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RESULTS
PD-L1 expression in human liver allografts
In liver grafts PD-L1 expression is up-regulated immediately after LT due to ischemia 
and reperfusion injury14. However, whether PD-L1 is expressed in liver allografts during 
acute rejection episodes is unknown. Therefore, we examined the expression of PD-
L1 by immunohistochemistry in pre-LT donor liver biopsies obtained at the end of the 
cold ischemic period and in post-LT liver allograft biopsies taken during acute rejection 
episodes using a validated antibody (405.9A11). Second-trimester placental tissue was 
used as positive control, and we observed strong PD-L1 staining at the microvillous 
membrane and moderate staining in the cytoplasm of the villous syncytiotrophoblasts 
(Fig.1A), in agreement with a previous study20. Absence or low level PD-L1 expression 
was observed in the pre-LT donor biopsies (Fig.1B), but increased expression was found 
in post-LT rejection biopsies in both portal and lobular regions (Fig.1C). In portal regions, 
PD-L1 was expressed by cholangiocytes and infiltrating leukocytes (Fig.1D, left). In the 
lobular region, we observed PD-L1 expression by hepatocytes and along liver sinusoids 
(Fig.1D, right). While cholangiocytes, infiltrating leukocytes and sinusoidal cells showed 
both surface and cytoplasmic staining, PD-L1 expression by hepatocytes was restricted 
to cytoplasm. Immunohistochemistry staining using another validated anti-PD-L1 
antibody (5H1) showed a similar PD-L1 expression pattern (Supplementary Fig.1A). 
The degree of PD-L1 staining was graded in parenchyma and in portal tract (Fig.1E). 
Both early and late rejection biopsies showed significantly higher PD-L1 expression by 
cholangiocytes, infiltrating leukocytes and cells along the liver sinusoids than healthy 
donor liver biopsies. The expression on hepatocytes also tended to be higher in rejection 
biopsies than in healthy donor biopsies, but the difference was not significant. No 
significant difference in PD-L1 expression was observed between early and late rejection 
biopsies. Nevertheless, hepatic PD-L1 is not exclusively induced in liver during graft 
rejection, for example liver with chronic HBV infection showed a similar expression 
pattern (Supplementary Fig.1B). This is in line with a previous study showing that 
hepatic PD-L1 expression is related to inflammation rather than to the etiology of liver 
damage13.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
PD
-1
/P
D-
L1
 In
ter
ac
tio
n 
in
 G
ra
ft 
Re
jec
tio
n
99
Fig.1. PD-L1 expression in liver allograft biopsies. PD-L1 expression was evaluated by 
immunohistochemistry. Representative images of (A) second-trimester placenta tissue, (B) pre-LT 
donor biopsies, and (C) post-LT biopsies with acute rejection, stained with anti-PD-L1 antibody 
(405.9A11, left) or negative control (right). Expression of PD-L1 in post-LT biopsies was observed in 
(D, left) hepatocytes, cholangiocytes, infiltrating leukocytes, and (D, right) along the liver sinusoids. 
(E) The PD-L1 expression level of different cell types was graded and compared between healthy 
donor biopsies (HC), early and late acute rejection biopsies (n=14, 8, 11 respectively). Original 
magnification ×200 (A, B, C) and ×400 (D). *P<0.05, **P<0.01.
PD-1 is highly expressed on graft infiltrating T cells, and PD-1/PD-L1 blockade 
enhances graft infiltrating T-cell proliferation in response to alloantigen
We studied PD-1 expression by flow cytometry on paired samples of peripheral blood 
T cells and allograft-infiltrating T cells isolated from transplanted liver tissues (n=19, 
Supplementary Table 1), and also hepatic T cells isolated from healthy donor liver 
perfusates (n=20). Compared to circulating T cells, PD-1 was expressed at higher levels 
on graft-infiltrating T cells, but no difference was observed between PD-1 expression on 
T cells isolated from transplanted liver and healthy liver perfusates (Fig.2A). There was 
also no difference in PD-1 expression between T cells isolated from rejection biopsies, 
non-rejection biopsies or liver explants due to re-LT (Fig.2B). Together with PD-1, the 
expression of other T-cell co-inhibitory receptors TIM-3, LAG3, CD160 and 2B4 was 
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determined. Compared to PD-1- T cells, their PD-1+ counterparts expressed the other co-
inhibitory receptors at higher levels (except for CD160 expression on CD8 T cells)(Fig.2C). 
To study whether the PD-1/PD-L1 expression is functionally relevant in regulating 
allogeneic responses of graft-infiltrating T cells, we used larger quantities of graft-
infiltrating leukocytes that were isolated from re-LT liver explants (n=5, Supplementary 
Table 1). Allograft-infiltrating cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE), and were stimulated by either donor or third-party derived splenocytes. Co-
cultures were performed in the presence of 10-µg/ml anti-PD-L1 antibody or matched 
isotype. After 5 days, T-cell proliferation was determined by CFSE dilution (Fig.2D). 
Fig.2. PD-1 expression on allograft-infiltrating T cells and the effect of blockade on T-cell 
proliferation. (A) PD-1 expression was measured by flow-cytometry on graft infiltrating T cells, 
and was compared to that on T cells in paired PBMC samples (n=19) and perfusates of healthy 
donor livers (n=20). (B) PD-1 expression on T cells isolated from rejection biopsies (n=7), non-
rejection biopsies (n=7), and re-LT explants (n=5) was also comparted. (C) The expression of other 
T-cell co-inhibitory receptors was compared between PD-1+ and PD-1- graft-infiltrating T cells 
(n=11). (D) Graft-infiltrating leukocytes isolated from explant biopsies were labeled by CFSE and 
were stimulated by donor or third-party splenocytes for 5 days. T-cell proliferation in the presence 
of anti-PD-L1 blocking antibody or isotype-matched control antibody was determined by CFSE 
dilution. *P<0.05, **P<0.01, ***P<0.001.
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Proliferation of both CD4+ and CD8+ graft-infiltrating T cells in response to both donor 
and third-party stimulation were enhanced by PD-1/PD-L1 blockade (with only one 
exception in CD4 proliferation). These results prompted us to further investigate the 
involvement of the PD-1/PD-L1 pathway in the regulation of acute rejection after LT.
Genetic study population and genotyping
For this purpose, we studied the associations between SNPs within donor and recipient 
PD-1 and PD-L1 genes and acute rejection in a large and well-characterized cohort of LT 
patients. 584 patients that underwent LT between 1992 and 2012 were included in this 
study (Table 1). The majority of the recipients (85.6%, 500/584), and all donors, were 
Caucasians. The main indication for LT was autoimmune-related liver diseases (PBC, PSC 
and AIH; 26.4%, 154/584), the second was acute hepatic failure (AHF, 14.6%, 85/584), and 
the third was cirrhosis caused by viral hepatitis (12.2%, 71/584). The overall incidence 
of early (≤ 6 months after LT) acute rejection was 21.4% (125/584), which developed at 
median 10 (range 2-167) days after LT. Recipient age (HR=0.982, p=0.009), donation after 
cardiac death (DCD, HR=0.386, p=0.005), basiliximab as induction immunosuppression 
(HR=0.465, p<0.001), and use of tacrolimus as CNI (HR=0.402, p<0.001), were associated 
with early acute rejection (Supplementary Table 2). The incidence of late (> 6 months 
after LT) acute rejection was 7.0% (41/584), which developed at median 645 (range 186-
6368) days after LT. Previous early acute rejection or re-transplantation did not predispose 
patients to the development of late acute rejection in our cohort (Supplementary Table 
2). As late acute rejection is more likely to occur during the immunosuppression dose 
reduction over time after LT, we compared the blood levels of immunosuppressive 
drugs prior to the occurrence of late acute rejection to the target levels. Blood levels of 
immunosuppressive drugs of 22 (54%) of 41 patients who developed late acute rejection 
were lower than the target level, while 18 (44%) patients remained within normal 
range (Supplementary Table 3). However also in patients without late acute rejection, 
immunosuppression lower than target level is a very common phenomena during 
follow-up. The observed genotype frequencies of all five SNPs in both recipient and 
donor subjects were in agreement with HWE (p>0.05) (Table 2). All call rates were above 
95%, ranging from 95.9% to 97.5%, assuring the genotyping accuracy. No strong linkage 
disequilibrium (LD) was observed between any of the SNPs that we studied (r2<0.8).
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Table 2. Distribution of genotype frequencies and Hardy–Weinberg Equilibrium (HWE)
Genotype Recipient n=5281 2 3 Total MAF χ2 P Call rate
PD-1 GG GA AA      
rs11568821 386 119 7 512 0.13 0.41 0.52 97.0%
PD-1 TT TC CC  
rs2227981 182 242 86 510 0.41 0.13 0.72 96.6%
PD-1 GG GA AA      
rs10204525 404 98 11 513 0.12 2.90 0.09 97.2%
PD-L1 GG GA AA  
rs1411262 261 201 53 515 0.30 2.33 0.13 97.5%
PD-L1 GG GC CC      
rs4143815 281 190 44 515 0.27 2.10 0.15 97.5%
Genotype Donor n=4101 2 3 Total MAF χ2 P Call rate
PD-1 GG GA AA      
rs11568821 291 104 4 399 0.14 2.56 0.11 97.3%
PD-1 TT TC CC  
rs2227981 131 189 73 393 0.43 0.11 0.74 95.9%
PD-1 GG GA AA      
rs10204525 320 69 4 393 0.10 0.02 0.90 95.9%
PD-L1 GG GA AA  
rs1411262 218 156 23 397 0.25 0.51 0.48 96.8%
PD-L1 GG GC CC      
rs4143815 199 165 34 398 0.29 0.00 0.98 97.1%
MAF, minor allele frequency
Univariate analysis of associations between donor and recipient SNPs and acute 
rejection
Early and late acute rejection were used as separate endpoints in the univariate analysis 
by Cox proportional-hazards regression model. Due to the small sample size of the minor 
allele homozygous groups, we compared patients or donors carrying minor alleles to 
those major allele homozygotes. We first analyzed the correlation between donor SNPs 
and acute rejection (Fig.3A). SNPs within donor PD-1 gene were not associated with 
the occurrence of acute rejection. In addition, donor PD-L1 SNPs were not significantly 
associated with the development of early acute rejection. However, patients receiving 
liver grafts obtained from donors carrying the C allele of PD-L1 rs4143815 had a lower 
incidence of late acute rejection (HR=0.32; 95%CI=0.14-0.76; p=0.006). Next we analyzed 
the correlation between recipient SNPs and acute rejection (Fig.3B). Recipients carrying 
the A allele of PD-1 rs11568821 had an increased risk to develop late acute rejection 
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(HR=2.21; 95%CI=1.16-4.17; p=0.019). This association was marginally non-significant if 
Bonferroni correction was applied (to a p-value<0.01), however it became more significant 
when only Caucasian recipients were taken into account (HR=2.48; 95%CI=1.26-4.92; 
p=0.011). None of the recipient PD-L1 SNPs was significantly associated with the 
development of acute rejection.
Fig.3. Univariate analysis of associations between SNPs and acute rejection after LT. The 
associations between (A) donor / (B) recipient SNPs and acute rejection were analyzed by Cox 
proportional-hazards regression model with a likelihood ratio test, and 180 days post-LT was used 
as the cut-off to define early and late acute rejection.
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Multivariate analysis of associations of SNPs and baseline characteristics with acute 
rejection
Firstly, both recipient PD-1 rs11568821 and donor PD-L1 rs4143815 were analyzed in 
the multivariate Cox proportional-hazards regression model together with patient age 
(continuous), ethnicity, primary liver diseases, type of donation, basiliximab as induction 
immunosuppression, and the type of CNI. The year of transplantation (continuous) was 
also included in the model as patient management has been significantly improved 
overtime during our study period (Table 3). After adjusting for covariates, both 
donor PD-L1 rs4143815 (HR=0.230; 95%CI=0.081-0.654; P=0.002)(Fig.4A) and recipient 
PD-1 rs11568821 (HR=3.739; 95%CI=1.534-9.116; P=0.004)(Fig.4B) were found to be 
independent factors significantly associated with acute rejection late after LT. Next 
we stratified patients by combinations of recipient PD-1 rs11568821 and donor PD-L1 
rs4143815 (Table 3). Recipient PD-1 AA/AG and donor PD-L1 GG combination showed 
the highest risk to develop acute rejection late after LT adjusted for covariates (compared 
to combination of recipient PD-1 GG and donor PD-L1 GG; HR=5.248; 95%CI=1.932-
14.26; p=0.0003)(Fig.4C). Finally we analyzed the multiplicative interaction between 
recipient PD-1 rs11568821 and donor PD-L1 rs4143815 (Table 3), however the interaction 
was not significant (p=0.128).
Table 3. Multivariate analysis of recipient and donor SNPs adjusted for patient characteristics
Variables HR 95% CI P-value
Recipient PD-1 rs11568821 AA+AG vs GG 3.739 (1.534-9.116) 0.004
Donor PD-L1 rs4143815 CC+CG vs GG 0.230 (0.081-0.654) 0.002
Combinations of recipient PD-1 rs11568821 and donor PD-L1 
rs4143815   0.0003
   Recipient PD-1 GG / Donor PD-L1 GG 1.000  
   Recipient PD-1 GG / Donor PD-L1 CC+GC 0.441 (0.125-1.552)  
   Recipient PD-1 AA+AG / Donor PD-L1 GG 5.248 (1.932-14.26)  
   Recipient PD-1 AA+AG / Donor PD-L1 CC+GC 0.389 (0.047-3.231)  
Multiplicative interaction of recipient PD-1 rs11568821 and donor 
PD-L1 rs4143815    
   Recipient PD-1 rs11568821 AA+AG vs GG 5.248 (1.932-14.26) 0.001
   Donor PD-L1 rs4143815 CC+CG vs GG 0.441 (0.125-1.552) 0.185
   Recipient PD-1 rs11568821 × Donor PD-L1 rs4143815 0.168 (0.014-2.035) 0.128
Adjusted for patient ethnicity, age, primary liver diseases, types of donor, induction immuno-
suppression, CNI, and year of transplantation. 
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Fig.4. Multivariate analysis of the associations between donor and recipient SNPs and acute 
rejection late after LT. Cox proportional hazards model survival functions of the relationship 
between (A) donor PD-L1 rs4143815, (B) recipient PD-1 rs11568821, (C) combination of recipient 
PD-1 rs11568821 and donor PD-L1 rs4143815 with acute rejection late after LT, adjusted for recipient 
age, ethnicity, primary liver diseases, type of donor, types of induction immunosuppression and 
CNI, and the year of transplantation. 
PD-L1 rs4143815 is associated with differential PD-L1 expression by hepatic dendritic 
cells upon IFN-γ stimulation
Whether PD-L1 rs4143815 alters PD-L1 expression was unknown, thus we aimed to 
determine PD-L1 expression on donor liver cells of different genotypes. Due to the 
unavailability of viable liver parenchymal cells with known genotypes, we determined 
PD-L1 expression on hepatic leukocytes derived from donor liver perfusates as an 
alternative. PD-L1 expression on hepatic T cells, B cells, NK cells, NKT cells, macrophages/
monocytes or BDCA1+ dendritic cells (DC) did not differ between donors with different 
rs4143815 genotypes (PD-L1 rs1411262 genotypes were matched between groups). 
When we used IFN-γ to induce PD-L1 expression, after 24 hours PD-L1 expression on 
macrophages/monocytes and DCs was strongly enhanced in a dose-dependent manner, 
but not on T cells, B cells, NK cells nor NKT cells (Fig.5A). Interestingly, hepatic BDCA1+ 
DCs with rs4143815 CC genotype showed higher PD-L1 expression than those with 
GG genotype after IFN-γ stimulation (Fig.5B). No difference was observed in PD-L1 
expression on macrophages/monocytes from donors with different rs4143815 genotypes 
(Fig.5C).
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Fig.5. PD-L1 rs4143815 is associated with differential IFN-γ-induced PD-L1 expression on 
hepatic BDCA1+ dendritic cells. (A) Representative histograms showing the effects of different 
concentrations of IFN-γ on PD-L1 expression on hepatic leukocytes isolated from liver allograft 
perfusates. PD-L1 expression on (B) hepatic dendritic cells (DCs) and (C) macrophages/monocytes 
were compared between rs4143815 genotypes, shown by mean fluorescence intensity (MFI) (CC 
n=10, CG n=8, GG n=9). *P<0.05.
DISCUSSION
Although several studies have shown the involvement of PD-1/PD-L1 co-inhibitory 
pathway in modulation of graft tolerance in animal models, evidence for a role in 
regulating alloimmune responses and graft rejection in humans is still lacking. In the 
present study, we first showed that PD-L1 and PD-1 are abundantly expressed in liver 
allografts, and that PD-1/PD-L1 blockade leads to enhanced intragraft T-cell proliferation 
to allostimulation. Next, in the genetic association analysis, we found that recipient PD-1 
rs11568821 and donor PD-L1 rs4143815 are associated with acute rejection late after 
transplantation, both in univariate and multivariate analysis. Finally, we showed that 
PD-L1 rs4143815 is associated with differential PD-L1 expression on hepatic BDCA1+ 
DCs upon IFN-γ stimulation. To the best of our knowledge, this is the first study showing 
that PD-L1/PD-1 interaction is regulating graft rejection after organ transplantation in 
humans, and our data support an interplay between donor PD-L1 and recipient PD-1.
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Intrahepatic PD-L1 expression was up-regulated in rejection biopsies compared to 
healthy donor liver, similar to what has been observed in inflamed livers of different 
etiologies13. Up-regulation of PD-L1 in liver has been shown to be driven by IFN-γ11, 
and we conclude that it represents a counter-regulatory mechanism to dampen ongoing 
intrahepatic T-cell alloreactivity. This is supported by a recent study describing a immune 
control mechanism utilized by murine liver allografts to eliminate effector T cells and 
maintain tolerance, which is triggered by IFN-γ induced PD-L1 expression in the graft21. 
Hepatocytes showed only cytoplasmic and no membrane expression. Although PD-L1 
can exerts its inhibitory effect on T cell functions only when expressed on cell surface, 
cytoplasmic expression has been detected in many tissues22-24, including inflamed liver, 
and also in cultured hepatocytes13, 14. It has recently been hypothesized that cytoplasmic 
expression may represent intracellular stores of PD-L1, which may be deployed to the 
cell surface depending upon appropriate stimulation25. Alternatively, cytoplasmic PD-
L1 may be released from hepatocytes as a soluble form into the micro-environment and 
thereby exert suppressive effects26. Moreover we found that PD-1 is highly expressed 
on T cells infiltrating transplanted liver allografts irrespective from their graft damage 
etiology and on T cells in healthy livers, in agreement with the observations of Kroy 
et al9, suggesting that the abundant presence of PD-1 in liver may be a reflection of its 
immunologically tolerogenic environment. And this PD-1/PD-L1 interaction is non-
specifically limiting intrahepatic allogeneic T-cell responses rather than contributing to a 
donor-specific hypo-responsiveness.
 
PD-1 rs11568821 (also named as PD-1.3) is located in an enhancer-like structure in intron 
4 of PDCD1 gene, which is the binding site for transcription factor RUNX127. The minor 
A allele of PD-1 rs11568821 disrupts the binding of RUNX1 shown by electrophoretic 
mobility shift assays, leading to altered transcriptional activity of PD-1 mRNA, reduced 
PD-1 protein expression and impaired PD-1 inhibitory effect27-30. However in a luciferase 
reporter assay, the A allele did not alter the gene transcriptional activity, casting doubts 
on the functional relevance of rs1156882131. Despite this controversy, the PD-1 rs11568821 
A/G polymorphism is associated with a variety of immune-related diseases, such as 
systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, primary biliary 
cirrhosis, type 1 diabetes, and also with cytomegalovirus infection and the sustained 
virological response of HCV patients in response to treatment. Two studies have analyzed 
the effect of PD-1 rs11568821 on LT outcome, and no association with acute rejection was 
found17, 18. However both studies were hampered by their small sample size, and only 
rejections within 1 month or 6 months after LT, respectively, were analyzed. In agreement 
with these two studies, we did not find an association of recipient PD-1 rs11568821 with 
acute rejection early after LT. However, it independently influenced the occurrence of 
acute rejection late after LT. 
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PD-L1 rs4143815 is located in the binding site of miR-570 to the 3’-UTR of PD-L1 gene32. 
Genetic variants in the 3’-UTR of target mRNA can affect gene expression by inducing an 
altered binding pattern between miRNA and mRNA33. The C allele of PD-L1 rs4143815 
resulted in an increased transcriptional activity in a luciferase reporter assay by interfering 
with miR-570 function, and was associated with increased gastric cancer risk, possibly 
as a result of suppression of immunological tumor surveillance by increased PD-L1 
expression32. In addition, the G allele of PD-L1 rs4143815 is more frequently observed 
in patients with type 1 diabetes, in whom also lower plasma PD-L1 concentrations were 
found34. We observed that patients receiving a donor liver carrying the C allele had an 
decreased risk to develop late acute rejection. No difference in the baseline expression 
of PD-L1 was found on donor hepatic leukocytes of distinct rs4143815 genotypes. PD-
L1 can be induced by pro-inflammatory cytokines such as IFN-γ in various cell types35. 
We found that donor hepatic BDCA1+ DCs carrying the C allele of rs4143815 expressed 
PD-L1 at higher levels in response to IFN-γ stimulation. On one hand, donor DCs are 
the main instigators of allogeneic responses after LT36, 37. On the other hand, they are 
important for the maintenance of a tolerogenic liver environment, which is partially 
mediated by PD-L138, 39. Thus, donor-derived hepatic BDCA1+ DCs carrying the C allele 
may counteract allogeneic T-cell responses after transplantation by increased expression 
of PD-L1. PD-L1 expression in other cell types within liver could also be regulated by 
this SNP. We showed that PD-L1 was also expressed by non-hematopoietic cells, such as 
hepatocytes and cholangiocytes in liver allografts. As donor-derived non-hematopoietic 
cells are less likely to be replaced by cells of recipient origin after LT than donor-derived 
hematopoietic cells, they may counter-regulate T-cell responses for a longer term after LT 
than donor-derived DCs. In addition, in experimental animal models, PD-L1 expressed 
on non-hematopoietic cells is better at limiting tissue immunopathology than that 
expressed on hematopoietic cells40. In agreement with heart transplantation studies in 
mice41, 42, our results indicate that donor PD-L1 may be more important than recipient 
PD-L1 in the regulation of liver allograft rejection, and support a central role of PD-L1 in 
regulating hepatic immunity in response to inflammation12. 
Furthermore, it is very interesting that the association between both SNPs and acute 
rejection is only observed late after transplantation. It could be that the high levels of 
immunosuppressive medication given early after transplantation overrule the effects 
of these SNPs. As a result of reduction of immunosuppression over time, the PD-1/
PD-L1 pathway might play a more dominant role in preventing rejection late after 
transplantation. In addition, high levels of immunosuppressive drugs, especially 
calcineurin inhibitors, can suppress the up-regulation of PD-1 upon T-cell activation, 
thereby inhibiting this immunoregulatory mechanism43.
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Our study has limitation that needs to be acknowledged. Even though this study is 
based on a large and unique cohort of LT patients containing both donor and recipient 
samples, the genetic associations should be validated in an independent cohort in the 
future. However, it would be even more interesting and clinically relevant to study 
the effects of PD-1/PD-L1 SNPs in immunosuppression withdrawal or minimization 
studies, which may help identifying patients that are more tolerant to no or low level of 
immunosuppression.
To conclude, we provide the first evidence of the involvement of PD-1/PD-L1 pathway 
in allograft rejection in humans. Our data suggest a critical interplay between donor PD-
L1 and recipient PD-1 in counter-regulating graft rejection, and that targeting of PD-1 by 
administration of an appropriate agonist, such as PD-L1 Ig fusion protein44, 45, may be an 
interesting avenue to develop novel immunosuppression strategies.
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SUPPLEMENTARY MATERIALS AND METHODS
Immunosuppression therapy
The standard immunosuppressive therapy in our center consisted of prednisone, 
calcineurin inhibitor (CNI; cyclosporine, CsA or tacrolimus, Tac), with or without 
azathioprine or mycophenolate mofetil (MMF). Since 1998 basiliximab was introduced 
as induction immunosuppression, and since 1996 CsA was gradually replaced by Tac. 
After CsA was initiated within 24 hours post-reperfusion in a dose of 10-15 mg/kg body 
weight/day, the dosage was adjusted to trough levels of 200-400 ng/mL during the first 
3 months and thereafter 100-200 ng/mL. Tac was initiated within the first 5 days after 
transplantation in a dose of 1-2 mg/kg body weight/day. The target trough level of Tac 
was 10–15 ng/ml in the first month, 8–12 ng/ml between 1 to 6 months, 5-10 ng/ml 
between 6 to 12 months, and 4-8 ng/ml after 1 year.
DNA extraction, selection and determination of gene polymorphisms
DNA was extracted from whole blood of recipients and from splenocytes of deceased 
donors using a DNA Purification kit (Promega, Madison, Wisconsin, USA) according to 
the manufacturer’s instructions. SNPs were selected based on the literature, which were 
either functionally relevant or had been found to be associated with immune-related 
diseases, and had a minor allele frequency >10%27-30, 32, 46-53. Genotyping was performed 
by LGC (http://www.lgcgroup.com/) using a competitive allele-specific PCR (KASPTM) 
technique. Pairwise linkage disequilibrium (LD) between the SNPs was calculated by 
SNAP pairwise LD tool (http://www.broadinstitute.org/mpg/snap/ldsearchpw.php)54.
Cell isolation
Intragraft leukocytes were isolated from needle liver biopsies, and from liver tissue of 
explanted allografts obtained during re-LT. Liver tissues were digested with 0.5 mg/
mL collagenase IV (Sigma-Aldrich, St. Louis, MO) and 0.1 mg/mL DNase I (Roche, 
Indianapolis, IN) for 30 minutes at 37°C. Tissues were smashed through 70 µm cell 
strainers, and cells which went through the strainers were collected. For explant tissues, 
additional Ficoll density gradient centrifugation was performed to purify mononuclear 
leukocytes. Isolation of PBMC from LT patients, and splenocytes from splenic tissue 
derived from liver donors, were performed as previously described55. Healthy liver graft 
perfusates were collected during the second back table flush. These perfusates contain 
donor liver leukocytes with minimal contamination of peripheral blood leukocytes56. 
Hepatic leukocytes from perfusates were isolated within 12 hours by Ficoll density 
gradient centrifugation, and were cryopreserved for future experiments.
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Cell culture and stimulation
Graft infiltrating leukocytes isolated from explant tissues were labeled with 0.1 µM 
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen, Carlsbad, CA) and co-cultured 
with either donor or third-party (mismatched at HLA-A, B and DR loci with both donor 
and recipient) splenocytes (from which CD3+ cells were depleted using CD3 microbeads, 
Miltenyi Biotec, Bergisch Gladbach, Germany), at a ratio of 1:1 for 5 days in round-bottom 
96-well plates. Co-culture was performed in the presence of blocking antibody for PD-
L1 (clone 5H1, 10 µg/ml, kindly provided by Dr. Haidong Dong, Mayo Foundation for 
Medical Education and Research)24, 57 or matched IgG1 isotype control antibody (10 µg/
ml, eBioscience, San Diego, CA). T-cell proliferation was measured by determination of 
CFSE-dilution in CD4+ and CD8+ T cells on day 5 by flow cytometry.
Donor hepatic leukocytes were stimulated with different concentrations of recombinant 
human IFN-γ (Miltenyi Biotec, Bergisch Gladbach, Germany) in RPMI 1640 culture 
medium supplemented with 10% heat-inactivated fetal calf serum and 1% Penicilline/
Streptomycine for 24 hours, and PD-L1 expression was measured by flow cytometry.
Flow cytometry and antibodies
The following antibodies were used: PD-L1-PE-Cy7, CD3-PE-Cy7, CD3-APC-eFluor780, 
CD4-APC-eFluor780, CD8-eFluor450, PD-1-APC, PD-1-PE-Cy7, 2B4-APC (eBioscience, 
San Diego, CA); CD19-HorizonV500 (BD Biosciences, San Diego, CA), CD56-APC 
(Beckman Coulter, Marseille, France), CD14-Pacific Blue (BD Pharmingen, Erembodegem, 
Belgium), BDCA1-PE (Miltenyi Biotec, Bergisch Gladbach, Germany), LAG-3-PE (R&D 
Systems, Minneapolis, MN), CD160-PerCP-Cy5.5, TIM3-Brilliant-Vio421 (Biolegend, San 
Diego, CA). Non-viable cells were excluded using 7-AAD (BD Biosciences, San Diego, 
CA) or LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Carlsbad, CA). 
Phenotypes of donor hepatic leukocytes were defined as follows: T cells (CD3+CD56-), B 
cells (CD19+), NK cells (CD3-CD56+), NKT cells (CD3+CD56+), macrophages/monocytes 
(CD14+), dendritic cells (DCs, CD19-BDCA1+). Flow cytometry was performed using a 
FACSCanto II flow cytometer (BD Biosciences, San Diego, CA). Data were analyzed with 
FlowJo software (FlowJo, Ashland, OR, USA).
Immunohistochemistry
PD-L1 expression was evaluated by Immunohistochemistry (IHC) on formalin-fixed, 
paraffin-embedded sections (4µm) from second-trimester placental villi tissue (positive 
control), in liver allograft biopsies with early acute rejection (n=8), late acute rejection 
(n=11) and in biopsies taken from the donor livers at the end of the cold ischemic period 
(n=14). Early and late rejection biopsies showed similar rejection activity manifested by 
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similar RAI score. Antigen-retrieval was performed by heating in a microwave in Tris/
ethylene diamine tetra-acetic acid (pH 9.0) buffer. Endogenous peroxidase blockage was 
performed by incubation for 15 minutes with 0.05% H2O2 in citric/phosphate buffer 
(pH 5.8). Tissue sections were labeled with an extensively validated mouse monoclonal 
anti-PD-L1 antibody (13 µg/mL, clone 405.9A11)58, 59, kindly provided by Dr. Gordon 
Freeman, Dana-Farber Cancer Institute, Boston, MA. The EnVision system HRP labelled 
polymer goat-anti-mouse antibody (Dako, Glostrup, Denmark) was used to visualize 
PD-L1 expression. Counterstaining was performed using hematoxylin. In addition, a 
selection of biopsies were stained using another validated anti-PD-L1 antibody (5H1), 
according to a previously described protocol with minor modifications60. Scoring of 
immunohistochemical stainings was performed by two investigators and differences 
were resolved by mutual agreement. PD-L1 expression on biopsies was graded on a 0-2 
scale. Mean values of at least 3 microscopic fields of parenchymal tissue and of 3 different 
portal tracts were calculated for each biopsy.
Statistics
Calculation of Hardy–Weinberg Equilibrium (HWE) was performed at http://www.
oege.org/software/hwe-mr-calc.shtml61. Actual and expected genotype frequencies of 
both donors and recipients were compared using Chi-Square analysis and p-values of 
>0.05 were considered as no deviation from HWE.
Patient baseline characteristics were summarized using median with range for continuous 
variables and percentages for discrete variables. Early and late acute rejections were used 
as separate endpoints in analysis. The associations between acute rejections and patient 
characteristics, as well as SNPs, were analyzed using the Cox proportional-hazards 
regression model with a likelihood ratio test. We first performed univariate analysis for 
each SNP. SNPs with p-values <0.05 were included in the multivariate analysis together 
with recipient age, ethnicity, primary liver diseases, type of donation, use of basiliximab 
as induction immunosuppression, type of CNI, and the year of transplantation. Linearity 
of continuous variables and clinically relevant interactions were tested. Where multiple 
pairwise comparisons were made, a Bonferroni correction was applied, and p-values 
<0.01 were considered significant. SPSS v. 21 was used for statistical analysis.
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Supplementary Fig.1. (A) Representative immunohistochemistry staining of PD-L1 on acute 
rejection biopsies (clone 5H1). (B) Representative immunohistochemistry staining of PD-L1 on 
biopsies with chronic HBV-infection (clone 405.9A11).
Supplementary Table 1. List of patients studied for liver allograft infiltrating T cells
 Total n=19 Rejection biopsies    n=7
Non-rejection biopsies 
n=7
Re-LT explants
n=5
Primary liver diseases    
   Viral 1 2 0
   Autoimmune 4 1 2
   Others 2 4 3
*Time after LT, months 6 11 57
Indications for re-LT    
   PSC recurrence - - 2
   Chronic rejection - - 2
   ITBL - - 1
*AST, U/L 79 82 1394
*ALT, U/L 134 239 603
*RAI score 5 2 0
*Median values are displayed. PSC, primary sclerosing cholangitis; ITBL, ischemic-type biliary 
lesions; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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Supplementary Table 2. Association between patient characteristics and acute rejection
Patient characteristics Early acute rejection Late acute rejectionHR 95%CI P-value HR 95%CI P-value
Recipient age 0.982 (0.969-0.995) 0.009 0.982 (0.958-1.005) 0.137
Recipient gender, female 1.250 (0.878-1.780) 0.217 1.173 (0.631-2.179) 0.615
Donor age 0.999 (0.988-1.010) 0.812 0.984 (0.965-1.003) 0.099
Donor gender, female 0.904 (0.637-1.284) 0.573 1.034 (0.560-1.909) 0.914
Patient ethnicity  0.548 0.983
   Caucasian 1.000  1.000  
   African 1.051 (0.550-2.008)  0.905 (0.278-2.942)  
   Asian 0.656 (0.288-1.492)  1.041 (0.320-3.390)  
Primary liver diseases  0.136 0.220
   HBV/HCV 1.000  1.000  
   AHF 1.746 (0.893-3.413)  1.261 (0.437-3.635)  
   HCC 0.666 (0.285-1.557)  0.455 (0.091-2.264)  
   PBC/PSC/AIH 1.398 (0.745-2.625)  1.495 (0.589-3.794)  
   Alcoholic cirrhosis 0.960 (0.430-2.143)  0.437 (0.088-2.165)  
   Cryptogenic 0.786 (0.280-2.206)  1.060 (0.265-4.240)  
   Metabolic 0.750 (0.214-2.630)  0.628 (0.076-5.219)  
   others 1.388 (0.695-2.772)  0.360 (0.073-1.785)  
re-LTx 1.116 (0.640-1.946) 0.703 0.855 (0.263-2.776) 0.789
Type of donor, DCD 0.386 (0.180-0.826) 0.005 0.560 (0.134-2.333) 0.384
Basiliximab induction 0.465 (0.327-0.663) 0.000 0.801 (0.417-1.539) 0.510
Tacrolimus as CNI 0.402 (0.283-0.572) 0.000 0.621 (0.324-1.188) 0.152
Early acute rejection - - - 1.382 (0.713-2.676) 0.348
The associations between acute rejections and baseline characteristics were analyzed using the Cox 
proportional-hazards regression model. P-values were calculated with a likelihood ratio test.
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Supplementary Table 3. The level of immunosuppressive drugs prior to the occurrence of late 
acute rejection.
Immunosuppression Target level n %
CsA C0 n=13 <100 ng/mL 9 69%
 100-200 ng/mL 3 23%
 >200 ng/mL 1 8%
CsA C2 n=5 <400 ng/mL 2 40%
 400-600 ng/mL 3 60%
Tac C0 n=17 <4 ng/mL 9 53%
 4-8 ng/mL 6 35%
 >8 ng/mL 2 12%
MMF C0 n=3 <1 mg/L 1 33%
 1-3.5 mg/L 2 67%
Everolimus C0 n=2 <8 1 50%
 8-12 1 50%
All patients n=41 lower than target level 22 54%
 within normal range 18 44%
 unknown 1 2%
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ABSTRACT
Studies on indirect allorecognition in transplanted patients are hampered by the lack 
of a reliable in vitro method to present alloantigens indirectly to T cells. The aim of this 
study is to develop a novel approach enabling specific detection of human CD4+ T cells 
with indirect allospecificity. By in vitro transcription we engineered mRNA encoding 
HLA-A*0201, but we excluded the transmembrane region from the DNA construct to 
prevent the possibility of direct allorecognition. HLA-A*0201neg/HLA-DRB1*0101pos 
peripheral B cells were expanded and differentiated into antigen presenting B-cell blasts 
(CD40-B), and transfected with HLA-A*0201-encoding mRNA. No surface expression of 
HLA-A2 was observed on transfected CD40-B, but an HLA-DRB1*0101 restricted CD4+ 
T-cell clone recognizing an HLA-A*0201 derived peptide produced IFN-γ upon co-culture 
with the transfected CD40-B, which could be completely prevented by MHC class II 
blockade. Using autologous CD40-B transfected with HLA-A*0201 mRNA, CD4+ T cells 
responding to indirectly presented HLA-A2 were detected in HLA-A2-negative liver 
transplant patients transplanted with livers of HLA-A2 positive donors. In conclusion, 
using engineered HLA mRNA, we developed a novel technique to specifically measure 
human T cells with indirect allospecificity, which may be a promising tool to study 
indirect allorecognition in human transplant recipients.
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INTRODUCTION
T cells that recognize mismatched donor HLA-molecules are the major driving force 
of allograft rejection. Recipient T cells can recognize foreign HLA-molecules via two 
different mechanisms, the direct pathway and the indirect pathway1. The direct pathway 
describes the recognition of intact allogeneic HLA molecules expressed on donor cells 
by recipient T cells, while the indirect recognition pathway describes a more “natural” 
process of T-cell activation, in which recipient antigen-presenting cells (APCs) take 
up alloantigens from the transplanted organ, process and present them as peptides 
to recipient CD4+ T cells. More recently, another semi-direct pathway of alloantigen 
recognition has been suggested, in which recipient T cells recognize intact donor MHC 
molecules taken up and presented as intact molecules by recipient antigen-presenting 
cells (APC)2, 3.
It is believed that the direct pathway drives early acute allograft rejection, but that it 
subsides upon gradual depletion of donor-derived APC later after transplantation. 
Meanwhile the indirect pathway kicks in and remains active as long as the graft is 
present4, 5. Recipient T cells recognizing donor HLA via the indirect pathway are therefore 
thought to be related to long-term transplant outcomes, such as chronic rejection. Indeed, 
augmented T-cell responses to donor HLA-derived peptides presented by recipient MHC 
have been observed in transplanted patients with chronic rejection6-15. Experimental 
animal studies have shown that CD4+ T cells which indirectly recognize alloantigens 
provide help to cytotoxic CD8+ T cells and to donor-reactive B cells to produce donor-
specific antibodies16-20. In addition, recent evidences suggest that regulatory T cells with 
indirect allospecificity are superior in promoting allograft tolerance than Treg with direct 
allospecificity, and constrain both cellular and humoral allogeneic immune responses21-24.
However, studies on indirect allorecognition in humans are hampered by the lack of 
a reliable ex vivo assay to detect T cells with indirect allospecificity. Two different 
techniques have been mainly used to detect indirect T-cell allorecognition, which have 
been previously reviewed25. In the first approach, recipient APC are incubated with 
donor-derived cellular fragments, which has the advantage that it may result in the 
presentation of the full natural peptide repertoire of donor-derived alloantigens8, 10, 11, 
13. However the major drawback of this technique is that the cellular fragments contain 
intact HLA molecules and costimulatory molecules, which may activate T cells via direct 
or semi-direct pathways. A recent study showed that the use of cellular fragments indeed 
induces T-cell responses via the semi-direct pathway, casting doubts on previous studies 
using this technique to study indirect alloreactivity26. Another common technique uses 
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synthetic peptides derived from mismatched donor HLA. Since little is known about the 
immunodominance of HLA-peptides, either randomly selected or overlapping peptides 
are used in such studies6, 7, 12, 15, 17. However, apart from the practical difficulty of testing 
ex vivo T-cell responses to a large library of different peptides to cover the complete 
potential peptidome of mismatched HLA, the generation of synthetic peptides involves 
an unnatural way of antigen processing, which may introduce neo-epitopes that do not 
exist in vivo. Indeed, by using synthetic HLA-peptides ex vivo T-cell responses to self 
HLA have been observed in patients awaiting renal transplantation, in healthy subjects, 
and even in cord blood25, 27.
The aim of this study is to develop a novel ex vivo assay, which overcomes the 
disadvantages of the previous methods, to monitor T-cell responses with indirect 
allospecificity in patients after organ transplantation. Since CD8+ T cells with indirect 
specificity are thought to be less relevant in organ transplantation28, we focus on indirect 
alloantigen presentation to CD4+ T cells. We introduce indirect alloantigen presentation 
by electroporation of autologous APC with in vitro transcribed messenger RNA (mRNA) 
encoding for mismatched donor HLA. The transfected autologous APC utilize their 
cellular machinery to synthesize and process mismatched donor HLA, and present a 
full repertoire of natural allo-HLA peptides to T cells. This technique has previously 
been demonstrated to be very effective in generating antigen-specific T-cell responses 
to tumor-associated antigens, however has not been yet applied in the transplant-
immunology field29-33.
MATERIALS & METHODS
Expansion of human B cells by stimulation with trimeric CD40-ligand
PBMC were isolated by Ficoll gradient centrifugation from HLA-typed buffy coats 
obtained from the Sanquin Blood Bank (Rotterdam, The Netherlands), or from peripheral 
blood of HLA-A2 negative liver transplant (LT) recipients transplanted with allografts 
from HLA-A2 positive donors (Erasmus MC, Rotterdam, The Netherlands). The study 
was approved by the Medical Ethics Committee of Erasmus MC, and written informed 
consent was obtained from all patients. On day 0, PBMC were seeded on 6-well plates 
(Costar, Cambridge, USA) at a concentration of 2-3×106 cells/ml in IMDM (Lonza, Breda, 
The Netherlands) with 10% heat inactivated human serum, 1% penicillin/streptomycin, 
1% insulin-transferrin-selenium solution (Gibco-Invitrogen, Breda, the Netherlands), 
40 IU/ml recombinant human interleukin-4 (rhIL-4, Strathmann Bioscience, Germany), 
and 1 µg/ml soluble human trimeric CD40 ligand (sCD40L, kindly provided by 
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Celldex Therapeutics, Hampton, NJ, USA). During the first 7 days of culture, 1 µg/ml 
cyclosporine A (CsA, Novartis, Basel, Switzerland) was also added to prevent T-cell 
expansion. CD3+ cells were depleted by magnetic-activated cell sorting using CD3 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) on day 7. Since then cells 
were passed every 3-4 days at a concentration of 0.8×106 CD19+ cells/ml in the presence 
of rhIL-4 and sCD40L but without CsA. The purity of CD40-stimulated B cells (CD40-B) 
was checked during every passage using flow-cytometry.
In vitro generation of engineered HLA messenger RNA
A schematic overview of the constructed vectors is depicted in Figure 1. The back bone 
vector pST1 was kindly provided by U. Sahin (Johannes-Gutenberg University, Mainz, 
Germany)34. The first vector, pST1-HLA-A*0201, contains the complete HLA-A*0201 
sequence, including the transmembrane and cytoplasmic parts. The second vector, 
pST1-HLA-A*0201-delTM-DCL, contains a codon-optimized insert that encodes 
the α1, α2 and α3 domains of the HLA-A*0201 protein except the transmembrane 
region, to prevent surface expression of HLA-molecules that might result in direct 
allorecognition. The extracellular part of HLA-A2 in this construct is directly followed 
by a sequence encoding the transmembrane and luminal regions of Dendritic Cell 
Lysosome Associated Membrane Protein (DCLamp), which is a targeting signal for the 
endo-lysosomal compartment, resulting in peptide loading in MHC-II35-39. Both HLA 
inserts were synthesized by GeneArt (Life Technologies, Gent, Belgium). Prior to in vitro 
transcription, the DNA plasmids were linearized with SapI. In vitro RNA transcription 
was performed using T7 RNA polymerase according to the manufacturer’s instructions 
(Ambion mMESSAGE mMACHINETM kit, Austin, TX, USA). The quality of the in 
vitro transcribed mRNA was confirmed by agarose gel electrophoresis and the mRNA 
concentration was measured by spectrophotometry.The obtained mRNA were stored in 
small aliquots at -20°C till use.
Messenger RNA electroporation
Before electroporation, CD40-B were washed twice, first with serum-free IMDM (Lonza, 
Breda, The Netherlands) and subsequently with Opti-MEM (Life technologies, Bleiswijk, 
The Netherlands). 8-10×106 CD40-B were resuspended in a final volume of 200 µL of 
Opti-MEM containing 20 µg of mRNA. Electroporation was performed in a 4 mm gap 
cuvette using a Gene Pulser XcellTM electroporation system (Bio-Rad Laboratories, 
Hercules, CA). We used a square wave pulse of 600 V in a pulse time of 0.6 ms in all 
experiments, which was found to yield optimal CD40-B survival, HLA-A2 surface 
expression and T-cell activation (data not shown). Immediately after electroporation, 
CD40-B were transferred into IMDM without phenol red (Life Technologies, Bleiswijk, 
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The Netherlands) with 10% heat-inactivated human serum, 1% penicillin/streptomycin 
and 1% insulin-transferrin-selenium solution. Two hours after electroporation, cells were 
harvested for further experiments.
Figure 1. Schematic representation of the DNA constructs used for in vitro generation of HLA 
mRNA. (A) The T7 promotor, 3’ flanked untranslated region (3’UTR), 120bp-long poly-A tail, and 
the unique HindIII, BamH1 and Sapl sites of the pST1 backbone vector are shown. The 3’ UTR 
and the 120 poly-A tail are attached to increase stability of the mRNA. The non-functional parts 
of the plasmids are not shown. pST1-HLA-A*0201 contains an insert that encodes the complete 
HLA-A*0201 protein. pST1-HLA-A*0201-delTM-DCL contains an insert that encodes the three 
α units of HLA-A*0201 protein except the transmembrane part, and also DCLamp (DCL). (B) 
Schematic overview of HLA class I protein, consisting of the MHC class I-encoded α-chain and β2-
microglobulin, expressed on cell surface. 
Flow cytometry and antibodies
The following antibodies were used: CD19-APC-eFluor780, HLA-DR-PE, CD83-FITC, 
CD27-APC (eBioscience, San Diego, CA); CD3-PerCP-Cy5.5 (BD Biosciences, San 
Diego, CA); HLA-A2-APC (BD Pharmingen, Erembodegem, Belgium); HLA-A,B,C-
FITC, CD80-PE-Cy7, CD86-Pacific Blue, CD3-PE, CD40-PerCP-Cy5.5 (Biolegend, San 
Diego, CA); CD38-Pacific Blue (Exbio, Vestec, Czech Republic). Non-viable cells were 
excluded using 7-AAD (BD Biosciences, San Diego, CA) or LIVE/DEAD Fixable Aqua 
Dead Cell Stain Kit (Invitrogen, Carlsbad, CA). Flow cytometry was performed using a 
FACSCanto II flow cytometer (BD Biosciences, San Diego, CA). Data were analyzed with 
FlowJo software (FlowJo, Ashland, OR, USA).
CD4+ T-cell clone
A previously described HLA-DRB1*0101 restricted HLA-A*0201-specific CD4+ clone 
4.43, generated from an HLA-A*0201 positive patient with severe graft-versus-host 
disease after hematopoietic stem cell transplantation and donor lymphocyte infusion 
from an HLA-A*0201 negative donor40, was used as responder cells for testing indirect 
presentation of HLA-A*0201. Cells were expanded by non-specific stimulation with 
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2 µg/ml PHA and irradiated allogeneic third-party PBMC as feeder cells, in IMDM 
supplemented with 5% fetal calf serum, 5% human serum, 1% penicillin/streptomycin, 
L-glutamine, and 2 µg/mL IL-2. Every three days T cells were further expanded by 
splitting the cultures and replenishing fresh culture medium without feeder cells. At day 
9, cells were harvested and cryopreserved till further use.
Indirect alloantigen presentation assay
To detect indirectly presented alloantigen, 1x104 cells of the T-cell clone 4.43 were co-
cultured with 5x104 mRNA-transfected CD40-B from an HLA-A*0201 negative/HLA-
DRB1*0101 positive blood bank donor, in triplicate for 24 hours in 96-well U-bottom 
microtiter plates in IMDM supplemented with 10% heat inactivated human serum, 1% 
penicillin/streptomycin and 1% insulin-transferrin-selenium. 4.43 co-cultured with 
CD40-B from an HLA-A*0201 positive/HLA-DRB1*0101 positive donor was used as 
positive control, and 4.43 co-cultured with non-transfected HLA-A2 negative/HLA-
DRB1*0101 positive CD40-B, or 4.43 alone, were used as negative controls. After 24 hours 
incubation, cell-free supernatant was collected and the concentrations of IFN-γ were 
determined by a standard enzyme-linked immunosorbent assay (ELISA) according to 
the manufacturer’s instructions (Life technologies, Bleiswijk, The Netherlands). To check 
for MHC class II restriction, mouse anti-human MHC class II mAb (clone PdV5.2, Santa 
Cruz Biotechnology; 10 µg/ml) was added to the co-cultures.
Detection of patient CD4+ T cells with indirect allospecificity by IFN-γ ELISPOT
CD4+ T cells were isolated by MACS negative selection (Miltenyi Biotec, Bergisch 
Gladbach, Germany) from PBMC samples of HLA-A2 negative patients that were 
transplanted with livers from HLA-A2 positive donors. CD4+ T cells were stimulated 
by pST1-HLA-A*0201-delTM-DCL transfected autologous CD40-B for 7 days in RPMI 
supplemented with 10% human serum, 2 mM L-glutamine, 20 µM β-mercaptoethanol 
and 1% penicillin/streptomycin. On day 7 CD4+ T cells were harvested, B cells were 
depleted using CD19 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), and 
CD4+ T cells were re-stimulated by either pST1-HLA-A*0201-delTM-DCL transfected or 
non-transfected autologous CD40-B in IFN-γ-pre-coated enzyme-linked immunospot 
plates (ELISPOT, Mabtech, Sweden) overnight following manufacture’s protocol. 
Depending on the yields, 2×104 to 1×105 CD4+ T cells were co-cultured with 1×105 
CD40-B per well in triplicate in 200 µl RPMI supplemented with 10% FCS and 1% 
penicillin/streptomycin for 24 hours. The numbers of spot-forming cells were counted 
using an automated ELISPOT reader system (AID, Strassberg, Germany), and numbers 
of triplicate wells were added together. The numbers of spots reacting to non-transfected 
autologous CD40-B were subtracted to determine the specific response to indirectly 
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presented HLA-A2, and fewer than 10 spots per 3 wells above background in co-cultures 
with non-transfected autologous CD40-B was considered as a negative result. Results 
were normalized to spots per million CD4+ T cells.
RESULTS
Expansion of CD40-stimulated B cells as antigen-presenting cells using soluble 
trimeric CD40 ligand
Dendritic cells are the most common APC used in assays to detect antigen-specific T-cell 
responses in vitro, however only limited numbers can be isolated from human blood or 
differentiated ex vivo from circulating monocytes, and they lack proliferative capacity 
in vitro. B cells activated via CD40 stimulation are potent APC, which can be expanded 
vigorously from small numbers of both fresh and cryopreserved human PBMC41. 
Previously we used CD40L-transfected mouse fibroblasts to expand CD40-B, however 
the protocol was labor intensive and included xenogeneic cells which might result in 
stimulation of xenogeneic T-cell responses when these expanded B cells are used for 
T-cell stimulation assays42. Now we used a recombinant soluble human trimeric CD40L 
to stimulate and expand B cells from PBMC. The absolute numbers of B cells expanded 
4×103-fold (Figure 2A, mean value, range 2×102-1×104) within 4 weeks of culture. The 
purity of CD40-B reached around 99% between day 10-14. For further experiments, 
CD40-B were harvested at day 17 or 21 with a purity >99%. The phenotype of CD40-B 
upon harvesting was determined by flow-cytometry. High levels of MHC-I, HLA-
DR, and costimulatory molecule CD86 were consistently observed, suggesting potent 
antigen-presenting capacity. The costimulatory molecule CD80 was also expressed, but 
at a lower level. Part of the CD40-B expressed CD27 indicating that they were memory 
B cells. CD40 (costimulatory receptor), CD38 and CD83 (activation markers) were also 
highly expressed on CD40-B.
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Figure 2. Expansion of CD40-stimulated B cells as antigen presenting cells using soluble trimeric 
CD40 ligand. PBMCs obtained from blood donors were cultured in the presence of IL-4 (40 IU/ml) 
and soluble human trimeric CD40 ligand (1 µg/ml). Cells were passed every 3-4 days, meanwhile 
the purity and numbers of cells were monitored (n=6 independent experiments). (A) The absolute 
numbers of B cells during a four-week expansion period is shown (the absolute number of B cells 
on day 0 was normalized to 1×106). (B) The phenotype of CD40-B was examined by the end of 
culture period using flow-cytometry analysis. Flow-cytometry histograms from a representative 
donor are shown.
Electroporation with mRNA encoding HLA-A2 without transmembrane part prevents 
surface expression of HLA-A2 on HLA-A2 negative CD40-B
We made two mRNA constructs to transfect HLA-A2 negative CD40-B with HLA-A2. 
pST1-HLA-A*0201 encoded for the intact α chain of HLA-A*0201 (α1, α2 and α3; 
Figure 1B), while pST1-HLA-A*0201-delTM-DCL encoded for the α chain without the 
transmembrane region. We hypothesized that deletion of the transmembrane region 
would completely eliminate the surface expression of the molecule, thereby preventing 
activation of T cells with direct or semi-direct allospecificity. Both mRNAs were used to 
transfect HLA-A2 negative CD40-B by electroporation. Surface expression of HLA-A2 
was examined by flow-cytometry at 2, 8 and 24 hours after electroporation. Transfection 
using pST1-HLA-A*0201 led to rapid surface HLA-A2 expression on HLA-A2 negative 
CD40-B (Figure 3A, left panel); 38%, 82% and 89% of the CD40-B became HLA-A2 
positive at 2, 8 and 24 hours after electroporation respectively (Figure 3B, mean values). 
Meanwhile, no surface HLA-A2 expression was detected on pST1-HLA-A*0201-delTM-
DCL transfected CD40-B (Figure 3A, right panel).
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Figure 3. Electroporation of CD40-B with pST1-HLA-A*0201 mRNA leads to surface expression 
of HLA-A2 on HLA-A2 negative CD40-B but electroporation with pST1-HLA-A*0201-delTM-
DCL mRNA not. Two mRNA constructs, pST1-HLA-A*0201 and HLA-A*0201-delTM-DCL, were 
used to transfect HLA-A2 negative CD40-B by electroporation. The surface expression of HLA-A2 
was determined by flow-cytometry at 2, 8, 24 hours after electroporation. Non-electroporated 
HLA-A2 negative and HLA-A2 positive CD40-B were used as negative and positive controls, 
respectively. (A) Representative histograms from one experiment showing the surface expression 
of HLA-A2 after mRNA electroporation. (B) Pooled data summarizing the HLA-A2 expression 
after electroporation with pST1-HLA-A*0201 (n=3 independent experiments). Column bar graphs 
represent means with SEM.
CD40-B electroporated with pST1-HLA-A*0201-delTM-DCL mRNA activate CD4+ 
T-cell clone specific for HLA-A2 presented by MHC class II
To test whether CD40-B transfected with pST1-HLA-A*0201 or pST1-HLA-A*0201-
delTM-DCL mRNA were able to activate CD4+ T cells which specifically recognize 
HLA-A*0201 via the indirect alloantigen presentation pathway, we utilized a previously 
described CD4+ T-cell clone strictly recognizing HLA-A*0201 derived peptide presented 
by HLA-DRB1*0101 (referred to as 4.43) to establish a model for indirect allorecognition40. 
We expanded CD40-B from HLA-A2 negative/HLA-DRB1*0101 positive healthy blood 
donors. After electroporation with pST1-HLA-A*0201 or pST1-HLA-A*0201-delTM-DCL 
mRNA, the transfected CD40-B were co-cultured with T-cell clone 4.43 for 24 hours. As 
a positive control, 4.43 T cells were co-cultured with non-transfected CD40-B from an 
HLA-A*0201 positive/HLA-DRB1*0101 positive donor which are expected to present its 
native peptide ligand, while 4.43 co-cultured with non-transfected HLA-A2 negative/
HLA-DRB1*0101 positive CD40-B, or 4.43 alone, served as negative controls. After 24 
hours, culture supernatant was collected to measure the IFN-γ production by the T-cell 
clone. Both pST1-HLA-A*0201 transfected CD40-B and pST1-HLA-A*0201-delTM-DCL 
transfected CD40-B were able to activate T-cell clone 4.43, however the amount of IFN-γ 
production by 4.43 was 5-fold higher using pST1-HLA-A*0201-delTM-DCL transfected 
CD40-B (Figure 4A).When an anti-MHC-II blocking antibody was added to the co-
culture, IFN-γ production was almost completely abrogated, illustrating that antigen 
presentation was restricted by MHC-II (Figure 4B). Thus we concluded that transfection 
of autologous CD40-B using pST1-HLA-A*0201-delTM-DCL was a suitable tool to study 
CD4+ T-cell indirect HLA allorecognition.
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Figure 4. CD40-B electroporated with pST1-HLA-A*0201-delTM-DCL mRNA activate CD4+ T-cell 
clone specific for HLA-A2 presented by MHC class II. (A) HLA-A*0201neg/HLA-DRB1*0101pos 
CD40-B cells electroporated with pST1-HLA-A*0201 or HLA-A*0201-delTM-DCL mRNA were 
co-cultured with CD4+ T-cell clone 4.43. T-cell clone 4.43 co-cultured with HLA-A*0201pos/
HLA-DRB1*0101pos CD40-B was used as positive control. T-cell clone 4.43 co-cultured with non-
electroporated HLA-A*0201neg/HLA-DRB1*0101pos CD40-B, or T-cell clone 4.43 alone, served as 
negative controls. After 24 hours, supernatants were collected and the concentrations of IFN-γ 
were measured by ELISA (n=4 independent experiments). (B) HLA-A*0201neg/HLA-DRB1*0101pos 
CD40-B electroporated with HLA-A*0201-delTM-DCL mRNA were co-cultured with CD4+ T-cell 
clone 4.43 with or without a blocking anti-MHC-II monoclonal antibody (mAb) (n=5 independent 
experiments). Column bar graphs represent mean with SEM.
Detection of CD4+ T cells with indirect allospecificity for HLA-A2 in LT patients
We applied this technique to detect CD4+ T-cell responses with indirect allospecificity 
for HLA-A2 in 8 patients after LT by IFN-γ ELISPOT. All selected patients were HLA-A2 
negative and had been transplanted with livers from HLA-A2 positive donors. Patient 
characteristics are described in Table 1. In patients 1-4, samples at pre-LT, 1 month, 6 
months and 1 year after LT were studied, while in patients 5-8, samples at pre-LT, and 
between 5-11 years after LT were studied. Overall indirect HLA-A2-specific CD4+ T 
cells producing IFN-γ were detected in 4 patients (Figure 5). Of the 4 patients analyzed 
short-term after LT, only patient 4 exhibited a strong response at 6 months after LT, 
interestingly during the occurrence of chronic rejection. Of the 4 stable patients analyzed 
late after LT, HLA-A2-specific indirect responses were detected in 3 patients at 9-11 years 
after LT. Only patient 8 showed response prior to transplantation, which might be due to 
alloantigen exposure via previous blood transfusion or pregnancy.
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Table 1. Patients studied for the CD4+ T-cell response to indirectly presented HLA-A2
# Primary liver 
diseases
Sex Acute rejection Chronic rejection Sample time-points
1 HCV M - 2 years after LT pre-LT, 1, 6 months post-LT
2 PSC M 2 years after LT - pre-LT, 1, 12 months post-LT
3 HCC M - - pre-LT, 1, 6, 12 months post-LT
4 NASH M - 6 months after LT pre-LT, 6 months post-LT
5 Alcoholic cirrhosis M 2 years after LT - pre-LT, 5 years post-LT
6 HCC M - - pre-LT, 9 years post-LT
7 HBV M - - pre-LT, 11 years post-LT
8 PSC F - - pre-LT, 9 years post-LT
Figure 5. Detection of CD4+ T cells with indirect allospecificity for HLA-A2 by IFN-γ ELISpot in 
LT patients. CD4+ T cells were isolated from PBMC samples of 8 LT patients and co-cultured for 7 
days with pST1-HLA-A*0201-delTM-DCL transfected autologous CD40-B. Thereafter, CD4+ T cells 
were re-stimulated by either pST1-HLA-A*0201-delTM-DCL transfected or mock-electroporated 
autologous CD40-B in IFN-γ-pre-coated ELISPOT plates. In patients 1-4, samples at pre-LT, 1 
month, 6 months and 1 year after LT were examined, while in patients 5-8, samples at pre-LT, or 
between 5-11 years after LT were examined. The frequencies of IFN-γ producing CD4+ T cells in 
response to indirectly presented HLA-A2 after subtraction of frequencies of spots in response to 
mock-electroporated CD40-B, are plotted as spots per million CD4+ T cells (y-axis) for each time-
point and patient (x-axis). * indicates that fewer than 10 spots per triplicate wells were observed 
above background, which was considered as a negative result.
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DISCUSSION
The role of indirect allorecognition in the long-term transplant outcomes in humans is not 
well-understood, largely due to the lack of a proper ex vivo assay that specifically detects 
T cells responding to indirectly presented alloantigens. In this study we demonstrate 
that electroporation of CD40-B with in vitro transcribed mRNA that encodes a genetically 
disparate HLA-A molecule without the transmembrane region results in self-MHC class 
II restricted presentation of peptides derived from this molecule to CD4+ T cells, while it 
does not lead to surface expression of HLA-A*0201 and therefore cannot be recognized 
by T cells via the direct pathway of allorecognition. We show that this technique enables 
detection of CD4+ T cells responding to indirectly presented HLA-A2 in HLA-A2 
mismatched patients after LT.
The way of alloantigen introduction is the key to develop a successful assay to measure 
ex vivo T-cell responses to indirectly presented alloantigens. Transfection of mRNA has 
been proven to be a potent technique to achieve antigen presentation to CD4+ and CD8+ T 
cells, with similar efficacy as lentiviral gene transduction32, 39. It is applicable for different 
cell types, such as PBMC43, monocytes44, moDC29, 31, 32, and CD40-B30, 41. When compared 
to other methods of RNA gene transfer, like lipofection and passive pulsation, mRNA 
electroporation has been shown to be superior in terms of gene transfection efficiency 
and reduced cell toxicity29. We used HLA-A2 as a model alloantigen because, in contrast 
to expression of donor MHC class II which extinguishes after disappearance of donor-
derived APC from the graft, expression of donor MHC class I in organ graft is expected 
to be long-lived, and HLA-A2 is the most prevalent HLA-A allele in Caucasians. Deletion 
of the transmembrane region not only prevented surface expression, but also resulted 
in enhanced indirect CD4+ T-cell activation compared to mRNA which encoded the 
intact HLA-A*0201. This could be due to increased protein degradation and presentation 
on MHC-II, as it does not lead to surface expression. In addition, the DCLamp signal 
included is expected to result in better targeting of the HLA-A2 protein to the endo-
lysosomal system resulting in a more efficient antigen presentation on MHC-II39. 
The novel technique of indirect alloantigen presentation presented in this study has 
several advantages. Firstly, allorecognition via the direct or semi-direct pathways 
is completely excluded, since the sequence encoding the transmembrane region of 
the HLA-molecule is lacking, which prevents expression on the cell surface. Recently 
Breman et al. used synthetic HLA class I monomers to achieve indirect presentation to 
CD4+ T cells26. Although they demonstrated that this technique did not lead to semi-
direct HLA antigen presentation to a CD8+ T cell clone, the design of their technique does 
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not exclude the possibility of semi-direct antigen presentation to occur when using T 
cells from patients. Secondly, compared to overlapping synthetic peptides, the technique 
presented here does not create neo-epitopes, as the alloantigen is processed by the natural 
processing machinery of CD40-B. Thirdly, compared to known HLA-epitopes, such as 
the HLA-A2 derived peptide 103-120, our technique conveys the full antigenic spectrum 
of HLA molecules and is not restricted by HLA-typing of the patients. Moreover, 
mRNAs encoding for different antigens can be co-electroporated together, enabling 
transfection with different HLA-encoding mRNAs in case of multiple HLA mismatches 
between donor and recipient33. Lastly, using CD40-B as a source of APC, which can be 
rapidly expanded to large amounts from a limited amount of blood, ensures availability 
of sufficient amounts of APC for repetitive patient monitoring. Although dendritic 
cells are considered to be the most professional APC of the immune system, obtaining 
sufficient numbers for repetitive ex vivo assays will be difficult in transplant patients in 
whom numbers of circulating immune cells are repressed due to immunosuppressive 
medication45.
In future research it should be evaluated that whether this assay, either or not in 
combination with quantification of T cell responses to directly presented donor 
alloantigens, is associated with and/or can predict the risk of (chronic) allograft rejection 
and other long-term outcomes in transplant recipients, thereby enabling personalized 
immunosuppression strategies in clinical practice. It will be particularly relevant to 
determine whether operationally tolerant LT recipients can be identified using this 
technique. However, for this purpose a library of DNA constructs encoding a broad 
spectrum of prevalent human HLA molecules should first be constructed. 
To conclude, we developed a novel ex vivo assay to measure CD4+ T-cell responses to 
indirectly presented alloantigen in transplanted patients with high specificity, which may 
help to better understand the full spectrum of allogeneic T-cell responses in humans. In 
addition, this technique may be useful to guide personalized immunosuppression.
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CHAPTER 7
Correspondence
Long-lived intragraft donor leukocytes or relocated 
donor HSPCs can cause long-term hematopoietic 
chimerism after liver transplantation
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To the editor:
We read with great interest the article in HEPATOLOGY by Wang et al.1, which 
characterized blood chimerism in liver transplant (LT) patients and showed that 
multipotent hematopoietic stem/progenitor cells (HSPCs) reside in adult human 
livers. The authors concluded that there are two types of chimerism after LT: transient 
chimerism resulting from migration of mature donor leukocytes from the liver graft, 
which usually disappears within 3 weeks after LT, and long-term chimerism derived 
from putative donor HSPCs in the liver graft. Finally, the authors asked whether donor 
HSPCs generate mature leukocytes inside the grafted liver or circulate to recipient bone 
marrow for hematopoiesis. 
In a previous study on liver NK cell precursors2, we observed that mature NK cells of 
donor origin were detectable in liver grafts up to 2 years after LT, while all donor-derived 
NK-cell precursors were replaced by recipient-derived precursors within 1 week after 
LT. To study whether other types of mature donor leukocytes remain present in liver 
grafts after LT, we now determined intragraft chimerism of CD3+ T cells, CD56+ T cells, 
and CD14+ monocytes/Kupffer cells in leukocytes isolated from first liver grafts of 5 
LT patients undergoing re-LT. We selected recipient/donor pairs that were mismatched 
for HLA-A2 or HLA-Bw4 during the first transplantation. Using flow-cytometry with 
mAb for HLA-A2 or HLA-Bw4 we could differentiate donor from recipient cells. In all 
5 patients, we detected considerable percentages of donor-derived mature leukocytes 
in the first graft, even up to 2 years after transplantation (Table I). These data are not 
consistent with the hypothesis of Wang et al 1 that donor-derived leukocytes disappear 
within 3 weeks after LT, at least within the grafted liver, but demonstrate the possible 
existence of long-lived donor-derived leukocytes resident in the liver graft. 
We also measured chimerism in lineage-CD34+ HSPCs (at least 2×106 events were recor-
ded), which contain the multipotent lin-CD34+CD38-CD90+ HSPCs described in the article1. 
We found that all 5 explanted liver grafts contained only recipient-derived, but no donor-
derived, HSPCs (Table I), indicating that donor-derived hepatic HSPCs are replaced by 
circulating HSPCs of recipient origin within the first week after transplantation. 
Our data suggest that the long-term chimerism described in the paper of Wang is probably 
caused by long-lived donor leukocytes resident in liver grafts, and/or hematopoiesis of 
relocated donor HSPCs. The latter concept is supported by a study of Massberg et al. 3, 
which describes the liver as one of the peripheral organs in which HPSCs reside shortly 
before returning to the blood and re-migrating to the bone marrow. The relocation of 
HSPCs from transplanted liver remains to be investigated. 
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Table I: Percentages of donor-derived leukocytes in first liver grafts explanted during re-LT.
Numbers between parentheses indicate the percentages of donor-derived cells within each subset. 
% of total intragraft leukocytes (% of donor-derived within each subset)
 Patient 1(7 days)
Patient 2
(16 days)
Patient 3
(1 year)
Patient 4
(2 years)
Patient 5
(2 years)
CD56+ T cells 7.5 (6.8) 1.7 (18.2) 5.7 (1.6) 5.1 (3.7) 6.6 (16.3)
CD3+ T cells 12.5 (2.1) 76.5 (6.6) 22.8 (0.8) 10.5 (16) 8.8 (18.6)
CD14+ cells 15.4 (63.3) 15.9 (90.5) 7.8 (27.5) 7.2 (37.0) 22.2 (46.0)
Lin-CD34+ HSPCs 0.5 (0) 0.2 (0) 0.1 (0) 0.3 (0) 0.1 (0)
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CHAPTER 8
Summary and discussion
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The transplantation of a liver from a genetic disparate donor is always accompanied 
by immune responses targeting the allograft. These immune responses are associated 
with post-transplant complications, such as graft rejection. Therefore the used of long-
term immunosuppressive medication is a necessity to suppress the post-transplant 
alloimmune responses, which is associated with adverse effects affecting long-term 
outcome. The aim of this thesis is to improve our understanding of environmental and 
genetic factors shaping and regulating allogeneic T-cell responses and graft rejection in 
liver transplant patients, in order to facilitate personalized patient management and to 
achieve a better long-term patient outcome.
I. CMV infection restricts allogeneic CD8+ T-cell responses and may promote 
tolerance in patients after liver transplantation
From experimental animal models we learned that viral infections after organ 
transplantation break transplant tolerance1-3, not only caused by the excessive 
inflammation associated with infection but also due to the activation of pathogen-
specific memory T cells that are cross-reactive to allo-antigens4. Clinical studies have 
provided evidence for a positive association between infections and organ transplant 
rejection in humans, however it is difficult to determine a causal relationship5. Therefore, 
in this thesis we studied the influence of CMV infection, one of the most common viral 
infections after organ transplantation, on T-cell alloreactivity after liver transplantation, 
and its correlation with allograft rejection and tolerance. In Chapter 2, we find that, even 
though CMV primary infection after liver transplantation drives expansion of a memory 
T-cell pool, it is associated with the development of donor-specific hyporesponsiveness 
of CD8+ T cells. Further analysis of a large cohort of liver transplant patients shows that, 
while CMV viremia is associated with an increased risk of early acute rejection, CMV 
primary infection is associated with a lower risk of late acute rejection. In addition, we 
showed that CMV primary infection is associated with the highest Vδ1/Vδ2 γδ T-cell 
ratio in the circulation, a cell-signature that is related to operational tolerance after 
liver transplantation, indicating that these patients probably have a higher chance to 
achieve operational tolerance after immunosuppression withdrawal. In Chapter 3, 
we studied the expression of a series of co-inhibitory receptors on T cells after liver 
transplantation, of which the expression of CD160 and CD244 showed a magnificent 
and sustained up-regulation on CD8+ T cells after transplantation. The long-lasting up-
regulation of CD244 on CD8 T cells was found to be associated with CMV infection after 
transplantation. In vitro, purified CD244+ CD8 T cells proliferated less in response to 
allogeneic stimulation compared to their CD244- counterparts, which could explain the 
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lower proliferative capacity of CD8 T cells in response to allostimulation in patients with 
CMV infection. In addition, we showed the majority of CMV-specific CD8+ T cells are 
CD244 positive. In conclusion, CMV infection after LTx is associated with the expansion 
of a dysfunctional CD244+ T-cell subset and development of systemic allogeneic CD8+ 
T-cell hyporesponsiveness. Taken together, results from these two chapters suggest that 
CMV infection restrains CD8+ T-cell alloresponses, and may actually promote transplant 
tolerance after human liver transplantation.
The most surprising finding of our study is the paradoxical relationship that we 
observed between CMV infection and early versus late liver allograft rejection: while 
CMV viremia is associated with more early acute rejection episodes, CMV primary 
infection is associated with fewer late acute rejection episodes, donor-specific CD8+ 
T-cell hyporesponsiveness, and a tolerance-related cell-signature. In the majority of 
the cases, early acute rejection occurs earlier than CMV infection. This is in line with 
the hypothesis that inflammation associated with allogeneic immune responses may 
trigger the replication of CMV from latency6. On the contrary, the lower risk of late 
acute rejection can be the consequence of the earlier primary infection of CMV, which 
usually occurs within the first six months after transplantation. Medication incompliance 
or insufficient amount of immunosuppressive medication are generally considered as 
the main causes of late acute rejection7. However, inadequate immunosuppression, or 
immunosuppression with a trough level below the target, is very common in patients 
late after transplantation. But not all these patients develop acute rejection, and thereby 
we interpret absence of rejection in the majority of under-immunosuppressed patients as 
a sign of (partial) tolerance to their liver graft. These paradoxical effects and bidirectional 
relationships between CMV infection and early versus late acute rejection may explain 
the inconsistency of previous clinical study results regarding the association between 
CMV infection and allograft rejection5. 
How CMV restrains CD8+ T-cell alloreactivity after liver transplantation remains elusive, 
and whether CMV-induced γδ T-cell signatures play a functional role in promoting 
tolerance is as yet unknown. The well-established immune evasion strategies of CMV 
provide possible clues. For example, CMV produces viral IL-10 to establish latency, 
which may also have a systemic immunosuppressive effect8, 9. CMV infection is also 
associated with the sustained inflation of circulating memory T-cells and immune 
senescence10. It has been postulated that the massively expanded CMV-specific effector 
memory T-cell pool competes with newly generated T cells for niches and survival 
factors, and as a consequence T-cell diversity and responses to other pathogens are 
restricted11, 12. Moreover, CMV has been recently shown to significantly modulate 
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peripheral mixed T-cell chimerism after HSCT, facilitating the reconstitution of donor-
derived cells13. In contrast to the common short-term hematopoietic chimerism observed 
after organ transplantation, long-term hematopoietic chimerism is rare in peripheral 
blood. However it is more commonly observed within grafted organ14, 15. It has been 
suggested in a case report that severe CMV disease early after LT contributed to the 
development of long-term hematopoietic chimerism and subsequent donor-specific 
T-cell hyporesponsiveness16. In addition, we hypothesize that inflammation provoked 
by CMV infection may contribute to the induction of liver allograft tolerance. CMV is 
known to drive T helper 1 cell (Th1) polarization. Within the human liver, CMV infection 
of sinusoidal endothelium triggers significant production of type I interferon by these 
cells, and recruits Th1 effector memory T cells and regulatory T cells17. Th1 cells produce 
high amounts of the pro-inflammatory cytokine IFN-γ, which is strikingly absolutely 
needed for liver transplant tolerance in animal models18. Recently, Morita et al. described 
a mesenchyme-mediated immune control (MMIC) mechanism utilized by liver allografts 
to eliminate effector T cells and maintain tolerance through IFN-γ and PD-L119. The 
importance of type I interferon signalling has also been highlighted recently by Bohne et 
al., showing in an immunosuppression withdrawal trial of HCV-infected liver transplant 
patients, that operational tolerant patients overexpress type 1 interferon and interferon-
stimulated genes (ISG) in their liver graft20. To sum, accumulating evidences suggest 
that in humans, infection of CMV does not necessarily preclude the establishment of 
transplant tolerance but, on the contrary, the immunomodulatory effects exerted by 
CMV could restrict alloimmune T-cell responses and promote transplant tolerance.
Inspired by our own finding that CMV infection may benefit liver transplant patients 
by promoting tolerance to their graft, we studied in depth scientific literature to find 
out whether CMV can benefit human health in other conditions, despite all the clinical 
problems that it cause. In Chapter 4, we summarized the possible beneficial effects that 
CMV can convey to its human hosts. For example, emerging evidences are showing that 
CMV infection after HSCT may reduce the risk of cancer recurrence in humans, which 
has been validated in several studies, particularly for patients with AML21-23. Studies on 
childhood immunity suggest that CMV exposure may boost the immunity of children 
to unrelated pathogens24. The mechanisms contributing to these clinical associations are 
still not fully understood. They are most likely related to the NK cell, γδ T-cell, and T 
cell responses triggered by CMV infection, , which convey a cross protection towards 
unrelated antigens. Considering the potential benefits that CMV infection may provide, 
we propose that more research should be done to better understand the virus-host inaction 
between CMV and humans: how CMV infection, directly or indirectly, is associated 
with beneficial clinical outcomes; how to skew the natural course of CMV infection, 
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or the related immune responses, to achieve those beneficial effects while limiting the 
established adverse effects of CMV infection; whether a universal vaccination strategy 
should be advocated at this moment.
II. Genetic variations in the PD-L1/PD-1 co-inhibitory pathway influence graft 
rejection after liver transplantation in humans
T-cell co-inhibitory receptor-ligand interactions fine-tune immune responses by 
negatively regulating T-cell functions25, 26. We hypothesized that T-cell co-inhibitory 
pathways are involved in the regulation of allogeneic T-cell responses and graft rejection 
in liver transplant recipients. In Chapter 5, we focused on the most prominent PD-1/
PD-L1 pathway. We find that compared to peripheral blood, PD-1 is highly expressed 
on T cells infiltrating liver allografts. Meanwhile, its ligand, PD-L1 is also highly 
expressed in liver allografts undergoing rejection. Blockade of this interaction increased 
the proliferation of graft-derived T cells in response to allostimulation. Next, from the 
genetic perspective, we analyzed the correlation between SNPs within PD-1/PD-L1 
genes and the incidence of graft rejection, and we foud that donor PD-L1 rs4143815 and 
recipient PD-1 rs11568821 are associated with the occurrence acute rejection late after 
transplantation, suggesting that this pathway is involved in the pathogenesis of graft 
rejection. Further we confirmed the functional relevance of the PD-L1 rs4143815, which 
results in altered PD-L1 expression on dendritic cells following IFN-γ stimulation. These 
data show that PD-L1/PD-1 pathway is actively involved in the regulation of allogeneic 
immune response and graft rejection, and that genetic variations in donor PD-L1 and 
recipient PD-1 contribute to inter-individual susceptibility to graft rejection after liver 
transplantation. 
It is very interesting that SNPs within PD-1/PD-L1 are only associated with the occurrence 
graft rejection late after transplantation but not those early episodes. Several possibilities 
might explain this observation. First of all, the functional relevance of the SNPs might 
not be as significant as other factors that are associated with early rejection, such as 
immunosuppressive therapies, which are more intensive early after transplantation. 
The allogeneic immune response driving acute rejection is also much stronger early 
after transplantation. Thereby the minor differences in co-inhibitory signaling caused 
by the SNPs may be over-shadowed by those more dominant factors. Secondly, early 
and late acute rejection might in fact have distinct pathogenesis. For instance, late graft 
rejection is more likely to occur during immunosuppression dose reduction, or during 
insufficient immunosuppression due to incompliance. PD-1/PD -L1 pathway might be 
more active in balancing the rejection versus tolerance in these situations with low level 
of immunosuppressive therapies. 
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Can we make use of these data in clinical practice. First of all, PD-1/PD-L1 pathway 
should be further studied in liver transplant patients that are operational tolerant, 
investigating whether patient/donor combinations with favorable n genetic variants 
provide advantages when discontinuing or minimizing immunosuppression. If this 
is the case, then SNPs within this pathway, together with other characteristics, such 
as circulating γδ T cells20, 27-29, can be used to identify operationally tolerant patients. 
Secondly, targeting of PD-1 by administration of an appropriate agonist, such as PD-L1 
Ig fusion protein30, 31, may be an interesting avenue to develop novel immunosuppression 
strategies. Considering the high expression of PD-1 on intrahepatic T cells, targeting 
PD-1 might selectively inhibit graft infiltrating T cells while leaving the peripheral T 
cells functionally intact.
III. In vitro transcribed messenger RNA can be used to monitor indirect 
allorecognition in human transplant recipients
After organ transplantation two pathways are mainly responsible for the activation of 
allogeneic T cells, namely the direct and the indirect pathway32. It has been hypothesized 
that the direct pathway is dominant early after transplantation and is responsible for the 
graft rejection early after transplantation. In contrast indirect pathway gradually takes 
over and is associated with immunological graft damage late after transplantation33, 34, 
such as chronic rejection. However current techniques detecting indirectly activated 
allogeneic T cells in human transplant recipients are flawed, as reviewed by Waanders et 
al.35, hampering interpretation of data regarding indirect pathway in human transplant 
recipients. In Chapter 6, we described a novel technique based on transfection of 
autologous APC with engineered HLA-encoding messenger RNA electroporation to 
detect CD4+ T cells with indirect allospecificity ex vivo. Compared to earlier methods, 
our technique has several advantages. Most importantly, this technique is highly specific 
to detect indirectly activated CD4+ T cells. We engineered a DNA construct from which 
HLA-A2 mRNA lacking the sequence encoding the transmembrane part can be transcribed 
in vitro. Transfection with this mRNA completely prevents surface expression of HLA-A2 
after protein translation, which excludes the possibility of activating T cells with direct 
or semi-direct allo-specificity. Secondly, compared to stimulation with short peptides 
containing one of a few known epitopes recognized by T cells, such as the HLA-A2 
derived peptide 103-120, this technique conveys the full antigenic spectrum of HLA 
molecules and is not restricted by HLA-typing of the patients. Thirdly, we use CD40-B as 
APC. CD40-B can be expanded into large quantities from very limited amounts of human 
blood samples, which makes them a source providing sufficient APC for repetitive assays 
in patients. We applied this technique to measure CD4+ T-cell responses to indirectly 
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presented donor HLA in a small number of HLA-A2 negative patients transplanted 
with liver from HLA-A2 donors, and indirect CD4+ T-cell responses towards HLA-A2 
could be detected in 4 patients out of 8 patients studied. Most interestingly, a very strong 
response was detected in a patient at the time of chronic rejection, which eventually 
caused the loss of graft. This is in line with previous studies suggesting that the T-cell 
indirect allo-activation pathway is participating in the process of chronic rejection36-45, 
and suggests that alternative therapies targeting indirect allo-antigen presentation might 
be useful in treating chronic rejection. Future research is required to obtain a better 
understanding of the clinical relevance of the indirect allo-antigen presentation pathway 
by measuring indirect T-cell responses during a variety of post-transplant complications. 
Then efforts can be made to develop novel immunosuppressive therapies targeting the 
indirect pathway, or selecting therapies better at limiting indirect alloresponse to achieve 
a better long-term graft outcome. In addition, the basis of our technique can be used 
for the generation of regulatory T cells with indirect allospecificity as an alternative 
immunosuppressive cell-therapy46, 47. Due to the long-term complications associated with 
conventional immunosuppressive medication, Treg-based immunoregulatory therapy 
holds promise for tolerance induction and improving long-term outcomes, with several 
ongoing clinical trials48, 49. Current studies focus on ex vivo expansion of polyclonal Tregs, 
or generation of donor-specific Tregs with direct alloreactivity. However, evidences from 
animal models suggest that Tregs involved in transplant tolerance are restricted to the 
indirect pathway50-52, and that Tregs with indirect allospecificity might be more crucial in 
the induction of tolerance than Tregs with direct allospecificity46, 47. A protocol generating 
donor-specific Tregs that are specific for indirectly presented alloantigens ex vivo is not 
available yet, and the present study may pave the way for developing such protocol. 
Lastly, the indirect alloresponse should also be determined in immunosuppression 
withdrawal or minimization studies, to establish whether it can contribute to identification 
of patients from whom immunosuppression can be safely withdrawn or minimized, in 
order to reduce the risk of immunosuppression related complications in the long-term.
IV. Long-term hematopoietic chimerism is common within liver allograft 
The clinical relevance of hematopoietic chimerism after liver transplantation is still not 
well-understood. Recently, Wang et al. studied the blood chimerism in a large cohort 
liver transplant patients and analyzed the putative hematopoietic stem/progenitor cells 
(HSPCs) in adult human livers53. The authors concluded that there are two types of 
chimerisms in LT patients: transient chimerism resulting from mature donor leucocytes, 
and long-term chimerism derived from putative donor HSPCs residing in the liver graft, 
and suggested that liver is a good ectopic niche for extra-marrow hematopoiesis. To 
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comment on their work, we studied the hematopoietic chimerism within transplanted 
liver allografts in Chapter 7. We find that leukocytes within allograft are composed of 
cells from both donor and recipient origin up to 2 years after transplantation, showing 
that long-term hematopoietic chimerism is common within transplanted allograft. In 
contrast, hepatic HSPCs after LTx are rapidly replaced by HSPCs of recipient origin. Our 
results suggest that the long-term chimerism described in the paper of Wang is probably 
caused by long-lived donor leukocytes resident in liver grafts, and/or hematopoiesis of 
relocated donor HSPCs. However it is also debatable whether intrahepatic leukocytes can 
be long-lived without repopulation by hematopoiesis from donor HSPCs. For example, 
NK cells possess features of memory cells and adaptive immunity has been described 
in literature54. However it is not yet known whether such memory NK cell population 
is present in liver and is able to undergo homeostatic proliferation without NK cell 
precursor. Kupffer cells are also known to have a short life-span55. Without extrahepatic 
hematopoiesis, the local precursor cells in liver might be responsible for the homeostatic 
proliferation of donor Kupffer cells. Therefore, it would be interesting to investigate the 
maintenance of donor leukocytes pool within the transplanted liver in future studies, 
how do they maintain their homeostatic proliferation, and how do they phenotypically 
and functionally differ from recipient derived leukocytes.
OVERALL CONCLUSIONS
In this thesis, we first show that CMV infection restricts allogeneic CD8+ T-cell responses 
and may promote tolerance in patients after liver transplantation. Next we provide 
evidences for the involvement of PD-1/PD-L1 pathway, including genetic variants 
in donor PD-L1 and recipient PD-1, in the regulation of graft rejection late after 
transplantation. In addition, we develop a novel technique enabling the determination 
of CD4+ T cells responding to indirectly presented allo-antigens. Finallyr, the existence of 
long-term hematopoietic chimerism within human liver allografts is described. Overall, 
this thesis provides suggestions for new clues that may be useful in patient selection 
strategies for immunosuppression withdrawal. In Table I the main findings of this 
thesis are summarized, including strengths and limitations of our studies, a summary of 
possible applications of the findings in clinical practice is provided, as well as suggestions 
for future study. 
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DUTCH SUMMARY / NEDERLANDSE SAMENVATTING
Transplantatie van een lever van een genetisch niet-identieke donor gaat altijd gepaard 
met immuunresponsen die de donor lever aanvallen. Deze immuunresponsen 
(zogenaamde “allogene T-cel responsen”) gaan gepaard met complicaties na de 
levertransplantatie, zoals afstoting van de donor lever. Transplantatiepatiënten 
moeten daarom levenslang afweeronderdrukkende (immunosuppressieve) medicijnen 
gebruiken om de immuunresponsen te onderdrukken, maar deze medicijnen hebben 
bijwerkingen die de lange termijn uitkomst van de transplantatie verslechteren. Het 
doel van dit proefschrift is om beter te begrijpen welke omgevingsfactoren en genetische 
factoren invloed hebben op de allogene T-celresponsen en daarmee op afstoting van 
de lever in transplantatiepatiënten. Deze inzichten moeten leiden tot een meer op de 
individuele patiënt afgemeten  behandeling en een betere lange termijn uitkomst van de 
patiënt na levertransplantatie.
I. CMV infectie vermindert allogene CD8+ T-cel responsen en kan tolerantie 
in levertransplantatiepatiënten bevorderen
Uit studies met experimentele diermodellen weten we dat virale infecties na 
orgaantransplantatie tolerantie na transplantatie verhinderen. Dit wordt onder anderen 
veroorzaakt door inflammatie die met de infectie gepaard gaat en door activatie van 
geheugen T-cellen die gaan kruisreageren tegen allo-antigenen van het donor orgaan. 
Ook klinische studies hebben een relatie laten zien tussen infecties en transplantaat 
afsoting in mensen, maar een causaal verband is niet duidelijk aangetoond. In dit 
proefschrift hebben we daarom onderzocht wat het effect van CMV infectie - een 
veelvoorkomende virale infectie na levertransplantatie – is op T cel responsen, afstoting 
en tolerantie na levertranplantatie. In Hoofdstuk 2 laten we zien dat, hoewel primaire 
CMV infectie na levertransplantatie toename van geheugen T cellen veroorzaakt, 
deze infectie juist geassocieerd is met donor-specifieke hyporesponsiviteit van CD8+ 
T cellen. Verdere analyse van dit verband in een groot cohort van levertransplantatie 
patiënten laat zien dat CMV viremie is geassocieerd met een verhoogd risico op vroege 
acute afstoting, maar primaire CMV infectie is geassocieerd met een lager risico op late 
acute afstoting. Verder toont dit hoofdstuk dat primaire CMV Infectie geassocieerd is 
met een hoge Vδ1/Vδ1 γδ T-cel ratio in de circulatie van deze patiënten, een kenmerk 
dat in eerdere studies is gerelateerd aan tolerantie na levertransplantatie. In Hoofdstuk 
3 bestuderen we de expressie van een aantal co-inhibitoire receptoren op T cellen van 
levertransplantatiepatiënten, waarbij we vinden dat de expressie van CD160 en CD244 
langdurig verhoogd zijn op CD8+ T cellen na transplantatie. Deze verhoogde expressie 
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is geassocieerd met CMV infectie na transplantatie. In vitro delen gesorteerde CD244+ 
CD8+ T cellen minder goed dan CD244- CD8+ T cellen in reactie op stimulatie met allo-
antigen, hetgeen een verklaring kan zijn voor de verminderde reactie van CD8+ T cellen 
in patiënten met CMV infectie. Daarnaast tonen we aan dat de meerderheid van de CMV-
specifeke CD8+ T cellen CD244+ zijn. In conclusie, CMV infectie na levertransplantatie 
is geassocieerd met de expansie van een dysfunctionele CD244+ T cel subset en met 
systemische hyporesponsiviteit van de CD8+ T cellen. Gezamenlijk laten deze twee 
hoofdstukken zien dat CMV infectie juist CD8+ T cel responsen vermindert en daarmee 
tolerantie na levertransplantatie kan bevorderen.
De meest verrassende bevinding van onze studie is het tegenstrijdige verband dat we 
vinden tussen CMV infectie en vroege versus late afstoting: terwijl CMV viremie is 
geassocieerd met meer vroege afstotingen, is primaire CMV infectie geassocieerd met 
minder late acute afstotingen, hyporesponsiviteit van donor-specifieke CD8+ T cellen 
en in het perifere bloed tekenen van tolerantie. In de meerderheid van de gevallen 
vindt vroege afstoting plaats vóór de CMV infectie. Dit is in lijn met de hypothese dat 
inflammatie die gepaard gaat met de allogene immuunrespons aanzet geeft tot replicatie 
van het latent aanwezige CMV. Anderzijds kan het lagere risico op late acute afstoting 
ook het gevolg zijn van de primaire CMV infectie, welke meestal optreedt in de eerste zes 
maanden na transplantatie. In deze patiënten wordt mogelijk om die reden de dosering 
van de immunosuppressieve medicatie verlaagd, wat in de literatuur beschreven 
is als één van de belangrijkste redenen voor late acute afstoting. Bovengenoemde 
factoren waarbij CMV infectie en afstoting een wisselwerking kunnen zijn van elkaars 
aanwezigheid kunnen mogelijk verklaren dat wij een omgekeerde relatie tussen CMV en 
afstoting vinden dan in sommige eerdere studies beschreven is. 
Hoe CMV immuunrespons van CD8+ T cellen vermindert, is nog niet precies bekend. 
Wel zijn in eerdere studies immunomudulatoire mechanismen beschreven waardoor 
CMV een latent aanwezig virus wordt, zoals: de productie van viraal IL-10, leidend 
tot een systemisch immunosuppressief effect; CMV is geassocieerd met verzwakte 
respons van immuuncellen; grote hoeveelheid geheugen T cellen gericht tegen CMV 
voorkomen dat er meer naieve T cellen bijkomen waardoor de diversiteit van T cellen en 
de respons tegen andere pathogenen afneemt; CMV leidt tot lange termijn chimerisme 
en daarmee donor-specifieke T cel hyporesponsiviteit; CMV induceert toename van Th1 
cellen en zet cellen in de lever aan tot het maken van type I Interferon, waardoor Th1 
cellen en regulatoire T cellen worden aangetrokken; Th1 cellen maken daarnaast grote 
hoeveelheden IFN-γ, waarvan in muismodellen is aangetoond dat dit bijdraagt aan 
tolerantie na transplantatie. Bovengenoemde immunomudulatoire mechanismen van 
CMV kunnen na levertransplantatie bijdragen aan tolerantie voor de donor lever.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Sa
m
en
va
tti
ng
 /
 D
ut
ch
 su
m
m
ar
y
161
Naar aanleiding van onze bevinding dat CMV infectie een gunstig effect zou kunnen 
hebben in lever transplantatie patiënten hebben we in Hoofdstuk 4 de literatuur 
betreffende dit onderwerp samengevat, waarin de gunstige effecten van CMV infectie 
in de mens beschreven worden. Een voorbeelden hiervan is dat CMV infectie na 
hematopoietische stamceltransplantatie het risico op terugkeer van kanker vermindert. 
Ons inziens zou meer onderzoek nodig zijn om de mechanismen te ontrafelen waarmee 
CMV zijn gunstige effecten op de mens uitoefent; om in de toekomst deze effecten te 
kunnen laten toenemen en ook de mogelijkheden en voordelen van een CMV vaccinatie 
strategie te onderzoeken.
II. Genetische variaties in de PD-L1/PD-1 co-inhibitoire pathway beïnvloeden 
afstoting na levertransplantatie in mensen
Co-inhibitoire receptoren op T cellen die interactie aangaan met hun liganden op 
diverse cellen zorgen ervoor dat immuunresponsen van T cellen geremd worden. Onze 
hypothese was dat deze co-inhibitoire pathways ook betrokken zijn bij het afremmen/
reguleren van allogene T cel responsen en bij afstoting in liver transplantatie patiënten. 
In Hoofdstuk 5 onderzoeken we de meest bekende co-inhibitoire pathway, namelijk 
de PD-1/PD-L1 pathway. We vinden dat de receptor PD-1 hoog tot expressie wordt 
gebracht op T cellen die de donor lever infiltreren en dat de ligand van PD-1 (PD-L1) 
hoog tot expressie komt in getransplanteerde levers waarin een afstoting plaatsvond. 
Wanneer we deze pathway blokkeren, vertonen T cellen afkomstig van deze levers 
meer celdeling in reactie op stimulatie met donor antigenen. Daarnaast vinden we een 
associatie tussen genetische variaties in deze pathway en het optreden van late acute 
afstotingen na lever transplantatie. Deze bevindingen laten ons inziens de rol zien van 
deze pathway in het optreden van afstoting na lever transplantatie. Daarnaast kunnen 
deze genetische variaties tussen patiënten bijdragen aan het verschil in vatbaarheid voor 
afstoting dat er is tussen patiënten. 
Het is interessant dat de genetische variaties in de PD-1/PD-L1 pathway alleen 
geassocieerd zijn met het optreden van late acute afstotingen. Een verklaring hiervoor 
kan zijn dat het optreden van vroege acute afstoting sterk gerelateerd is aan het gebruik 
van immunosuppressieve medicatie, welke vroeg na transplantatie in hogere dosering 
gegeven wordt. Ook de allogene immuunrespons is vroeg na transplantatie sterker dan 
laat na transplantatie. In die vroege periode worden de kleine variaties in co-inhibitoire 
pathways waarschijnlijk overschaduwd door deze sterkere factoren, terwijl later na 
transplantatie de rol van de PD-1/PD-L1 pathway wel zichtbaarder kan worden en voor 
verschillen in vatbaarheid voor afstoting kan zorgen.
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Voordat genetische verschillen in de PD-1/PD-L1 pathway in de klinische praktijk 
toegepast kunnen worden, is eerst meer onderzoek nodig. Allereerst zou de rol van deze 
pathway moeten worden onderzocht in levertransplantatie patiënten van wie bekend is 
dat ze operationeel tolerant zijn. Er zou onderzocht moeten worden of bepaalde donor/
ontvanger combinaties met gunstige genetische varianten de succeskans bij het afbouwen 
van immunosuppressieve medicatie kunnen verhogen. Als dit zo is, moet bekeken 
worden of deze genetische karakteristieken, tezamen met andere karakteristieken zoals 
γδT-cellen, kunnen worden gebruikt om tolerante patiënten te identificeren. Daarnaast 
zou PD-1 een doelwit kunnen zijn voor nieuwe immunosuppresieve medicatie, waarbij 
de remmende werking van PD-1 in transplantatie patiënten wordt gestimuleerd. Gezien 
de hoge expressie van PD-1 in de lever, zou het stimuleren van PD-1 in transplantatie 
patiënten heel gericht de lever infiltrerende T cellen moeten remmen, terwijl de werking 
van tegen pathogenen gerichte T cellen intact blijft.
III. In vitro getranscribeerd messenger RNA kan worden gebruikt voor 
monitoring van indirecte allo-herkenning in menselijke levertransplantatie 
patiënten 
Na levertransplantatie spelen twee pathways een rol bij het activeren van T cellen die 
reageren tegen donor antigenen, namelijk de directe en de indirecte pathway. De directe 
pathway is vermoedelijk dominant vroeg na transplantatie, en vroege afstoting wordt dus 
waarschijnlijk met name geïnduceerd door deze pathway. De indirecte pathway neemt 
het later na transplantatie geleidelijk van de directe pathway over en wordt geassocieerd 
met de latere schade aan het donororgaan, zoals chronische afstoting. Echter, op dit 
moment schieten technieken nog te kort om de T cellen te detecteren die via de indirecte 
pathway geactiveerd worden. In Hoofdstuk 6 beschrijven we hier een nieuwe techniek 
voor, die gebaseerd is op het door middel van electroporatie inbrengen van allogeen 
messenger RNA in autologe antigeen presenterende cellen (APC). Hiermee kunnen 
CD4+ T cellen die via de indirecte pathway tegen allo-antigenen reageren  gedecteerd 
worden. Onze nieuwe techniek heeft een aantal voordelen. Allereerst reageren via deze 
methode de CD4+ T cellen erg specifiek op alleen indirect gepresenteerd allo-antigen, 
omdat oppervlakte expressie van het allogene HLA wordt vookómen. Ten tweede zorgt 
deze techniek er, in tegenstelling tot het gebruik van slechts een aantal peptiden, voor 
dat het volledige antigen spectrum van de geëlectroporeerde HLA moleculen gebruikt 
wordt, waardoor de techniek niet beperkt wordt door HLA-typering van de patiënten. 
Ten derde gebruiken we CD40B-cellen als APC, welke in grote hoeveelheden kunnen 
worden geëxpandeerd vanuit kleine hoeveelheden bloedmonsters.
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Wanneer we in acht levertransplantatiepatiënten deze assay toepassen, vinden we in 
vier van hen CD4+ T cellen die tegen allo-antigen reageren via de indirecte pathway. 
Het meest interessant is dat in één van deze vier patiënten een zeer sterke respons te 
meten is en dat deze patiënt op dat moment een chronische afstoting doormaakt die zelfs 
geleid heeft tot verlies van het donor orgaan. Dit is in lijn met de hierboven beschreven 
hypothese dat de indirecte pathway waarschijnlijk een rol speelt bij chronische afstoting. 
Er is verder onderzoek nodig om beter te begrijpen bij welke post-transplantatie 
complicaties de indirecte pathway betrokken is en ook om de klinische relevantie 
ervan aan te tonen. Hier kunnen vervolgens immunosuppressieve therapieën beter op 
afgestemd worden om daarmee de lange termijn uitkomsten van levertransplantatie te 
verbeteren. Ook kan onze techniek gebruikt worden voor het genereren van regulatoire 
T cellen (Tregs) met indirecte allospecificiteit als alternatieve immunosuppressieve 
celtherapie. Op dit moment worden verschillende klinische trials uitgevoerd met Tregs 
als nieuwe immunosuppressieve therapie, maar deze studies gebruiken Tregs met directe 
allospecificiteit. In muismodellen is echter laten zien dat Tregs die geassocieerd zijn met 
tolerantie na transplantatie juist via de indirecte pathway reageren en dat Tregs met 
indirecte allospecificiteit meer cruciaal zijn in het induceren van tolerantie dan Tregs met 
directe allospecificiteit. Ten slotte, de indirecte allorespons moet ook worden bepaald in 
studies waarin patiënten geïdentificeerd worden die geschikt zijn voor het afbouwen 
van de immunosuppressieve medicatie, om te bepalen of de indirecte pathway ook in 
deze selectie een belangrijke factor is. Op deze manier kunnen we het risico op lange-
termijn complicaties van immunosuppressie zo veel mogelijk terugdringen.
IV. Lange termijn hematopoietisch chimerisme komt veel voor in 
getransplanteerde levers
De klinische relevantie van hematopoietisch chimerisme na levertransplantatie is nog 
niet precies bekend. Een onderzoek van Wang et al. liet zien dat er twee vormen van 
chimerisme zijn in levertransplantatie patiënten: 1. Tijdelijk chimerisme ten gevolge 
van rijpe donor leucocyten en 2. Lange-termijn chimerisme ten gevolge van donor 
hematopietische stamcellen afkomstig van de donor lever, waarbij gesuggereerd werd 
dat de lever een goede locatie is voor hematopoiese buiten het beenmerg. In Hoofdstuk 
7 beschrijven we een commentaar op de studie van Wang et al., waarbij we chimerisme 
binnen getransplanteerde levers onderzoeken. We vinden dat leucocyten in deze levers 
zowel van donor als ontvanger afkomstig zijn, zelfs tot twee jaar na transplantatie. Dit 
laat zien dat lange-termijn chimerisme veel voorkomt in getransplanteerde levers. In 
tegenstelling tot de leucocyten zijn de hematopietische stamcellen van de donor in de 
donorlevers kort na transplantatie al vervangen door hematopietische stamcellen van 
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de ontvanger. Deze resultaten suggereren dat het lange-termijn chimerisme dat Wang 
et al. beschreef mogelijk veroorzaakt wordt door langlevende donor leucocyten in het 
transplantaat en/of door hematopoiese van hematopoietische donor stamcellen die 
opnieuw naar de lever zijn gegaan. Het is echter niet bekend of intrahepatische leucocyten 
zo lang kunnen leven zonder de aanwezigheid van hematopietische donor stamcellen. 
Verder onderzoek is nodig om te weten te komen hoe deze in de lever aanwezige cellen 
zo lang in leven kunnen blijven en welk type cellen dit precies zijn.
CONCLUSIE
In dit proefschrift laten we allereerst zien dat CMV infectie allogene CD8+ T cel responsen 
vermindert en tolerantie in levertransplantatiepatiënten kan bevorderen. Daarnaast 
laten onze resultaten zien dat de PD-L1/PD-1 co-inhibitoire pathway betrokken is bij 
het reguleren van afstoting na levertransplantatie, namelijk genetische variaties in donor 
PD-L1 en ontvanger PD-1. Verder ontwikkelen we een nieuwe techniek die het mogelijk 
maakt om CD4+ T cellen te meten die reageren tegen indirect gepresenteerde allo-
antigenen. Ten slotte beschrijven we het vóórkomen van lange termijn hematopoietisch 
chimerisme in humane levertransplantaten. In conclusie geeft dit proefschrift nieuwe 
aanknopingspunten voor het ontwikkelen van behandelingsstrategieën waarbij patiënten 
kunnen worden geselecteerd/geïdentificeerd bij wie afbouwen van immunosuppresieve 
medicijnen succesvol kan zijn. 
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Zhanmin getting married, having Andrew, and watching him grow up. Raising a kid 
while pursuing PhD is so difficult, but with your devotion you handled both so well. I 
want to thank you & Zhanmin for everything you did for me and Danli. Whenever we 
need help and support, we went to you first and you’re always there. Not to mention that 
Danli and I often ran out of food and you two invited us too many times to enjoy both 
your delicious meals and funny gossips . I am sure that you will have a beautiful thesis 
in the end, so don’t worry about that! 
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Dear Wesley, we have shared the same man cave for four years, which was a lot of fun. 
And you are just so nice, both being a colleague and a friend. I am just wondering after 
we went to so many Chinese, Vietnamese and Dutch places together, how come you 
never took me to an Indonesia restaurant? I want to thank you for taking me to the gym 
on your bike for so many times (until once I broke it ). By the way you are the most 
“Chinese” Dutch person I know, so you should definitely visit China more often when I 
am there! Good luck with your future career, and your basketball skills!
Dear Elmer, the tallest and smartest guy in the man cave! You are a wonderful colleague 
and friend. I admire you so much because you show such discipline and energy at work, 
and you always spread your optimism to people around you. I am so glad that we also 
spent some time together after work, teaching you how to cook and eat crabs was certainly 
memorable! Thank you for sending your thesis all the way from the Netherlands to me in 
China, which took of course more than two months to arrive. It is a wonderful example 
for me! Good luck with your future career!
Dear Emmeloes, we have worked together the most during my entire PhD here, and I 
always admire the way you work, which is so efficient! I would like to thank you for 
teaching me so much at the beginning of my research life here, and also translating the 
thesis summary for me! Good luck to your future career and to your babies!
Dear Shanta, you are such a wonderful colleague! We worked together on projects for 
almost two years, and I can always rely on you. We have very different ways of working 
indeed. You are very organized, while I am flexible but chaotic sometimes, but certainly 
we developed chemistry along the way. I want to thank you for all the work you did for 
me, this thesis certainly cannot be finalized without your help!
Dear Patrick, you are such a nice person and colleague! When I arrived in Rotterdam I 
knew very little about lab techniques, and you helped me a lot since the very beginning. 
Every time when I have questions you are the one that I turn to, and you explain to me 
with patience, which has always been helpful. Thank you for everything, and I hope you 
will stay late at my graduation party like you always do.
Dear Guoying, 亲学妹啊！It has been loads of fun working with you, and there is 
always laughter with you in the office! You are never afraid to say what you are thinking, 
which does impress me so much! I wish you all the good luck finalizing your PhD and a 
beautiful life in the Netherlands!
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Dear Kostas, you have been a great colleague, always sharing your knowledge with me, 
and very fun to talk to! I will always remember those long rides that we share between 
Rotterdam and Nijmegen, and going all around Nijmegen in rain just trying to get some 
food, which was quite funny to think about afterwards! All the best on your career!
Dear Abdullah, you are such a brilliant but also humble person, a model that I look 
up to! Your enthusiasm in science and big-picture thinking while managing such a big 
research group amazed me so much! I want to thank you for all the suggestions that you 
gave me during these four years, and helping me to improve my manuscript. Every time 
we talked about research together, I can feel the passion you have about science, which 
really motivates me tremendously. I wish you a successful career, and “very easy, no 
problem” forever!
Dear Luc, you are such a knowledgeable scientist! I want to thank you for every advice 
you gave me during my study here, which were certainly very helpful. What a chance 
that we could meet again so soon in Shanghai, I was so glad that you liked local Chinese 
food very much! I hope we can do it again in Shanghai in the near future!
Dear Frank, you are such a dedicated person and a good friend! I want to thank you for 
being so strict with me during my master study, which certainly corrected some of my 
bad habits at work. You also take me to experience Dutch life. Watching opera and the 
performance of your band are certainly memorable experience for me! I look forward to 
receiving you in China and good luck on everything!
Dear Ling, you are wonderful both as a classmate and a friend! I am so glad that we can 
still collaborate and discuss projects together after the Master’s graduation. I appreciate 
you so much for cheering for me the first time that I won award at an academic conference 
(as well as a lot of your nice colleagues!), while not many colleagues of mine were present. 
My best wishes to you on your work and your life!
Dear Bettina, getting an appointment with you has always been difficult, but the time 
that I spent waiting was totally worthwhile ! I would like to thank you for all the input 
and suggestions to me, which resulted in two beautiful publications!
Dear Marion, I would like to thank you for everything that you did for me when I was 
on the other side of the earth preparing my thesis! While I was postponing deadlines all 
the times, you always make things done literally instantly!
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Da
nk
w
oo
rd
 /
 A
ck
no
w
led
ge
m
en
ts
169
Dear Dr. de Jonge, Dr. de Knegt, Dr. Rivadeneira, Dr. Betjes, Dr. van der Eijk, Dr. Kuball, 
Dr. Heirman, Dr. Heemskerk, Özlem and Margo, I would like to thank you all for your 
dedicated contributions to my projects! I hope we can collaborate again in future!
Dear all MDL members, you guys are all great! Rogier, Wenshi, Jasper, Vincent, Evelyn, 
Gwenny, Wanlu, Eelke, Renee, Alex, Petra, Monique, Henk, Marcel, Pauline, Sergey, 
Juan, Wenhui, Yijing, Lei, Yuebang, Xinying, Shan, André, Andrea, Nadine, Jun, Thomas, 
Sonja, Paula, Anthonie, Kim, Aniek, Martijn, Gertine, Asma, Miranda and Elly. I want to 
thank you all for helping me so much during my study here, and I will cherish the good 
times that we had together! Best wishes to you all!
感谢上海交通大学的姚玉峰教授，您是我科研的启蒙人，感谢您在我国内研究时的悉心
指导！感谢交大医学院国际交流处高红老师在我出国时提供的各种帮助！感谢奚志峰医
生在我回国进科时给予的巨大帮助！
最后感谢在荷兰和我一起分享最美好时光的小伙伴们：展民、同伟、长斌、吴斌、海
波、舟桥、高雅、高文、刘凡、温蓓、文世、婉璐、宝月、陈思、小俊、魁魁、鞠驰
恒、平臻、于雪、孙伟、郭贞敏、鲁涛、白冠男、若愚、静静、凯音、世豪、唐颖、李
杉、郭虹波，当然还有jianjian和miumiu。和大家在一起的时光总是显得很短暂，回国后
多少次梦回荷兰和大家一起玩耍 (*>﹏<*)！ 虽然分别了，祝福大家都有美好的前景！缘
分未尽，大家未来再见！
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